id	sid	tid	token	lemma	pos
njb-1	1	1	nepal	nepal	PROPN
njb-1	1	2	j	j	PROPN
njb-1	1	3	biotechnol	biotechnol	PROPN
njb-1	1	4	.	.	PUNCT
njb-1	2	1	2	2	NUM
njb-1	2	2	0	0	NUM
njb-1	2	3	2	2	NUM
njb-1	2	4	1	1	NUM
njb-1	2	5	d	d	X
njb-1	2	6	e	e	X
njb-1	2	7	c	c	PROPN
njb-1	2	8	.	.	PUNCT
njb-1	3	1	9	9	NUM
njb-1	3	2	(	(	PUNCT
njb-1	3	3	2	2	NUM
njb-1	3	4	):	):	PUNCT
njb-1	3	5	39	39	NUM
njb-1	3	6	-	-	SYM
njb-1	3	7	47	47	NUM
njb-1	3	8	review	review	NOUN
njb-1	3	9	article	article	NOUN
njb-1	3	10	doi	doi	PROPN
njb-1	3	11	:	:	PUNCT
njb-1	3	12	ttps://www.doi.org/10.54796/njb.v9i2.41914	ttps://www.doi.org/10.54796/njb.v9i2.41914	NOUN
njb-1	3	13	©	©	PROPN
njb-1	3	14	njb	njb	PROPN
njb-1	3	15	,	,	PUNCT
njb-1	3	16	bsn	bsn	PROPN
njb-1	3	17	39	39	NUM
njb-1	3	18	efficacy	efficacy	NOUN
njb-1	3	19	and	and	CCONJ
njb-1	3	20	toxicity	toxicity	NOUN
njb-1	3	21	of	of	ADP
njb-1	3	22	different	different	ADJ
njb-1	3	23	forms	form	NOUN
njb-1	3	24	of	of	ADP
njb-1	3	25	asparaginases	asparaginase	NOUN
njb-1	3	26	against	against	ADP
njb-1	3	27	acute	acute	ADJ
njb-1	3	28	lymphoblastic	lymphoblastic	NOUN
njb-1	3	29	leukemia	leukemia	NOUN
njb-1	3	30	:	:	PUNCT
njb-1	3	31	a	a	DET
njb-1	3	32	review	review	NOUN
njb-1	3	33	adesh	adesh	NOUN
njb-1	3	34	baral	baral	ADJ
njb-1	3	35	,	,	PUNCT
njb-1	3	36	ritesh	ritesh	PROPN
njb-1	3	37	gorkhali	gorkhali	PROPN
njb-1	3	38	,	,	PUNCT
njb-1	3	39	amit	amit	PROPN
njb-1	3	40	basnet	basnet	PROPN
njb-1	3	41	,	,	PUNCT
njb-1	3	42	shubham	shubham	PROPN
njb-1	3	43	koirala	koirala	PROPN
njb-1	3	44	,	,	PUNCT
njb-1	3	45	hitesh	hitesh	PROPN
njb-1	3	46	k.	k.	PROPN
njb-1	3	47	bhattarai	bhattarai	PROPN
njb-1	3	48	department	department	PROPN
njb-1	3	49	of	of	ADP
njb-1	3	50	biotechnology	biotechnology	NOUN
njb-1	3	51	,	,	PUNCT
njb-1	3	52	kathmandu	kathmandu	PROPN
njb-1	3	53	university	university	PROPN
njb-1	3	54	,	,	PUNCT
njb-1	3	55	dhulikhel	dhulikhel	PROPN
njb-1	3	56	,	,	PUNCT
njb-1	3	57	nepal	nepal	PROPN
njb-1	3	58	.	.	PUNCT
njb-1	4	1	received	receive	VERB
njb-1	4	2	:	:	PUNCT
njb-1	4	3	15th	15th	PROPN
njb-1	4	4	jun	jun	PROPN
njb-1	4	5	2021	2021	NUM
njb-1	4	6	;	;	PUNCT
njb-1	4	7	revised	revise	VERB
njb-1	4	8	:	:	PUNCT
njb-1	4	9	22nd	22nd	NOUN
njb-1	4	10	dec	dec	PROPN
njb-1	4	11	2021	2021	NUM
njb-1	4	12	;	;	PUNCT
njb-1	4	13	accepted	accept	VERB
njb-1	4	14	:	:	PUNCT
njb-1	4	15	25th	25th	NOUN
njb-1	4	16	dec	dec	PROPN
njb-1	4	17	2021	2021	NUM
njb-1	4	18	;	;	PUNCT
njb-1	4	19	published	publish	VERB
njb-1	4	20	online	online	ADV
njb-1	4	21	:	:	PUNCT
njb-1	4	22	31st	31st	PROPN
njb-1	5	1	dec	dec	PROPN
njb-1	5	2	2021	2021	NUM
njb-1	5	3	abstract	abstract	ADJ
njb-1	5	4	acute	acute	ADJ
njb-1	5	5	lymphoblastic	lymphoblastic	NOUN
njb-1	5	6	leukemia	leukemia	NOUN
njb-1	5	7	(	(	PUNCT
njb-1	5	8	all	all	ADV
njb-1	5	9	)	)	PUNCT
njb-1	5	10	is	be	AUX
njb-1	5	11	a	a	DET
njb-1	5	12	form	form	NOUN
njb-1	5	13	of	of	ADP
njb-1	5	14	blood	blood	NOUN
njb-1	5	15	cancer	cancer	NOUN
njb-1	5	16	that	that	PRON
njb-1	5	17	affects	affect	VERB
njb-1	5	18	white	white	ADJ
njb-1	5	19	blood	blood	NOUN
njb-1	5	20	cells	cell	NOUN
njb-1	5	21	and	and	CCONJ
njb-1	5	22	is	be	AUX
njb-1	5	23	among	among	ADP
njb-1	5	24	the	the	DET
njb-1	5	25	most	most	ADV
njb-1	5	26	common	common	ADJ
njb-1	5	27	forms	form	NOUN
njb-1	5	28	of	of	ADP
njb-1	5	29	leukemia	leukemia	NOUN
njb-1	5	30	with	with	ADP
njb-1	5	31	children	child	NOUN
njb-1	5	32	and	and	CCONJ
njb-1	5	33	adolescents	adolescent	NOUN
njb-1	5	34	showing	show	VERB
njb-1	5	35	the	the	DET
njb-1	5	36	highest	high	ADJ
njb-1	5	37	number	number	NOUN
njb-1	5	38	of	of	ADP
njb-1	5	39	cases	case	NOUN
njb-1	5	40	.	.	PUNCT
njb-1	6	1	most	most	ADJ
njb-1	6	2	treatment	treatment	NOUN
njb-1	6	3	protocols	protocol	NOUN
njb-1	6	4	include	include	VERB
njb-1	6	5	chemotherapy	chemotherapy	NOUN
njb-1	6	6	using	use	VERB
njb-1	6	7	asparaginase	asparaginase	NOUN
njb-1	6	8	.	.	PUNCT
njb-1	7	1	asparaginase	asparaginase	NOUN
njb-1	7	2	converts	convert	VERB
njb-1	7	3	asparagine	asparagine	NOUN
njb-1	7	4	to	to	ADP
njb-1	7	5	aspartic	aspartic	ADJ
njb-1	7	6	acid	acid	NOUN
njb-1	7	7	and	and	CCONJ
njb-1	7	8	ammonia	ammonia	NOUN
njb-1	7	9	.	.	PUNCT
njb-1	8	1	unlike	unlike	ADP
njb-1	8	2	normal	normal	ADJ
njb-1	8	3	,	,	PUNCT
njb-1	8	4	healthy	healthy	ADJ
njb-1	8	5	cells	cell	NOUN
njb-1	8	6	,	,	PUNCT
njb-1	8	7	cancerous	cancerous	ADJ
njb-1	8	8	cells	cell	NOUN
njb-1	8	9	depend	depend	VERB
njb-1	8	10	on	on	ADP
njb-1	8	11	asparagine	asparagine	NOUN
njb-1	8	12	for	for	ADP
njb-1	8	13	their	their	PRON
njb-1	8	14	growth	growth	NOUN
njb-1	8	15	.	.	PUNCT
njb-1	9	1	when	when	SCONJ
njb-1	9	2	these	these	DET
njb-1	9	3	cells	cell	NOUN
njb-1	9	4	are	be	AUX
njb-1	9	5	deprived	deprive	VERB
njb-1	9	6	of	of	ADP
njb-1	9	7	asparagine	asparagine	NOUN
njb-1	9	8	by	by	ADP
njb-1	9	9	the	the	DET
njb-1	9	10	action	action	NOUN
njb-1	9	11	of	of	ADP
njb-1	9	12	the	the	DET
njb-1	9	13	enzyme	enzyme	NOUN
njb-1	9	14	,	,	PUNCT
njb-1	9	15	the	the	DET
njb-1	9	16	cancer	cancer	NOUN
njb-1	9	17	cells	cell	NOUN
njb-1	9	18	selectively	selectively	ADV
njb-1	9	19	die	die	VERB
njb-1	9	20	.	.	PUNCT
njb-1	10	1	as	as	ADP
njb-1	10	2	of	of	ADP
njb-1	10	3	date	date	NOUN
njb-1	10	4	,	,	PUNCT
njb-1	10	5	several	several	ADJ
njb-1	10	6	forms	form	NOUN
njb-1	10	7	of	of	ADP
njb-1	10	8	asparaginases	asparaginase	NOUN
njb-1	10	9	are	be	AUX
njb-1	10	10	commercially	commercially	ADV
njb-1	10	11	available	available	ADJ
njb-1	10	12	and	and	CCONJ
njb-1	10	13	are	be	AUX
njb-1	10	14	administered	administer	VERB
njb-1	10	15	in	in	ADP
njb-1	10	16	all	all	DET
njb-1	10	17	therapy	therapy	NOUN
njb-1	10	18	.	.	PUNCT
njb-1	11	1	but	but	CCONJ
njb-1	11	2	due	due	ADP
njb-1	11	3	to	to	ADP
njb-1	11	4	limited	limited	ADJ
njb-1	11	5	study	study	NOUN
njb-1	11	6	,	,	PUNCT
njb-1	11	7	it	it	PRON
njb-1	11	8	will	will	AUX
njb-1	11	9	be	be	AUX
njb-1	11	10	early	early	ADJ
njb-1	11	11	and	and	CCONJ
njb-1	11	12	inaccurate	inaccurate	ADJ
njb-1	11	13	to	to	PART
njb-1	11	14	predict	predict	VERB
njb-1	11	15	which	which	PRON
njb-1	11	16	forms	form	NOUN
njb-1	11	17	of	of	ADP
njb-1	11	18	the	the	DET
njb-1	11	19	enzymes	enzyme	NOUN
njb-1	11	20	are	be	AUX
njb-1	11	21	better	well	ADJ
njb-1	11	22	.	.	PUNCT
njb-1	12	1	in	in	ADP
njb-1	12	2	this	this	DET
njb-1	12	3	review	review	NOUN
njb-1	12	4	,	,	PUNCT
njb-1	12	5	we	we	PRON
njb-1	12	6	aim	aim	VERB
njb-1	12	7	to	to	PART
njb-1	12	8	compare	compare	VERB
njb-1	12	9	the	the	DET
njb-1	12	10	efficacy	efficacy	NOUN
njb-1	12	11	and	and	CCONJ
njb-1	12	12	toxicity	toxicity	NOUN
njb-1	12	13	of	of	ADP
njb-1	12	14	four	four	NUM
njb-1	12	15	different	different	ADJ
njb-1	12	16	asparaginases	asparaginase	NOUN
njb-1	12	17	—	—	PUNCT
njb-1	12	18	native	native	ADJ
njb-1	12	19	escherichia	escherichia	NOUN
njb-1	12	20	coli	coli	PROPN
njb-1	12	21	asparaginase	asparaginase	NOUN
njb-1	12	22	,	,	PUNCT
njb-1	12	23	peg	peg	NOUN
njb-1	12	24	escherichia	escherichia	NOUN
njb-1	12	25	coli	coli	NOUN
njb-1	12	26	asparaginase	asparaginase	NOUN
njb-1	12	27	,	,	PUNCT
njb-1	12	28	erwinia	erwinia	PROPN
njb-1	12	29	chrysanthemi	chrysanthemi	PROPN
njb-1	12	30	asparaginase	asparaginase	PROPN
njb-1	12	31	and	and	CCONJ
njb-1	12	32	a	a	DET
njb-1	12	33	recombinant	recombinant	ADJ
njb-1	12	34	escherichia	escherichia	NOUN
njb-1	12	35	coli	coli	NOUN
njb-1	12	36	asparaginase	asparaginase	NOUN
njb-1	12	37	—	—	PUNCT
njb-1	12	38	used	use	VERB
njb-1	12	39	in	in	ADP
njb-1	12	40	all	all	DET
njb-1	12	41	therapy	therapy	NOUN
njb-1	12	42	in	in	ADP
njb-1	12	43	children	child	NOUN
njb-1	12	44	and	and	CCONJ
njb-1	12	45	adolescents	adolescent	NOUN
njb-1	12	46	using	use	VERB
njb-1	12	47	available	available	ADJ
njb-1	12	48	clinical	clinical	ADJ
njb-1	12	49	trial	trial	NOUN
njb-1	12	50	data	datum	NOUN
njb-1	12	51	.	.	PUNCT
njb-1	13	1	pubmed	pubmed	PROPN
njb-1	13	2	and	and	CCONJ
njb-1	13	3	clinical	clinical	ADJ
njb-1	13	4	trial.org	trial.org	PROPN
njb-1	13	5	databases	database	NOUN
njb-1	13	6	were	be	AUX
njb-1	13	7	used	use	VERB
njb-1	13	8	to	to	PART
njb-1	13	9	select	select	VERB
njb-1	13	10	studies	study	NOUN
njb-1	13	11	.	.	PUNCT
njb-1	14	1	asparaginase	asparaginase	NOUN
njb-1	14	2	activity	activity	NOUN
njb-1	14	3	,	,	PUNCT
njb-1	14	4	toxicity	toxicity	NOUN
njb-1	14	5	,	,	PUNCT
njb-1	14	6	anti	anti	ADJ
njb-1	14	7	-	-	ADJ
njb-1	14	8	asparaginase	asparaginase	ADJ
njb-1	14	9	antibody	antibody	NOUN
njb-1	14	10	level	level	NOUN
njb-1	14	11	and	and	CCONJ
njb-1	14	12	event	event	NOUN
njb-1	14	13	-	-	PUNCT
njb-1	14	14	free	free	ADJ
njb-1	14	15	,	,	PUNCT
njb-1	14	16	overall	overall	ADJ
njb-1	14	17	survival	survival	NOUN
njb-1	14	18	was	be	AUX
njb-1	14	19	compared	compare	VERB
njb-1	14	20	for	for	ADP
njb-1	14	21	different	different	ADJ
njb-1	14	22	asparaginases	asparaginase	NOUN
njb-1	14	23	.	.	PUNCT
njb-1	15	1	seventeen	seventeen	NUM
njb-1	15	2	randomized	randomize	VERB
njb-1	15	3	and	and	CCONJ
njb-1	15	4	non	non	ADJ
njb-1	15	5	-	-	ADJ
njb-1	15	6	randomized	randomized	ADJ
njb-1	15	7	controlled	control	VERB
njb-1	15	8	trials	trial	NOUN
njb-1	15	9	were	be	AUX
njb-1	15	10	included	include	VERB
njb-1	15	11	.	.	PUNCT
njb-1	16	1	evidence	evidence	NOUN
njb-1	16	2	was	be	AUX
njb-1	16	3	insufficient	insufficient	ADJ
njb-1	16	4	to	to	PART
njb-1	16	5	ascertain	ascertain	VERB
njb-1	16	6	which	which	PRON
njb-1	16	7	asparaginase	asparaginase	NOUN
njb-1	16	8	is	be	AUX
njb-1	16	9	the	the	DET
njb-1	16	10	best	good	ADJ
njb-1	16	11	.	.	PUNCT
njb-1	17	1	peg	peg	NOUN
njb-1	17	2	escherichia	escherichia	NOUN
njb-1	17	3	coli	coli	NOUN
njb-1	17	4	asparaginase	asparaginase	NOUN
njb-1	17	5	seems	seem	VERB
njb-1	17	6	to	to	PART
njb-1	17	7	be	be	AUX
njb-1	17	8	better	well	ADJ
njb-1	17	9	with	with	ADP
njb-1	17	10	a	a	DET
njb-1	17	11	high	high	ADJ
njb-1	17	12	activity	activity	NOUN
njb-1	17	13	among	among	ADP
njb-1	17	14	the	the	DET
njb-1	17	15	treated	treat	VERB
njb-1	17	16	patients	patient	NOUN
njb-1	17	17	but	but	CCONJ
njb-1	17	18	there	there	PRON
njb-1	17	19	remains	remain	VERB
njb-1	17	20	high	high	ADJ
njb-1	17	21	toxicity	toxicity	NOUN
njb-1	17	22	for	for	ADP
njb-1	17	23	all	all	DET
njb-1	17	24	available	available	ADJ
njb-1	17	25	asparaginases	asparaginase	NOUN
njb-1	17	26	.	.	PUNCT
njb-1	18	1	this	this	DET
njb-1	18	2	study	study	NOUN
njb-1	18	3	highlights	highlight	VERB
njb-1	18	4	a	a	DET
njb-1	18	5	need	need	NOUN
njb-1	18	6	to	to	PART
njb-1	18	7	discover	discover	VERB
njb-1	18	8	alternative	alternative	ADJ
njb-1	18	9	sources	source	NOUN
njb-1	18	10	of	of	ADP
njb-1	18	11	asparaginase	asparaginase	NOUN
njb-1	18	12	from	from	ADP
njb-1	18	13	the	the	DET
njb-1	18	14	organisms	organism	NOUN
njb-1	18	15	,	,	PUNCT
njb-1	18	16	which	which	PRON
njb-1	18	17	are	be	AUX
njb-1	18	18	evolutionarily	evolutionarily	ADV
njb-1	18	19	distant	distant	ADJ
njb-1	18	20	from	from	ADP
njb-1	18	21	escherichia	escherichia	NOUN
njb-1	18	22	coli	coli	NOUN
njb-1	18	23	and	and	CCONJ
njb-1	18	24	erwinia	erwinia	PROPN
njb-1	18	25	chrysanthemi	chrysanthemi	PROPN
njb-1	18	26	with	with	ADP
njb-1	18	27	high	high	ADJ
njb-1	18	28	higher	high	ADJ
njb-1	18	29	enzyme	enzyme	NOUN
njb-1	18	30	activity	activity	NOUN
njb-1	18	31	and	and	CCONJ
njb-1	18	32	reduced	reduce	VERB
njb-1	18	33	toxicity	toxicity	NOUN
njb-1	18	34	.	.	PUNCT
njb-1	19	1	keywords	keyword	NOUN
njb-1	19	2	:	:	PUNCT
njb-1	19	3	efficacy	efficacy	NOUN
njb-1	19	4	,	,	PUNCT
njb-1	19	5	acute	acute	ADJ
njb-1	19	6	lymphoblastic	lymphoblastic	NOUN
njb-1	19	7	leukemia	leukemia	NOUN
njb-1	19	8	,	,	PUNCT
njb-1	19	9	asparaginase	asparaginase	NOUN
njb-1	19	10	,	,	PUNCT
njb-1	19	11	clinical	clinical	ADJ
njb-1	19	12	trials	trial	NOUN
njb-1	19	13	.	.	PUNCT
njb-1	20	1	corresponding	correspond	VERB
njb-1	20	2	author	author	NOUN
njb-1	20	3	,	,	PUNCT
njb-1	20	4	email	email	NOUN
njb-1	20	5	:	:	PUNCT
njb-1	20	6	hitesh321@gmail.com	hitesh321@gmail.com	X
njb-1	20	7	introduction	introduction	NOUN
njb-1	20	8	acute	acute	ADJ
njb-1	20	9	lymphoblastic	lymphoblastic	NOUN
njb-1	20	10	leukemia	leukemia	NOUN
njb-1	20	11	or	or	CCONJ
njb-1	20	12	all	all	PRON
njb-1	20	13	is	be	AUX
njb-1	20	14	among	among	ADP
njb-1	20	15	the	the	DET
njb-1	20	16	most	most	ADV
njb-1	20	17	prevalent	prevalent	ADJ
njb-1	20	18	forms	form	NOUN
njb-1	20	19	of	of	ADP
njb-1	20	20	leukemia	leukemia	NOUN
njb-1	20	21	and	and	CCONJ
njb-1	20	22	most	most	ADV
njb-1	20	23	commonly	commonly	ADV
njb-1	20	24	affects	affect	VERB
njb-1	20	25	children	child	NOUN
njb-1	20	26	.	.	PUNCT
njb-1	21	1	all	all	PRON
njb-1	21	2	is	be	AUX
njb-1	21	3	caused	cause	VERB
njb-1	21	4	by	by	ADP
njb-1	21	5	unchecked	unchecked	ADJ
njb-1	21	6	and	and	CCONJ
njb-1	21	7	malignant	malignant	ADJ
njb-1	21	8	proliferation	proliferation	NOUN
njb-1	21	9	of	of	ADP
njb-1	21	10	lymphoid	lymphoid	ADJ
njb-1	21	11	progenitor	progenitor	NOUN
njb-1	21	12	cells	cell	NOUN
njb-1	21	13	in	in	ADP
njb-1	21	14	blood	blood	NOUN
njb-1	21	15	,	,	PUNCT
njb-1	21	16	bone	bone	NOUN
njb-1	21	17	marrow	marrow	NOUN
njb-1	21	18	,	,	PUNCT
njb-1	21	19	and	and	CCONJ
njb-1	21	20	extramedullary	extramedullary	ADJ
njb-1	21	21	sites	site	NOUN
njb-1	21	22	[	[	X
njb-1	21	23	1	1	NUM
njb-1	21	24	]	]	PUNCT
njb-1	21	25	.	.	PUNCT
njb-1	22	1	all	all	PRON
njb-1	22	2	presents	present	VERB
njb-1	22	3	itself	itself	PRON
njb-1	22	4	via	via	ADP
njb-1	22	5	three	three	NUM
njb-1	22	6	main	main	ADJ
njb-1	22	7	pathological	pathological	ADJ
njb-1	22	8	processes	process	NOUN
njb-1	22	9	:	:	PUNCT
njb-1	22	10	first	first	ADV
njb-1	22	11	is	be	AUX
njb-1	22	12	the	the	DET
njb-1	22	13	failure	failure	NOUN
njb-1	22	14	of	of	ADP
njb-1	22	15	bone	bone	NOUN
njb-1	22	16	marrow	marrow	NOUN
njb-1	22	17	,	,	PUNCT
njb-1	22	18	second	second	ADJ
njb-1	22	19	is	be	AUX
njb-1	22	20	the	the	DET
njb-1	22	21	infiltration	infiltration	NOUN
njb-1	22	22	of	of	ADP
njb-1	22	23	other	other	ADJ
njb-1	22	24	tissues	tissue	NOUN
njb-1	22	25	by	by	ADP
njb-1	22	26	blasts	blast	NOUN
njb-1	22	27	via	via	ADP
njb-1	22	28	malignancy	malignancy	NOUN
njb-1	22	29	and	and	CCONJ
njb-1	22	30	third	third	ADV
njb-1	22	31	is	be	AUX
njb-1	22	32	the	the	DET
njb-1	22	33	systemic	systemic	ADJ
njb-1	22	34	effects	effect	NOUN
njb-1	22	35	arising	arise	VERB
njb-1	22	36	from	from	ADP
njb-1	22	37	cytokines	cytokine	NOUN
njb-1	22	38	released	release	VERB
njb-1	22	39	by	by	ADP
njb-1	22	40	the	the	DET
njb-1	22	41	cancerous	cancerous	ADJ
njb-1	22	42	cells	cell	NOUN
njb-1	22	43	.	.	PUNCT
njb-1	23	1	all	all	PRON
njb-1	23	2	often	often	ADV
njb-1	23	3	shows	show	VERB
njb-1	23	4	common	common	ADJ
njb-1	23	5	signs	sign	NOUN
njb-1	23	6	and	and	CCONJ
njb-1	23	7	symptoms	symptom	NOUN
njb-1	23	8	among	among	ADP
njb-1	23	9	children	child	NOUN
njb-1	23	10	which	which	PRON
njb-1	23	11	include	include	VERB
njb-1	23	12	:	:	PUNCT
njb-1	23	13	anemia	anemia	NOUN
njb-1	23	14	,	,	PUNCT
njb-1	23	15	thrombocytopenia	thrombocytopenia	PROPN
njb-1	23	16	,	,	PUNCT
njb-1	23	17	and	and	CCONJ
njb-1	23	18	pronounced	pronounce	VERB
njb-1	23	19	hepatosplenomegaly	hepatosplenomegaly	NOUN
njb-1	23	20	or	or	CCONJ
njb-1	23	21	lymphadenopathy	lymphadenopathy	ADJ
njb-1	23	22	[	[	X
njb-1	23	23	1	1	NUM
njb-1	23	24	]	]	X
njb-1	23	25	.	.	PUNCT
njb-1	24	1	american	american	ADJ
njb-1	24	2	cancer	cancer	PROPN
njb-1	24	3	society	society	PROPN
njb-1	24	4	estimates	estimate	VERB
njb-1	24	5	that	that	SCONJ
njb-1	24	6	6590	6590	NUM
njb-1	24	7	cases	case	NOUN
njb-1	24	8	were	be	AUX
njb-1	24	9	diagnosed	diagnose	VERB
njb-1	24	10	in	in	ADP
njb-1	24	11	2016	2016	NUM
njb-1	24	12	alone	alone	ADJ
njb-1	24	13	with	with	ADP
njb-1	24	14	1400	1400	NUM
njb-1	24	15	death	death	NOUN
njb-1	24	16	[	[	PUNCT
njb-1	24	17	2	2	NUM
njb-1	24	18	]	]	PUNCT
njb-1	24	19	.	.	PUNCT
njb-1	25	1	it	it	PRON
njb-1	25	2	is	be	AUX
njb-1	25	3	suspected	suspect	VERB
njb-1	25	4	that	that	SCONJ
njb-1	25	5	a	a	DET
njb-1	25	6	combination	combination	NOUN
njb-1	25	7	of	of	ADP
njb-1	25	8	prenatal	prenatal	ADJ
njb-1	25	9	mutations	mutation	NOUN
njb-1	25	10	and	and	CCONJ
njb-1	25	11	environmental	environmental	ADJ
njb-1	25	12	factors	factor	NOUN
njb-1	25	13	cause	cause	VERB
njb-1	25	14	all	all	PRON
njb-1	25	15	.	.	PUNCT
njb-1	26	1	l	l	NOUN
njb-1	26	2	-	-	PUNCT
njb-1	26	3	asparaginase	asparaginase	NOUN
njb-1	26	4	is	be	AUX
njb-1	26	5	an	an	DET
njb-1	26	6	enzyme	enzyme	NOUN
njb-1	26	7	that	that	PRON
njb-1	26	8	catalyzes	catalyze	VERB
njb-1	26	9	the	the	DET
njb-1	26	10	formation	formation	NOUN
njb-1	26	11	aspartic	aspartic	ADJ
njb-1	26	12	acid	acid	NOUN
njb-1	26	13	and	and	CCONJ
njb-1	26	14	ammonia	ammonia	NOUN
njb-1	26	15	from	from	ADP
njb-1	26	16	asparagine	asparagine	NOUN
njb-1	26	17	.	.	PUNCT
njb-1	27	1	it	it	PRON
njb-1	27	2	is	be	AUX
njb-1	27	3	commonly	commonly	ADV
njb-1	27	4	produced	produce	VERB
njb-1	27	5	in	in	ADP
njb-1	27	6	bacteria	bacteria	NOUN
njb-1	27	7	,	,	PUNCT
njb-1	27	8	but	but	CCONJ
njb-1	27	9	not	not	PART
njb-1	27	10	in	in	ADP
njb-1	27	11	humans	human	NOUN
njb-1	27	12	.	.	PUNCT
njb-1	28	1	organisms	organism	NOUN
njb-1	28	2	produce	produce	VERB
njb-1	28	3	it	it	PRON
njb-1	28	4	in	in	ADP
njb-1	28	5	the	the	DET
njb-1	28	6	course	course	NOUN
njb-1	28	7	of	of	ADP
njb-1	28	8	their	their	PRON
njb-1	28	9	normal	normal	ADJ
njb-1	28	10	life	life	NOUN
njb-1	28	11	cycle	cycle	NOUN
njb-1	28	12	and	and	CCONJ
njb-1	28	13	it	it	PRON
njb-1	28	14	can	can	AUX
njb-1	28	15	be	be	AUX
njb-1	28	16	extracted	extract	VERB
njb-1	28	17	and	and	CCONJ
njb-1	28	18	purified	purify	VERB
njb-1	28	19	for	for	ADP
njb-1	28	20	industrial	industrial	ADJ
njb-1	28	21	and	and	CCONJ
njb-1	28	22	medical	medical	ADJ
njb-1	28	23	purposes	purpose	NOUN
njb-1	28	24	.	.	PUNCT
njb-1	29	1	l	l	NOUN
njb-1	29	2	-	-	PUNCT
njb-1	29	3	asparaginase	asparaginase	NOUN
njb-1	29	4	was	be	AUX
njb-1	29	5	introduced	introduce	VERB
njb-1	29	6	in	in	ADP
njb-1	29	7	the	the	DET
njb-1	29	8	early	early	ADJ
njb-1	29	9	70s	70	NOUN
njb-1	29	10	as	as	ADP
njb-1	29	11	part	part	NOUN
njb-1	29	12	of	of	ADP
njb-1	29	13	the	the	DET
njb-1	29	14	treatment	treatment	NOUN
njb-1	29	15	protocols	protocol	NOUN
njb-1	29	16	for	for	ADP
njb-1	29	17	all	all	PRON
njb-1	29	18	in	in	ADP
njb-1	29	19	children	child	NOUN
njb-1	29	20	.	.	PUNCT
njb-1	30	1	now	now	ADV
njb-1	30	2	,	,	PUNCT
njb-1	30	3	l	l	NOUN
njb-1	30	4	-	-	PUNCT
njb-1	30	5	asparaginase	asparaginase	NOUN
njb-1	30	6	has	have	AUX
njb-1	30	7	become	become	VERB
njb-1	30	8	a	a	DET
njb-1	30	9	routine	routine	ADJ
njb-1	30	10	part	part	NOUN
njb-1	30	11	of	of	ADP
njb-1	30	12	treatment	treatment	NOUN
njb-1	30	13	protocols	protocol	NOUN
njb-1	30	14	of	of	ADP
njb-1	30	15	all	all	PRON
njb-1	30	16	[	[	PUNCT
njb-1	30	17	3	3	NUM
njb-1	30	18	]	]	PUNCT
njb-1	30	19	.	.	PUNCT
njb-1	31	1	asparaginase	asparaginase	NOUN
njb-1	31	2	works	work	VERB
njb-1	31	3	via	via	ADP
njb-1	31	4	depletion	depletion	NOUN
njb-1	31	5	of	of	ADP
njb-1	31	6	asparagine	asparagine	NOUN
njb-1	31	7	in	in	ADP
njb-1	31	8	the	the	DET
njb-1	31	9	blood	blood	NOUN
njb-1	31	10	.	.	PUNCT
njb-1	32	1	l	l	X
njb-1	32	2	-	-	PUNCT
njb-1	32	3	asparagine	asparagine	NOUN
njb-1	32	4	is	be	AUX
njb-1	32	5	an	an	DET
njb-1	32	6	important	important	ADJ
njb-1	32	7	amino	amino	NOUN
njb-1	32	8	acid	acid	NOUN
njb-1	32	9	used	use	VERB
njb-1	32	10	by	by	ADP
njb-1	32	11	cells	cell	NOUN
njb-1	32	12	in	in	ADP
njb-1	32	13	protein	protein	NOUN
njb-1	32	14	synthesis	synthesis	NOUN
njb-1	32	15	.	.	PUNCT
njb-1	33	1	most	most	ADJ
njb-1	33	2	normal	normal	ADJ
njb-1	33	3	cells	cell	NOUN
njb-1	33	4	produce	produce	VERB
njb-1	33	5	lasparagine	lasparagine	NOUN
njb-1	33	6	for	for	ADP
njb-1	33	7	their	their	PRON
njb-1	33	8	growth	growth	NOUN
njb-1	33	9	using	use	VERB
njb-1	33	10	l	l	NOUN
njb-1	33	11	-	-	PUNCT
njb-1	33	12	asparagine	asparagine	ADJ
njb-1	33	13	synthetase	synthetase	ADJ
njb-1	33	14	enzyme	enzyme	NOUN
njb-1	33	15	,	,	PUNCT
njb-1	33	16	synthesizing	synthesize	VERB
njb-1	33	17	l	l	NOUN
njb-1	33	18	-	-	PUNCT
njb-1	33	19	asparagine	asparagine	NOUN
njb-1	33	20	from	from	ADP
njb-1	33	21	aspartic	aspartic	ADJ
njb-1	33	22	acid	acid	NOUN
njb-1	33	23	and	and	CCONJ
njb-1	33	24	glutamic	glutamic	ADJ
njb-1	33	25	acid	acid	NOUN
njb-1	33	26	.	.	PUNCT
njb-1	34	1	neoplastic	neoplastic	ADJ
njb-1	34	2	cells	cell	NOUN
njb-1	34	3	like	like	ADP
njb-1	34	4	all	all	DET
njb-1	34	5	cells	cell	NOUN
njb-1	34	6	are	be	AUX
njb-1	34	7	incapable	incapable	ADJ
njb-1	34	8	of	of	ADP
njb-1	34	9	producing	produce	VERB
njb-1	34	10	their	their	PRON
njb-1	34	11	own	own	ADJ
njb-1	34	12	lasparagine	lasparagine	NOUN
njb-1	34	13	because	because	SCONJ
njb-1	34	14	they	they	PRON
njb-1	34	15	lack	lack	VERB
njb-1	34	16	l	l	NOUN
njb-1	34	17	-	-	PUNCT
njb-1	34	18	asparaginase	asparaginase	NOUN
njb-1	34	19	synthetase	synthetase	ADJ
njb-1	34	20	enzyme	enzyme	NOUN
njb-1	34	21	.	.	PUNCT
njb-1	35	1	thus	thus	ADV
njb-1	35	2	,	,	PUNCT
njb-1	35	3	they	they	PRON
njb-1	35	4	are	be	AUX
njb-1	35	5	dependent	dependent	ADJ
njb-1	35	6	on	on	ADP
njb-1	35	7	the	the	DET
njb-1	35	8	extracellular	extracellular	ADJ
njb-1	35	9	supply	supply	NOUN
njb-1	35	10	of	of	ADP
njb-1	35	11	asparagine	asparagine	NOUN
njb-1	35	12	for	for	ADP
njb-1	35	13	their	their	PRON
njb-1	35	14	existence	existence	NOUN
njb-1	35	15	and	and	CCONJ
njb-1	35	16	reproduction	reproduction	NOUN
njb-1	35	17	.	.	PUNCT
njb-1	36	1	exogenous	exogenous	ADJ
njb-1	36	2	source	source	NOUN
njb-1	36	3	can	can	AUX
njb-1	36	4	be	be	AUX
njb-1	36	5	the	the	DET
njb-1	36	6	serum	serum	NOUN
njb-1	36	7	where	where	SCONJ
njb-1	36	8	asparagine	asparagine	NOUN
njb-1	36	9	from	from	ADP
njb-1	36	10	diet	diet	NOUN
njb-1	36	11	and	and	CCONJ
njb-1	36	12	normal	normal	ADJ
njb-1	36	13	cells	cell	NOUN
njb-1	36	14	are	be	AUX
njb-1	36	15	pooled	pool	VERB
njb-1	36	16	.	.	PUNCT
njb-1	37	1	consequently	consequently	ADV
njb-1	37	2	,	,	PUNCT
njb-1	37	3	l	l	NOUN
njb-1	37	4	-	-	PUNCT
njb-1	37	5	asparaginase	asparaginase	NOUN
njb-1	37	6	is	be	AUX
njb-1	37	7	used	use	VERB
njb-1	37	8	as	as	ADP
njb-1	37	9	a	a	DET
njb-1	37	10	therapeutic	therapeutic	ADJ
njb-1	37	11	agent	agent	NOUN
njb-1	37	12	against	against	ADP
njb-1	37	13	all	all	PRON
njb-1	37	14	.	.	PUNCT
njb-1	38	1	l	l	NOUN
njb-1	38	2	-	-	PUNCT
njb-1	38	3	asparaginase	asparaginase	NOUN
njb-1	38	4	catalyzes	catalyze	VERB
njb-1	38	5	the	the	DET
njb-1	38	6	degradation	degradation	NOUN
njb-1	38	7	of	of	ADP
njb-1	38	8	asparagine	asparagine	NOUN
njb-1	38	9	into	into	ADP
njb-1	38	10	ammonia	ammonia	NOUN
njb-1	38	11	and	and	CCONJ
njb-1	38	12	aspartate	aspartate	NOUN
njb-1	38	13	and	and	CCONJ
njb-1	38	14	depletes	deplete	VERB
njb-1	38	15	the	the	DET
njb-1	38	16	asparagine	asparagine	NOUN
njb-1	38	17	in	in	ADP
njb-1	38	18	the	the	DET
njb-1	38	19	blood	blood	NOUN
njb-1	38	20	serum	serum	NOUN
njb-1	38	21	,	,	PUNCT
njb-1	38	22	which	which	PRON
njb-1	38	23	leads	lead	VERB
njb-1	38	24	to	to	ADP
njb-1	38	25	starvation	starvation	NOUN
njb-1	38	26	of	of	ADP
njb-1	38	27	cancer	cancer	NOUN
njb-1	38	28	cells	cell	NOUN
njb-1	38	29	causing	cause	VERB
njb-1	38	30	cell	cell	NOUN
njb-1	38	31	death	death	NOUN
njb-1	38	32	[	[	PUNCT
njb-1	38	33	4	4	NUM
njb-1	38	34	]	]	PUNCT
njb-1	38	35	.	.	PUNCT
njb-1	39	1	l	l	X
njb-1	39	2	-	-	PUNCT
njb-1	39	3	asparaginase	asparaginase	NOUN
njb-1	39	4	is	be	AUX
njb-1	39	5	commercially	commercially	ADV
njb-1	39	6	extracted	extract	VERB
njb-1	39	7	mostly	mostly	ADV
njb-1	39	8	from	from	ADP
njb-1	39	9	erwinia	erwinia	PROPN
njb-1	39	10	chrysanthemi	chrysanthemi	PROPN
njb-1	39	11	and	and	CCONJ
njb-1	39	12	escherichia	escherichia	PROPN
njb-1	39	13	coli	coli	NOUN
njb-1	39	14	.	.	PUNCT
njb-1	40	1	the	the	DET
njb-1	40	2	enzyme	enzyme	NOUN
njb-1	40	3	can	can	AUX
njb-1	40	4	be	be	AUX
njb-1	40	5	used	use	VERB
njb-1	40	6	in	in	ADP
njb-1	40	7	its	its	PRON
njb-1	40	8	purified	purify	VERB
njb-1	40	9	native	native	ADJ
njb-1	40	10	state	state	NOUN
njb-1	40	11	or	or	CCONJ
njb-1	40	12	can	can	AUX
njb-1	40	13	be	be	AUX
njb-1	40	14	nepal	nepal	ADJ
njb-1	40	15	journal	journal	NOUN
njb-1	40	16	of	of	ADP
njb-1	40	17	biotechnology	biotechnology	NOUN
njb-1	40	18	publisher	publisher	NOUN
njb-1	40	19	:	:	PUNCT
njb-1	40	20	biotechnology	biotechnology	NOUN
njb-1	40	21	society	society	NOUN
njb-1	40	22	of	of	ADP
njb-1	40	23	nepal	nepal	PROPN
njb-1	40	24	issn	issn	PROPN
njb-1	40	25	(	(	PUNCT
njb-1	40	26	online	online	ADV
njb-1	40	27	):	):	PUNCT
njb-1	40	28	2467	2467	NUM
njb-1	40	29	-	-	SYM
njb-1	40	30	9313	9313	NUM
njb-1	40	31	journal	journal	NOUN
njb-1	40	32	homepage	homepage	NOUN
njb-1	40	33	:	:	PUNCT
njb-1	40	34	www.nepjol.info/index.php/njb	www.nepjol.info/index.php/njb	PROPN
njb-1	40	35	issn	issn	PROPN
njb-1	40	36	(	(	PUNCT
njb-1	40	37	print	print	NOUN
njb-1	40	38	):	):	PUNCT
njb-1	40	39	2091	2091	NUM
njb-1	40	40	-	-	SYM
njb-1	40	41	1130	1130	NUM
njb-1	40	42	https://orcid.org/0000-0002-7147-1411	https://orcid.org/0000-0002-7147-1411	NOUN
njb-1	40	43	mailto:hitesh321@gmail.com	mailto:hitesh321@gmail.com	X
njb-1	40	44	mailto:hitesh321@gmail.com	mailto:hitesh321@gmail.com	X
njb-1	40	45	nepal	nepal	ADJ
njb-1	40	46	j	j	NOUN
njb-1	40	47	biotechnol	biotechnol	PROPN
njb-1	40	48	.	.	PUNCT
njb-1	41	1	2	2	NUM
njb-1	41	2	0	0	NUM
njb-1	41	3	2	2	NUM
njb-1	41	4	1	1	NUM
njb-1	41	5	d	d	X
njb-1	41	6	e	e	X
njb-1	41	7	c	c	PROPN
njb-1	41	8	.	.	PUNCT
njb-1	42	1	9	9	NUM
njb-1	42	2	(	(	PUNCT
njb-1	42	3	2	2	NUM
njb-1	42	4	):	):	PUNCT
njb-1	42	5	39	39	NUM
njb-1	42	6	-	-	SYM
njb-1	42	7	47	47	NUM
njb-1	42	8	baral	baral	ADJ
njb-1	42	9	et	et	PROPN
njb-1	42	10	al	al	PROPN
njb-1	42	11	.	.	PUNCT
njb-1	43	1	©	©	PROPN
njb-1	43	2	njb	njb	PROPN
njb-1	43	3	,	,	PUNCT
njb-1	43	4	bsn	bsn	PROPN
njb-1	43	5	40	40	NUM
njb-1	43	6	conjugated	conjugate	VERB
njb-1	43	7	to	to	PART
njb-1	43	8	increase	increase	VERB
njb-1	43	9	its	its	PRON
njb-1	43	10	half	half	ADJ
njb-1	43	11	-	-	PUNCT
njb-1	43	12	life	life	NOUN
njb-1	43	13	.	.	PUNCT
njb-1	44	1	peg	peg	NOUN
njb-1	44	2	escherichia	escherichia	PROPN
njb-1	44	3	coli	coli	NOUN
njb-1	44	4	asparaginase	asparaginase	NOUN
njb-1	44	5	is	be	AUX
njb-1	44	6	a	a	DET
njb-1	44	7	variant	variant	NOUN
njb-1	44	8	made	make	VERB
njb-1	44	9	by	by	ADP
njb-1	44	10	conjugating	conjugate	VERB
njb-1	44	11	the	the	DET
njb-1	44	12	escherichia	escherichia	NOUN
njb-1	44	13	coli	coli	NOUN
njb-1	44	14	l	l	NOUN
njb-1	44	15	-	-	PUNCT
njb-1	44	16	asparaginase	asparaginase	NOUN
njb-1	44	17	with	with	ADP
njb-1	44	18	polyethylene	polyethylene	PROPN
njb-1	44	19	glycol	glycol	PROPN
njb-1	44	20	.	.	PUNCT
njb-1	45	1	there	there	PRON
njb-1	45	2	are	be	VERB
njb-1	45	3	many	many	ADJ
njb-1	45	4	commercially	commercially	ADV
njb-1	45	5	available	available	ADJ
njb-1	45	6	examples	example	NOUN
njb-1	45	7	of	of	ADP
njb-1	45	8	peg	peg	NOUN
njb-1	45	9	escherichia	escherichia	NOUN
njb-1	45	10	coli	coli	NOUN
njb-1	45	11	asparaginase	asparaginase	NOUN
njb-1	45	12	as	as	ADV
njb-1	45	13	well	well	ADV
njb-1	45	14	.	.	PUNCT
njb-1	46	1	usually	usually	ADV
njb-1	46	2	,	,	PUNCT
njb-1	46	3	pegasparaginase	pegasparaginase	NOUN
njb-1	46	4	can	can	AUX
njb-1	46	5	be	be	AUX
njb-1	46	6	used	use	VERB
njb-1	46	7	in	in	ADP
njb-1	46	8	lower	low	ADJ
njb-1	46	9	doses	dose	NOUN
njb-1	46	10	compared	compare	VERB
njb-1	46	11	to	to	ADP
njb-1	46	12	native	native	ADJ
njb-1	46	13	state	state	NOUN
njb-1	46	14	asparaginases	asparaginase	NOUN
njb-1	46	15	due	due	ADP
njb-1	46	16	to	to	ADP
njb-1	46	17	its	its	PRON
njb-1	46	18	greater	great	ADJ
njb-1	46	19	half	half	ADJ
njb-1	46	20	-	-	PUNCT
njb-1	46	21	life	life	NOUN
njb-1	46	22	[	[	X
njb-1	46	23	5	5	NUM
njb-1	46	24	]	]	PUNCT
njb-1	46	25	.	.	PUNCT
njb-1	47	1	some	some	DET
njb-1	47	2	people	people	NOUN
njb-1	47	3	can	can	AUX
njb-1	47	4	have	have	VERB
njb-1	47	5	allergic	allergic	ADJ
njb-1	47	6	reactions	reaction	NOUN
njb-1	47	7	to	to	ADP
njb-1	47	8	escherichia	escherichia	NOUN
njb-1	47	9	coli	coli	NOUN
njb-1	47	10	asparaginase	asparaginase	NOUN
njb-1	47	11	.	.	PUNCT
njb-1	48	1	erwinia	erwinia	PROPN
njb-1	48	2	chrysanthemi	chrysanthemi	PROPN
njb-1	48	3	asparaginase	asparaginase	PROPN
njb-1	48	4	is	be	AUX
njb-1	48	5	used	use	VERB
njb-1	48	6	as	as	ADP
njb-1	48	7	an	an	DET
njb-1	48	8	alternative	alternative	NOUN
njb-1	48	9	for	for	ADP
njb-1	48	10	these	these	DET
njb-1	48	11	cases	case	NOUN
njb-1	48	12	[	[	X
njb-1	48	13	3	3	NUM
njb-1	48	14	]	]	X
njb-1	48	15	.	.	PUNCT
njb-1	49	1	therapeutic	therapeutic	ADJ
njb-1	49	2	results	result	NOUN
njb-1	49	3	of	of	ADP
njb-1	49	4	combining	combine	VERB
njb-1	49	5	l	l	PROPN
njb-1	49	6	asparaginase	asparaginase	NOUN
njb-1	49	7	with	with	ADP
njb-1	49	8	chemotherapy	chemotherapy	NOUN
njb-1	49	9	protocols	protocol	NOUN
njb-1	49	10	have	have	AUX
njb-1	49	11	been	be	AUX
njb-1	49	12	generally	generally	ADV
njb-1	49	13	very	very	ADV
njb-1	49	14	successful	successful	ADJ
njb-1	49	15	.	.	PUNCT
njb-1	50	1	many	many	ADJ
njb-1	50	2	variations	variation	NOUN
njb-1	50	3	have	have	AUX
njb-1	50	4	been	be	AUX
njb-1	50	5	made	make	VERB
njb-1	50	6	to	to	PART
njb-1	50	7	improve	improve	VERB
njb-1	50	8	the	the	DET
njb-1	50	9	results	result	NOUN
njb-1	50	10	of	of	ADP
njb-1	50	11	these	these	DET
njb-1	50	12	therapies	therapy	NOUN
njb-1	50	13	,	,	PUNCT
njb-1	50	14	usually	usually	ADV
njb-1	50	15	centered	center	VERB
njb-1	50	16	around	around	ADP
njb-1	50	17	reducing	reduce	VERB
njb-1	50	18	enzyme	enzyme	NOUN
njb-1	50	19	related	related	ADJ
njb-1	50	20	side	side	NOUN
njb-1	50	21	effects	effect	NOUN
njb-1	50	22	that	that	PRON
njb-1	50	23	are	be	AUX
njb-1	50	24	common	common	ADJ
njb-1	50	25	in	in	ADP
njb-1	50	26	these	these	PRON
njb-1	50	27	therapies[6	therapies[6	X
njb-1	50	28	]	]	PUNCT
njb-1	50	29	.	.	PUNCT
njb-1	50	30	though	though	SCONJ
njb-1	50	31	all	all	DET
njb-1	50	32	three	three	NUM
njb-1	50	33	forms	form	NOUN
njb-1	50	34	of	of	ADP
njb-1	50	35	l	l	NOUN
njb-1	50	36	asparaginase	asparaginase	NOUN
njb-1	50	37	have	have	AUX
njb-1	50	38	been	be	AUX
njb-1	50	39	extensively	extensively	ADV
njb-1	50	40	studied	study	VERB
njb-1	50	41	for	for	ADP
njb-1	50	42	their	their	PRON
njb-1	50	43	effectiveness	effectiveness	NOUN
njb-1	50	44	and	and	CCONJ
njb-1	50	45	safety	safety	NOUN
njb-1	50	46	,	,	PUNCT
njb-1	50	47	unintended	unintended	ADJ
njb-1	50	48	enzyme	enzyme	NOUN
njb-1	50	49	-	-	PUNCT
njb-1	50	50	related	relate	VERB
njb-1	50	51	side	side	NOUN
njb-1	50	52	-	-	PUNCT
njb-1	50	53	effects	effect	NOUN
njb-1	50	54	like	like	ADP
njb-1	50	55	hypersensitivity	hypersensitivity	NOUN
njb-1	50	56	and	and	CCONJ
njb-1	50	57	allergic	allergic	ADJ
njb-1	50	58	reactions	reaction	NOUN
njb-1	50	59	abound	abound	VERB
njb-1	50	60	[	[	SYM
njb-1	50	61	7	7	NUM
njb-1	50	62	]	]	PUNCT
njb-1	50	63	.	.	PUNCT
njb-1	51	1	till	till	SCONJ
njb-1	51	2	date	date	NOUN
njb-1	51	3	,	,	PUNCT
njb-1	51	4	there	there	PRON
njb-1	51	5	has	have	AUX
njb-1	51	6	been	be	AUX
njb-1	51	7	limited	limit	VERB
njb-1	51	8	study	study	NOUN
njb-1	51	9	to	to	PART
njb-1	51	10	address	address	VERB
njb-1	51	11	the	the	DET
njb-1	51	12	efficacy	efficacy	NOUN
njb-1	51	13	and	and	CCONJ
njb-1	51	14	toxicity	toxicity	NOUN
njb-1	51	15	of	of	ADP
njb-1	51	16	different	different	ADJ
njb-1	51	17	forms	form	NOUN
njb-1	51	18	of	of	ADP
njb-1	51	19	asparaginases	asparaginase	NOUN
njb-1	51	20	available	available	ADJ
njb-1	51	21	for	for	ADP
njb-1	51	22	therapy	therapy	NOUN
njb-1	51	23	because	because	SCONJ
njb-1	51	24	of	of	ADP
njb-1	51	25	which	which	PRON
njb-1	51	26	individuals	individual	NOUN
njb-1	51	27	who	who	PRON
njb-1	51	28	are	be	AUX
njb-1	51	29	under	under	ADP
njb-1	51	30	therapy	therapy	NOUN
njb-1	51	31	are	be	AUX
njb-1	51	32	at	at	ADP
njb-1	51	33	high	high	ADJ
njb-1	51	34	risk	risk	NOUN
njb-1	51	35	.	.	PUNCT
njb-1	52	1	this	this	PRON
njb-1	52	2	creates	create	VERB
njb-1	52	3	an	an	DET
njb-1	52	4	urgent	urgent	ADJ
njb-1	52	5	need	need	NOUN
njb-1	52	6	to	to	PART
njb-1	52	7	address	address	VERB
njb-1	52	8	and	and	CCONJ
njb-1	52	9	minimize	minimize	VERB
njb-1	52	10	the	the	DET
njb-1	52	11	risk	risk	NOUN
njb-1	52	12	by	by	ADP
njb-1	52	13	providing	provide	VERB
njb-1	52	14	necessary	necessary	ADJ
njb-1	52	15	and	and	CCONJ
njb-1	52	16	relevant	relevant	ADJ
njb-1	52	17	information	information	NOUN
njb-1	52	18	on	on	ADP
njb-1	52	19	safety	safety	NOUN
njb-1	52	20	and	and	CCONJ
njb-1	52	21	fill	fill	VERB
njb-1	52	22	in	in	ADP
njb-1	52	23	the	the	DET
njb-1	52	24	research	research	NOUN
njb-1	52	25	gap	gap	NOUN
njb-1	52	26	.	.	PUNCT
njb-1	53	1	in	in	ADP
njb-1	53	2	this	this	DET
njb-1	53	3	study	study	NOUN
njb-1	53	4	,	,	PUNCT
njb-1	53	5	we	we	PRON
njb-1	53	6	have	have	AUX
njb-1	53	7	attempted	attempt	VERB
njb-1	53	8	to	to	PART
njb-1	53	9	compile	compile	VERB
njb-1	53	10	and	and	CCONJ
njb-1	53	11	examine	examine	VERB
njb-1	53	12	a	a	DET
njb-1	53	13	list	list	NOUN
njb-1	53	14	of	of	ADP
njb-1	53	15	studies	study	NOUN
njb-1	53	16	to	to	PART
njb-1	53	17	understand	understand	VERB
njb-1	53	18	efficacy	efficacy	NOUN
njb-1	53	19	,	,	PUNCT
njb-1	53	20	safety	safety	NOUN
njb-1	53	21	and	and	CCONJ
njb-1	53	22	toxicity	toxicity	NOUN
njb-1	53	23	of	of	ADP
njb-1	53	24	peg	peg	NOUN
njb-1	53	25	escherichia	escherichia	NOUN
njb-1	53	26	coli	coli	NOUN
njb-1	53	27	asparaginase	asparaginase	NOUN
njb-1	53	28	,	,	PUNCT
njb-1	53	29	erwinia	erwinia	PROPN
njb-1	53	30	chrysanthemi	chrysanthemi	PROPN
njb-1	53	31	asparaginase	asparaginase	PROPN
njb-1	53	32	,	,	PUNCT
njb-1	53	33	and	and	CCONJ
njb-1	53	34	native	native	ADJ
njb-1	53	35	escherichia	escherichia	NOUN
njb-1	53	36	coli	coli	NOUN
njb-1	53	37	asparaginase	asparaginase	NOUN
njb-1	53	38	to	to	PART
njb-1	53	39	determine	determine	VERB
njb-1	53	40	if	if	SCONJ
njb-1	53	41	there	there	PRON
njb-1	53	42	is	be	VERB
njb-1	53	43	a	a	DET
njb-1	53	44	need	need	NOUN
njb-1	53	45	for	for	ADP
njb-1	53	46	an	an	DET
njb-1	53	47	alternative	alternative	ADJ
njb-1	53	48	source	source	NOUN
njb-1	53	49	of	of	ADP
njb-1	53	50	asparaginase	asparaginase	NOUN
njb-1	53	51	to	to	PART
njb-1	53	52	reduce	reduce	VERB
njb-1	53	53	these	these	DET
njb-1	53	54	unwanted	unwanted	ADJ
njb-1	53	55	side	side	NOUN
njb-1	53	56	effects	effect	NOUN
njb-1	53	57	.	.	PUNCT
njb-1	54	1	asparagine	asparagine	ADJ
njb-1	54	2	concentration	concentration	NOUN
njb-1	54	3	:	:	PUNCT
njb-1	54	4	ogawa	ogawa	PROPN
njb-1	54	5	et	et	PROPN
njb-1	54	6	al	al	PROPN
njb-1	54	7	.	.	PROPN
njb-1	54	8	reported	report	VERB
njb-1	54	9	that	that	SCONJ
njb-1	54	10	the	the	DET
njb-1	54	11	average	average	ADJ
njb-1	54	12	plasma	plasma	NOUN
njb-1	54	13	asparagine	asparagine	NOUN
njb-1	54	14	concentration	concentration	NOUN
njb-1	54	15	of	of	ADP
njb-1	54	16	patients	patient	NOUN
njb-1	54	17	treated	treat	VERB
njb-1	54	18	with	with	ADP
njb-1	54	19	e.	e.	PROPN
njb-1	54	20	chrysanthemi	chrysanthemi	PROPN
njb-1	54	21	asparaginase	asparaginase	PROPN
njb-1	54	22	was	be	AUX
njb-1	54	23	0.218	0.218	NUM
njb-1	54	24	𝝁m	𝝁m	PRON
njb-1	55	1	[	[	X
njb-1	55	2	8	8	NUM
njb-1	55	3	]	]	PUNCT
njb-1	55	4	.	.	PUNCT
njb-1	56	1	concentration	concentration	NOUN
njb-1	56	2	of	of	ADP
njb-1	56	3	<	<	X
njb-1	56	4	0.5	0.5	NUM
njb-1	56	5	𝝁m	𝝁m	PROPN
njb-1	56	6	is	be	AUX
njb-1	56	7	considered	consider	VERB
njb-1	56	8	as	as	ADP
njb-1	56	9	complete	complete	ADJ
njb-1	56	10	depletion	depletion	NOUN
njb-1	56	11	of	of	ADP
njb-1	56	12	asparagine	asparagine	NOUN
njb-1	56	13	from	from	ADP
njb-1	56	14	the	the	DET
njb-1	56	15	blood	blood	NOUN
njb-1	56	16	[	[	X
njb-1	56	17	9	9	NUM
njb-1	56	18	]	]	PUNCT
njb-1	56	19	.	.	PUNCT
njb-1	57	1	van	van	PROPN
njb-1	57	2	der	der	PROPN
njb-1	57	3	sluis	sluis	PROPN
njb-1	57	4	et	et	PROPN
njb-1	57	5	al	al	PROPN
njb-1	57	6	reported	report	VERB
njb-1	57	7	that	that	SCONJ
njb-1	57	8	complete	complete	ADJ
njb-1	57	9	depletion	depletion	NOUN
njb-1	57	10	of	of	ADP
njb-1	57	11	asparagine	asparagine	NOUN
njb-1	57	12	was	be	AUX
njb-1	57	13	seen	see	VERB
njb-1	57	14	in	in	ADP
njb-1	57	15	97.8	97.8	NUM
njb-1	57	16	%	%	NOUN
njb-1	57	17	of	of	ADP
njb-1	57	18	patients	patient	NOUN
njb-1	57	19	treated	treat	VERB
njb-1	57	20	with	with	ADP
njb-1	57	21	recombinant	recombinant	ADJ
njb-1	57	22	asparaginase	asparaginase	NOUN
njb-1	57	23	and	and	CCONJ
njb-1	57	24	97.9	97.9	NUM
njb-1	57	25	%	%	NOUN
njb-1	57	26	of	of	ADP
njb-1	57	27	patients	patient	NOUN
njb-1	57	28	treated	treat	VERB
njb-1	57	29	with	with	ADP
njb-1	57	30	native	native	PROPN
njb-1	57	31	e.	e.	PROPN
njb-1	57	32	coli	coli	PROPN
njb-1	57	33	asparaginase	asparaginase	NOUN
njb-1	57	34	[	[	PUNCT
njb-1	57	35	10	10	NUM
njb-1	57	36	]	]	PUNCT
njb-1	57	37	.	.	PUNCT
njb-1	58	1	likewise	likewise	ADV
njb-1	58	2	,	,	PUNCT
njb-1	58	3	pieters	pieter	NOUN
njb-1	58	4	et	et	PROPN
njb-1	58	5	al	al	PROPN
njb-1	58	6	.	.	PROPN
njb-1	58	7	claimed	claim	VERB
njb-1	58	8	that	that	SCONJ
njb-1	58	9	the	the	DET
njb-1	58	10	mean	mean	ADJ
njb-1	58	11	asparagine	asparagine	NOUN
njb-1	58	12	concentration	concentration	NOUN
njb-1	58	13	dropped	drop	VERB
njb-1	58	14	to	to	ADP
njb-1	58	15	0.5	0.5	NUM
njb-1	58	16	µm	µm	NOUN
njb-1	58	17	under	under	ADP
njb-1	58	18	both	both	DET
njb-1	58	19	recombinant	recombinant	ADJ
njb-1	58	20	e.	e.	PROPN
njb-1	58	21	coli	coli	PROPN
njb-1	58	22	asparaginase	asparaginase	NOUN
njb-1	58	23	and	and	CCONJ
njb-1	58	24	native	native	PROPN
njb-1	58	25	e.	e.	PROPN
njb-1	58	26	coli	coli	PROPN
njb-1	58	27	asparaginase	asparaginase	NOUN
njb-1	58	28	in	in	ADP
njb-1	58	29	99	99	NUM
njb-1	58	30	%	%	NOUN
njb-1	58	31	of	of	ADP
njb-1	58	32	patients	patient	NOUN
njb-1	58	33	[	[	PUNCT
njb-1	58	34	11	11	NUM
njb-1	58	35	]	]	PUNCT
njb-1	58	36	.	.	PUNCT
njb-1	59	1	in	in	ADP
njb-1	59	2	another	another	DET
njb-1	59	3	study	study	NOUN
njb-1	59	4	by	by	ADP
njb-1	59	5	van	van	PROPN
njb-1	59	6	der	der	PROPN
njb-1	59	7	sluis	sluis	PROPN
njb-1	59	8	et	et	X
njb-1	59	9	al	al	PROPN
njb-1	59	10	.	.	PUNCT
njb-1	60	1	the	the	DET
njb-1	60	2	mean	mean	ADJ
njb-1	60	3	asparagine	asparagine	NOUN
njb-1	60	4	concentration	concentration	NOUN
njb-1	60	5	dropped	drop	VERB
njb-1	60	6	to	to	ADP
njb-1	60	7	<	<	X
njb-1	60	8	0.5	0.5	NUM
njb-1	60	9	𝝁m	𝝁m	NOUN
njb-1	60	10	in	in	ADP
njb-1	60	11	all	all	DET
njb-1	60	12	patients	patient	NOUN
njb-1	60	13	at	at	ADP
njb-1	60	14	all	all	DET
njb-1	60	15	time	time	NOUN
njb-1	60	16	points	point	NOUN
njb-1	60	17	measured	measure	VERB
njb-1	60	18	with	with	ADP
njb-1	60	19	recombinant	recombinant	ADJ
njb-1	60	20	e.	e.	PROPN
njb-1	60	21	coli	coli	PROPN
njb-1	60	22	asparaginase[12	asparaginase[12	NOUN
njb-1	60	23	]	]	PUNCT
njb-1	60	24	.	.	PUNCT
njb-1	61	1	in	in	ADP
njb-1	61	2	a	a	DET
njb-1	61	3	comparison	comparison	NOUN
njb-1	61	4	done	do	VERB
njb-1	61	5	between	between	ADP
njb-1	61	6	intermittent	intermittent	ADJ
njb-1	61	7	and	and	CCONJ
njb-1	61	8	continuous	continuous	ADJ
njb-1	61	9	routes	route	NOUN
njb-1	61	10	of	of	ADP
njb-1	61	11	peg	peg	PROPN
njb-1	61	12	e.	e.	PROPN
njb-1	61	13	coli	coli	PROPN
njb-1	61	14	asparaginase	asparaginase	NOUN
njb-1	61	15	among	among	ADP
njb-1	61	16	625	625	NUM
njb-1	61	17	children	child	NOUN
njb-1	61	18	of	of	ADP
njb-1	61	19	europe	europe	PROPN
njb-1	61	20	,	,	PUNCT
njb-1	61	21	it	it	PRON
njb-1	61	22	was	be	AUX
njb-1	61	23	found	find	VERB
njb-1	61	24	that	that	SCONJ
njb-1	61	25	95	95	NUM
njb-1	61	26	%	%	NOUN
njb-1	61	27	of	of	ADP
njb-1	61	28	patients	patient	NOUN
njb-1	61	29	were	be	AUX
njb-1	61	30	asparagine	asparagine	NOUN
njb-1	61	31	depleted	deplete	VERB
njb-1	61	32	during	during	ADP
njb-1	61	33	treatment	treatment	NOUN
njb-1	61	34	[	[	PUNCT
njb-1	61	35	13	13	NUM
njb-1	61	36	]	]	PUNCT
njb-1	61	37	.	.	PUNCT
njb-1	62	1	in	in	ADP
njb-1	62	2	2011	2011	NUM
njb-1	62	3	,	,	PUNCT
njb-1	62	4	a	a	DET
njb-1	62	5	study	study	NOUN
njb-1	62	6	conducted	conduct	VERB
njb-1	62	7	to	to	PART
njb-1	62	8	demonstrate	demonstrate	VERB
njb-1	62	9	peg	peg	NOUN
njb-1	62	10	e.	e.	PROPN
njb-1	62	11	coli	coli	PROPN
njb-1	62	12	asparaginase	asparaginase	NOUN
njb-1	62	13	as	as	ADP
njb-1	62	14	a	a	DET
njb-1	62	15	viable	viable	ADJ
njb-1	62	16	alternative	alternative	NOUN
njb-1	62	17	in	in	ADP
njb-1	62	18	patients	patient	NOUN
njb-1	62	19	that	that	PRON
njb-1	62	20	have	have	AUX
njb-1	62	21	shown	show	VERB
njb-1	62	22	allergic	allergic	ADJ
njb-1	62	23	reactions	reaction	NOUN
njb-1	62	24	to	to	ADP
njb-1	62	25	treatments	treatment	NOUN
njb-1	62	26	using	use	VERB
njb-1	62	27	native	native	PROPN
njb-1	62	28	e.	e.	PROPN
njb-1	62	29	coli	coli	PROPN
njb-1	62	30	asparaginase	asparaginase	NOUN
njb-1	62	31	,	,	PUNCT
njb-1	62	32	it	it	PRON
njb-1	62	33	was	be	AUX
njb-1	62	34	found	find	VERB
njb-1	62	35	that	that	SCONJ
njb-1	62	36	asparagine	asparagine	ADJ
njb-1	62	37	level	level	NOUN
njb-1	62	38	depleted	deplete	VERB
njb-1	62	39	to	to	ADP
njb-1	62	40	40	40	NUM
njb-1	62	41	%	%	NOUN
njb-1	62	42	and	and	CCONJ
njb-1	62	43	20	20	NUM
njb-1	62	44	%	%	NOUN
njb-1	62	45	at	at	ADP
njb-1	62	46	day	day	NOUN
njb-1	62	47	7	7	NUM
njb-1	62	48	and	and	CCONJ
njb-1	62	49	day	day	NOUN
njb-1	62	50	14	14	NUM
njb-1	62	51	respectively	respectively	ADV
njb-1	62	52	for	for	ADP
njb-1	62	53	hypersensitive	hypersensitive	ADJ
njb-1	62	54	patients	patient	NOUN
njb-1	62	55	using	use	VERB
njb-1	62	56	peg	peg	NOUN
njb-1	62	57	asparaginase	asparaginase	NOUN
njb-1	62	58	.	.	PUNCT
njb-1	63	1	similarly	similarly	ADV
njb-1	63	2	for	for	ADP
njb-1	63	3	non	non	ADJ
njb-1	63	4	-	-	ADJ
njb-1	63	5	hypersensitive	hypersensitive	ADJ
njb-1	63	6	patients	patient	NOUN
njb-1	63	7	,	,	PUNCT
njb-1	63	8	it	it	PRON
njb-1	63	9	was	be	AUX
njb-1	63	10	depleted	deplete	VERB
njb-1	63	11	to	to	ADP
njb-1	63	12	50	50	NUM
njb-1	63	13	%	%	NOUN
njb-1	63	14	at	at	ADP
njb-1	63	15	day	day	NOUN
njb-1	63	16	14	14	NUM
njb-1	63	17	but	but	CCONJ
njb-1	63	18	while	while	SCONJ
njb-1	63	19	using	use	VERB
njb-1	63	20	native	native	PROPN
njb-1	63	21	e.	e.	PROPN
njb-1	63	22	coli	coli	PROPN
njb-1	63	23	asparaginase	asparaginase	NOUN
njb-1	63	24	it	it	PRON
njb-1	63	25	was	be	AUX
njb-1	63	26	depleted	deplete	VERB
njb-1	63	27	to	to	ADP
njb-1	63	28	only	only	ADV
njb-1	63	29	86	86	NUM
njb-1	63	30	%	%	NOUN
njb-1	63	31	on	on	ADP
njb-1	63	32	day	day	NOUN
njb-1	63	33	14	14	NUM
njb-1	64	1	[	[	PUNCT
njb-1	64	2	14	14	NUM
njb-1	64	3	]	]	PUNCT
njb-1	64	4	.	.	PUNCT
njb-1	65	1	26	26	NUM
njb-1	65	2	%	%	NOUN
njb-1	65	3	of	of	ADP
njb-1	65	4	patients	patient	NOUN
njb-1	65	5	receiving	receive	VERB
njb-1	65	6	e.	e.	PROPN
njb-1	65	7	chrysanthemi	chrysanthemi	PROPN
njb-1	65	8	asparaginase	asparaginase	PROPN
njb-1	65	9	showed	show	VERB
njb-1	65	10	asparagine	asparagine	NOUN
njb-1	65	11	depletion	depletion	NOUN
njb-1	65	12	during	during	ADP
njb-1	65	13	reinduction	reinduction	NOUN
njb-1	65	14	.	.	PUNCT
njb-1	66	1	with	with	ADP
njb-1	66	2	e.	e.	PROPN
njb-1	66	3	coli	coli	PROPN
njb-1	66	4	asparaginase	asparaginase	NOUN
njb-1	66	5	receiving	receive	VERB
njb-1	66	6	patients	patient	NOUN
njb-1	66	7	,	,	PUNCT
njb-1	66	8	asparagine	asparagine	ADJ
njb-1	66	9	depletion	depletion	NOUN
njb-1	66	10	was	be	AUX
njb-1	66	11	seen	see	VERB
njb-1	66	12	in	in	ADP
njb-1	66	13	60	60	NUM
njb-1	66	14	%	%	NOUN
njb-1	66	15	to	to	PART
njb-1	66	16	90	90	NUM
njb-1	66	17	%	%	NOUN
njb-1	66	18	during	during	ADP
njb-1	66	19	the	the	DET
njb-1	66	20	re	re	NOUN
njb-1	66	21	-	-	NOUN
njb-1	66	22	induction	induction	ADJ
njb-1	66	23	phase	phase	NOUN
njb-1	66	24	.	.	PUNCT
njb-1	67	1	serum	serum	NOUN
njb-1	67	2	asparagine	asparagine	ADJ
njb-1	67	3	levels	level	NOUN
njb-1	67	4	recovered	recover	VERB
njb-1	67	5	after	after	ADP
njb-1	67	6	4	4	NUM
njb-1	67	7	days	day	NOUN
njb-1	67	8	for	for	ADP
njb-1	67	9	patients	patient	NOUN
njb-1	67	10	administered	administer	VERB
njb-1	67	11	with	with	ADP
njb-1	67	12	e.	e.	PROPN
njb-1	67	13	chrysanthemi	chrysanthemi	PROPN
njb-1	67	14	asparaginase	asparaginase	PROPN
njb-1	67	15	compared	compare	VERB
njb-1	67	16	to	to	ADP
njb-1	67	17	11	11	NUM
njb-1	67	18	days	day	NOUN
njb-1	67	19	for	for	ADP
njb-1	67	20	e.	e.	PROPN
njb-1	67	21	coli	coli	PROPN
njb-1	67	22	asparaginase	asparaginase	NOUN
njb-1	67	23	[	[	PUNCT
njb-1	67	24	15	15	NUM
njb-1	67	25	]	]	PUNCT
njb-1	67	26	(	(	PUNCT
njb-1	67	27	table	table	NOUN
njb-1	67	28	1	1	NUM
njb-1	67	29	)	)	PUNCT
njb-1	67	30	.	.	PUNCT
njb-1	68	1	table	table	NOUN
njb-1	68	2	1	1	NUM
njb-1	68	3	.	.	PUNCT
njb-1	69	1	average	average	ADJ
njb-1	69	2	asparagine	asparagine	ADJ
njb-1	69	3	concentration	concentration	NOUN
njb-1	69	4	in	in	ADP
njb-1	69	5	treated	treat	VERB
njb-1	69	6	patients	patient	NOUN
njb-1	69	7	from	from	ADP
njb-1	69	8	individual	individual	ADJ
njb-1	69	9	trials	trial	NOUN
njb-1	69	10	clinical	clinical	ADJ
njb-1	69	11	trial	trial	NOUN
njb-1	69	12	type	type	NOUN
njb-1	69	13	of	of	ADP
njb-1	69	14	asparaginase	asparaginase	NOUN
njb-1	69	15	average	average	ADJ
njb-1	69	16	concentration(𝝁m	concentration(𝝁m	PROPN
njb-1	69	17	)	)	PUNCT
njb-1	70	1	[	[	PUNCT
njb-1	70	2	8	8	NUM
njb-1	70	3	]	]	PUNCT
njb-1	70	4	erwinia	erwinia	PROPN
njb-1	70	5	chrysanthemi	chrysanthemi	PROPN
njb-1	70	6	0.218	0.218	NUM
njb-1	71	1	[	[	PUNCT
njb-1	71	2	16	16	NUM
njb-1	71	3	]	]	PUNCT
njb-1	71	4	native	native	ADJ
njb-1	71	5	escherichia	escherichia	NOUN
njb-1	71	6	coli	coli	NOUN
njb-1	71	7	0.13	0.13	NUM
njb-1	72	1	[	[	PUNCT
njb-1	72	2	10	10	NUM
njb-1	72	3	]	]	PUNCT
njb-1	72	4	native	native	ADJ
njb-1	72	5	escherichia	escherichia	NOUN
njb-1	72	6	coli	coli	NOUN
njb-1	72	7	(	(	PUNCT
njb-1	72	8	asparaginase	asparaginase	NOUN
njb-1	72	9	medac	medac	PROPN
njb-1	72	10	)	)	PUNCT
njb-1	72	11	<	<	X
njb-1	72	12	0.5	0.5	NUM
njb-1	72	13	[	[	PUNCT
njb-1	72	14	10	10	NUM
njb-1	72	15	]	]	PUNCT
njb-1	72	16	recombinant	recombinant	ADJ
njb-1	72	17	escherichia	escherichia	NOUN
njb-1	72	18	coli	coli	NOUN
njb-1	72	19	<	<	X
njb-1	72	20	0.5	0.5	NUM
njb-1	72	21	[	[	PUNCT
njb-1	72	22	17	17	NUM
njb-1	72	23	]	]	PUNCT
njb-1	72	24	native	native	ADJ
njb-1	72	25	escherichia	escherichia	NOUN
njb-1	72	26	coli	coli	NOUN
njb-1	72	27	(	(	PUNCT
njb-1	72	28	asparaginase	asparaginase	NOUN
njb-1	72	29	medac	medac	PROPN
njb-1	72	30	)	)	PUNCT
njb-1	72	31	<	<	X
njb-1	72	32	0.5	0.5	NUM
njb-1	72	33	[	[	PUNCT
njb-1	72	34	17	17	NUM
njb-1	72	35	]	]	PUNCT
njb-1	72	36	recombinant	recombinant	ADJ
njb-1	72	37	escherichia	escherichia	NOUN
njb-1	72	38	coli	coli	NOUN
njb-1	72	39	<	<	X
njb-1	72	40	0.5	0.5	NUM
njb-1	72	41	[	[	PUNCT
njb-1	72	42	12	12	NUM
njb-1	72	43	]	]	PUNCT
njb-1	72	44	recombinant	recombinant	ADJ
njb-1	72	45	escherichia	escherichia	NOUN
njb-1	72	46	coli	coli	NOUN
njb-1	72	47	<	<	X
njb-1	72	48	0.5	0.5	NUM
njb-1	72	49	[	[	PUNCT
njb-1	72	50	13	13	NUM
njb-1	72	51	]	]	X
njb-1	72	52	peg	peg	NOUN
njb-1	72	53	escherichia	escherichia	NOUN
njb-1	72	54	coli	coli	NOUN
njb-1	72	55	<	<	X
njb-1	72	56	0.5	0.5	NUM
njb-1	72	57	[	[	PUNCT
njb-1	72	58	14	14	NUM
njb-1	72	59	]	]	PUNCT
njb-1	72	60	native	native	ADJ
njb-1	72	61	escherichia	escherichia	PROPN
njb-1	72	62	coli	coli	PROPN
njb-1	72	63	<	<	X
njb-1	72	64	0.5	0.5	NUM
njb-1	72	65	asparaginase	asparaginase	NOUN
njb-1	72	66	activity	activity	NOUN
njb-1	72	67	:	:	PUNCT
njb-1	73	1	measurement	measurement	NOUN
njb-1	73	2	of	of	ADP
njb-1	73	3	asparaginase	asparaginase	NOUN
njb-1	73	4	concentration	concentration	NOUN
njb-1	73	5	during	during	ADP
njb-1	73	6	the	the	DET
njb-1	73	7	therapy	therapy	NOUN
njb-1	73	8	has	have	VERB
njb-1	73	9	lots	lot	NOUN
njb-1	73	10	of	of	ADP
njb-1	73	11	technical	technical	ADJ
njb-1	73	12	limitations	limitation	NOUN
njb-1	73	13	,	,	PUNCT
njb-1	73	14	which	which	PRON
njb-1	73	15	is	be	AUX
njb-1	73	16	why	why	SCONJ
njb-1	73	17	asparaginase	asparaginase	NOUN
njb-1	73	18	-	-	PUNCT
njb-1	73	19	enzyme	enzyme	NOUN
njb-1	73	20	activity	activity	NOUN
njb-1	73	21	is	be	AUX
njb-1	73	22	generally	generally	ADV
njb-1	73	23	used	use	VERB
njb-1	73	24	to	to	PART
njb-1	73	25	monitor	monitor	VERB
njb-1	73	26	asparaginase	asparaginase	NOUN
njb-1	73	27	.	.	PUNCT
njb-1	74	1	as	as	ADP
njb-1	74	2	per	per	ADP
njb-1	74	3	u.s	u.s	PROPN
njb-1	74	4	fda	fda	PROPN
njb-1	74	5	,	,	PUNCT
njb-1	74	6	effective	effective	ADJ
njb-1	74	7	plasma	plasma	NOUN
njb-1	74	8	level	level	NOUN
njb-1	74	9	of	of	ADP
njb-1	74	10	asparaginase	asparaginase	NOUN
njb-1	74	11	was	be	AUX
njb-1	74	12	defined	define	VERB
njb-1	74	13	as	as	ADP
njb-1	74	14	≥	≥	NOUN
njb-1	74	15	0.1	0.1	NUM
njb-1	74	16	iu	iu	PROPN
njb-1	74	17	/	/	SYM
njb-1	74	18	ml	ml	PROPN
njb-1	74	19	and	and	CCONJ
njb-1	74	20	used	use	VERB
njb-1	74	21	for	for	ADP
njb-1	74	22	determination	determination	NOUN
njb-1	74	23	of	of	ADP
njb-1	74	24	efficacy	efficacy	NOUN
njb-1	74	25	in	in	ADP
njb-1	74	26	the	the	DET
njb-1	74	27	approval	approval	NOUN
njb-1	74	28	process	process	NOUN
njb-1	74	29	for	for	ADP
njb-1	74	30	asparaginase	asparaginase	NOUN
njb-1	74	31	[	[	PUNCT
njb-1	74	32	18	18	NUM
njb-1	74	33	]	]	PUNCT
njb-1	74	34	.	.	PUNCT
njb-1	75	1	ogawa	ogawa	PROPN
njb-1	75	2	et	et	PROPN
njb-1	75	3	al	al	PROPN
njb-1	75	4	.	.	PROPN
njb-1	75	5	reported	report	VERB
njb-1	75	6	that	that	SCONJ
njb-1	75	7	the	the	DET
njb-1	75	8	average	average	ADJ
njb-1	75	9	activity	activity	NOUN
njb-1	75	10	of	of	ADP
njb-1	75	11	e.	e.	PROPN
njb-1	75	12	chrysanthemi	chrysanthemi	PROPN
njb-1	75	13	asparaginase	asparaginase	PROPN
njb-1	75	14	in	in	ADP
njb-1	75	15	treated	treat	VERB
njb-1	75	16	patients	patient	NOUN
njb-1	75	17	throughout	throughout	ADP
njb-1	75	18	the	the	DET
njb-1	75	19	study	study	NOUN
njb-1	75	20	was	be	AUX
njb-1	75	21	0.36	0.36	NUM
njb-1	75	22	iu	iu	PROPN
njb-1	75	23	/	/	SYM
njb-1	75	24	ml	ml	PROPN
njb-1	75	25	,	,	PUNCT
njb-1	75	26	which	which	PRON
njb-1	75	27	was	be	AUX
njb-1	75	28	much	much	ADV
njb-1	75	29	higher	high	ADJ
njb-1	75	30	than	than	ADP
njb-1	75	31	the	the	DET
njb-1	75	32	therapeutic	therapeutic	ADJ
njb-1	75	33	level	level	NOUN
njb-1	75	34	of	of	ADP
njb-1	75	35	asparaginase	asparaginase	NOUN
njb-1	75	36	[	[	PUNCT
njb-1	75	37	8	8	NUM
njb-1	75	38	]	]	PUNCT
njb-1	75	39	.	.	PUNCT
njb-1	76	1	all	all	DET
njb-1	76	2	the	the	DET
njb-1	76	3	treated	treat	VERB
njb-1	76	4	patients	patient	NOUN
njb-1	76	5	in	in	ADP
njb-1	76	6	their	their	PRON
njb-1	76	7	study	study	NOUN
njb-1	76	8	achieved	achieve	VERB
njb-1	76	9	a	a	DET
njb-1	76	10	therapeutic	therapeutic	ADJ
njb-1	76	11	level	level	NOUN
njb-1	76	12	of	of	ADP
njb-1	76	13	asparaginase	asparaginase	NOUN
njb-1	76	14	.	.	PUNCT
njb-1	77	1	likewise	likewise	ADV
njb-1	77	2	,	,	PUNCT
njb-1	77	3	vyas	vyas	PROPN
njb-1	77	4	et	et	PROPN
njb-1	77	5	al	al	PROPN
njb-1	77	6	.	.	PROPN
njb-1	77	7	noted	note	VERB
njb-1	77	8	in	in	ADP
njb-1	77	9	patients	patient	NOUN
njb-1	77	10	treated	treat	VERB
njb-1	77	11	with	with	ADP
njb-1	77	12	native	native	PROPN
njb-1	77	13	e.	e.	PROPN
njb-1	77	14	coli	coli	PROPN
njb-1	77	15	nepal	nepal	PROPN
njb-1	77	16	j	j	PROPN
njb-1	77	17	biotechnol	biotechnol	PROPN
njb-1	77	18	.	.	PUNCT
njb-1	78	1	2	2	NUM
njb-1	78	2	0	0	NUM
njb-1	78	3	2	2	NUM
njb-1	78	4	1	1	NUM
njb-1	78	5	d	d	X
njb-1	78	6	e	e	X
njb-1	78	7	c	c	PROPN
njb-1	78	8	.	.	PUNCT
njb-1	79	1	9	9	NUM
njb-1	79	2	(	(	PUNCT
njb-1	79	3	2	2	NUM
njb-1	79	4	):	):	PUNCT
njb-1	79	5	39	39	NUM
njb-1	79	6	-	-	SYM
njb-1	79	7	47	47	NUM
njb-1	79	8	baral	baral	ADJ
njb-1	79	9	et	et	PROPN
njb-1	79	10	al	al	PROPN
njb-1	79	11	.	.	PUNCT
njb-1	80	1	©	©	PROPN
njb-1	80	2	njb	njb	PROPN
njb-1	80	3	,	,	PUNCT
njb-1	80	4	bsn	bsn	PROPN
njb-1	80	5	41	41	NUM
njb-1	80	6	asparaginase	asparaginase	NOUN
njb-1	80	7	and	and	CCONJ
njb-1	80	8	peg	peg	PROPN
njb-1	80	9	e.	e.	PROPN
njb-1	80	10	coli	coli	PROPN
njb-1	80	11	asparaginase	asparaginase	NOUN
njb-1	80	12	,	,	PUNCT
njb-1	80	13	the	the	DET
njb-1	80	14	activity	activity	NOUN
njb-1	80	15	of	of	ADP
njb-1	80	16	the	the	DET
njb-1	80	17	enzymes	enzyme	NOUN
njb-1	80	18	were	be	AUX
njb-1	80	19	0.13	0.13	NUM
njb-1	80	20	iu	iu	NOUN
njb-1	80	21	/	/	SYM
njb-1	80	22	ml	ml	PROPN
njb-1	80	23	for	for	ADP
njb-1	80	24	native	native	PROPN
njb-1	80	25	e.	e.	PROPN
njb-1	80	26	coli	coli	PROPN
njb-1	80	27	asparaginase	asparaginase	NOUN
njb-1	80	28	and	and	CCONJ
njb-1	80	29	0.30	0.30	NUM
njb-1	80	30	iu	iu	NOUN
njb-1	80	31	/	/	SYM
njb-1	80	32	ml	ml	PROPN
njb-1	80	33	for	for	ADP
njb-1	80	34	peg	peg	PROPN
njb-1	80	35	e.	e.	PROPN
njb-1	80	36	coli	coli	PROPN
njb-1	80	37	asparaginase	asparaginase	NOUN
njb-1	80	38	with	with	ADP
njb-1	80	39	86	86	NUM
njb-1	80	40	%	%	NOUN
njb-1	80	41	in	in	ADP
njb-1	80	42	the	the	DET
njb-1	80	43	native	native	PROPN
njb-1	80	44	e.	e.	PROPN
njb-1	80	45	coli	coli	PROPN
njb-1	80	46	group	group	NOUN
njb-1	80	47	and	and	CCONJ
njb-1	80	48	94	94	NUM
njb-1	80	49	%	%	NOUN
njb-1	80	50	generic	generic	ADJ
njb-1	80	51	peg	peg	PROPN
njb-1	80	52	e.	e.	PROPN
njb-1	80	53	coli	coli	PROPN
njb-1	80	54	group	group	NOUN
njb-1	80	55	achieving	achieve	VERB
njb-1	80	56	a	a	DET
njb-1	80	57	therapeutic	therapeutic	ADJ
njb-1	80	58	level	level	NOUN
njb-1	80	59	of	of	ADP
njb-1	80	60	asparaginase	asparaginase	NOUN
njb-1	80	61	[	[	PUNCT
njb-1	80	62	16	16	NUM
njb-1	80	63	]	]	PUNCT
njb-1	80	64	.	.	PUNCT
njb-1	81	1	in	in	ADP
njb-1	81	2	case	case	NOUN
njb-1	81	3	of	of	ADP
njb-1	81	4	recombinant	recombinant	ADJ
njb-1	81	5	escherichia	escherichia	NOUN
njb-1	81	6	coli	coli	NOUN
njb-1	81	7	asparaginase	asparaginase	NOUN
njb-1	81	8	,	,	PUNCT
njb-1	81	9	van	van	PROPN
njb-1	81	10	der	der	PROPN
njb-1	81	11	sluis	sluis	PROPN
njb-1	81	12	et	et	PROPN
njb-1	81	13	al	al	PROPN
njb-1	81	14	.	.	PROPN
njb-1	81	15	reported	report	VERB
njb-1	81	16	that	that	SCONJ
njb-1	81	17	the	the	DET
njb-1	81	18	average	average	ADJ
njb-1	81	19	asparaginase	asparaginase	NOUN
njb-1	81	20	activity	activity	NOUN
njb-1	81	21	was	be	AUX
njb-1	81	22	0.17	0.17	NUM
njb-1	81	23	iu	iu	NOUN
njb-1	81	24	/	/	SYM
njb-1	81	25	ml	ml	NOUN
njb-1	81	26	with	with	ADP
njb-1	81	27	62.2	62.2	NUM
njb-1	81	28	%	%	NOUN
njb-1	81	29	of	of	ADP
njb-1	81	30	patients	patient	NOUN
njb-1	81	31	achieving	achieve	VERB
njb-1	81	32	the	the	DET
njb-1	81	33	therapeutic	therapeutic	ADJ
njb-1	81	34	level	level	NOUN
njb-1	81	35	of	of	ADP
njb-1	81	36	asparaginase	asparaginase	NOUN
njb-1	81	37	and	and	CCONJ
njb-1	81	38	in	in	ADP
njb-1	81	39	native	native	PROPN
njb-1	81	40	e.	e.	PROPN
njb-1	81	41	coli	coli	PROPN
njb-1	81	42	asparaginase	asparaginase	NOUN
njb-1	81	43	average	average	ADJ
njb-1	81	44	asparaginase	asparaginase	NOUN
njb-1	81	45	activity	activity	NOUN
njb-1	81	46	was	be	AUX
njb-1	81	47	0.16	0.16	NUM
njb-1	81	48	iu	iu	NOUN
njb-1	81	49	/	/	SYM
njb-1	81	50	ml	ml	X
njb-1	81	51	with	with	ADP
njb-1	81	52	65.9	65.9	NUM
njb-1	81	53	%	%	NOUN
njb-1	81	54	patients	patient	NOUN
njb-1	81	55	achieving	achieve	VERB
njb-1	81	56	the	the	DET
njb-1	81	57	therapeutic	therapeutic	ADJ
njb-1	81	58	level	level	NOUN
njb-1	81	59	of	of	ADP
njb-1	81	60	asparaginase	asparaginase	NOUN
njb-1	81	61	[	[	PUNCT
njb-1	81	62	10	10	NUM
njb-1	81	63	]	]	PUNCT
njb-1	81	64	.	.	PUNCT
njb-1	82	1	similarly	similarly	ADV
njb-1	82	2	,	,	PUNCT
njb-1	82	3	place	place	PROPN
njb-1	82	4	et	et	PROPN
njb-1	82	5	al	al	PROPN
njb-1	82	6	.	.	PROPN
njb-1	83	1	claimed	claim	VERB
njb-1	83	2	that	that	SCONJ
njb-1	83	3	peg	peg	PROPN
njb-1	83	4	e.	e.	PROPN
njb-1	83	5	coli	coli	PROPN
njb-1	83	6	asparaginase	asparaginase	NOUN
njb-1	83	7	activity	activity	NOUN
njb-1	83	8	was	be	AUX
njb-1	83	9	around	around	ADV
njb-1	83	10	0.7	0.7	NUM
njb-1	83	11	iu	iu	NOUN
njb-1	83	12	/	/	SYM
njb-1	83	13	ml	ml	PROPN
njb-1	83	14	is	be	AUX
njb-1	83	15	treated	treat	VERB
njb-1	83	16	patients	patient	NOUN
njb-1	83	17	and	and	CCONJ
njb-1	83	18	native	native	PROPN
njb-1	83	19	e.	e.	PROPN
njb-1	83	20	coli	coli	PROPN
njb-1	83	21	asparaginase	asparaginase	NOUN
njb-1	83	22	activity	activity	NOUN
njb-1	83	23	was	be	AUX
njb-1	83	24	around	around	ADP
njb-1	83	25	0.1	0.1	NUM
njb-1	83	26	-	-	SYM
njb-1	83	27	0.2	0.2	NUM
njb-1	83	28	iu	iu	NOUN
njb-1	83	29	/	/	SYM
njb-1	83	30	ml[19	ml[19	NOUN
njb-1	83	31	]	]	PUNCT
njb-1	83	32	.	.	PUNCT
njb-1	84	1	in	in	ADP
njb-1	84	2	a	a	DET
njb-1	84	3	phase	phase	PROPN
njb-1	84	4	ii	ii	PROPN
njb-1	84	5	study	study	NOUN
njb-1	84	6	conducted	conduct	VERB
njb-1	84	7	by	by	ADP
njb-1	84	8	dinndorf	dinndorf	PROPN
njb-1	84	9	et	et	PROPN
njb-1	84	10	al	al	PROPN
njb-1	84	11	.	.	PUNCT
njb-1	85	1	for	for	ADP
njb-1	85	2	the	the	DET
njb-1	85	3	fda	fda	PROPN
njb-1	85	4	,	,	PUNCT
njb-1	85	5	the	the	DET
njb-1	85	6	asparaginase	asparaginase	NOUN
njb-1	85	7	activity	activity	NOUN
njb-1	85	8	and	and	CCONJ
njb-1	85	9	the	the	DET
njb-1	85	10	depletion	depletion	NOUN
njb-1	85	11	of	of	ADP
njb-1	85	12	asparagine	asparagine	NOUN
njb-1	85	13	were	be	AUX
njb-1	85	14	measured	measure	VERB
njb-1	85	15	in	in	ADP
njb-1	85	16	days	day	NOUN
njb-1	85	17	after	after	ADP
njb-1	85	18	the	the	DET
njb-1	85	19	first	first	ADJ
njb-1	85	20	dose	dose	NOUN
njb-1	85	21	.	.	PUNCT
njb-1	86	1	they	they	PRON
njb-1	86	2	found	find	VERB
njb-1	86	3	that	that	SCONJ
njb-1	86	4	between	between	ADP
njb-1	86	5	the	the	DET
njb-1	86	6	2nd	2nd	ADJ
njb-1	86	7	and	and	CCONJ
njb-1	86	8	7th	7th	ADJ
njb-1	86	9	day	day	NOUN
njb-1	86	10	after	after	ADP
njb-1	86	11	the	the	DET
njb-1	86	12	first	first	ADJ
njb-1	86	13	dose	dose	NOUN
njb-1	86	14	both	both	CCONJ
njb-1	86	15	native	native	ADJ
njb-1	86	16	e.	e.	PROPN
njb-1	86	17	coli	coli	PROPN
njb-1	86	18	asparaginase	asparaginase	NOUN
njb-1	86	19	and	and	CCONJ
njb-1	86	20	the	the	DET
njb-1	86	21	peg	peg	NOUN
njb-1	86	22	escherichia	escherichia	NOUN
njb-1	86	23	coli	coli	NOUN
njb-1	86	24	asparaginase	asparaginase	NOUN
njb-1	86	25	had	have	VERB
njb-1	86	26	activities	activity	NOUN
njb-1	86	27	above	above	ADP
njb-1	86	28	0.03	0.03	NUM
njb-1	86	29	iu	iu	PROPN
njb-1	86	30	/	/	SYM
njb-1	86	31	ml	ml	NOUN
njb-1	86	32	in	in	ADP
njb-1	86	33	50	50	NUM
njb-1	86	34	patients	patient	NOUN
njb-1	86	35	.	.	PUNCT
njb-1	87	1	this	this	DET
njb-1	87	2	number	number	NOUN
njb-1	87	3	decreased	decrease	VERB
njb-1	87	4	to	to	ADP
njb-1	87	5	below	below	ADP
njb-1	87	6	10	10	NUM
njb-1	87	7	patients	patient	NOUN
njb-1	87	8	for	for	ADP
njb-1	87	9	native	native	PROPN
njb-1	87	10	e.	e.	PROPN
njb-1	87	11	coli	coli	PROPN
njb-1	87	12	asparaginase	asparaginase	NOUN
njb-1	87	13	group	group	NOUN
njb-1	87	14	while	while	SCONJ
njb-1	87	15	it	it	PRON
njb-1	87	16	reached	reach	VERB
njb-1	87	17	20	20	NUM
njb-1	87	18	for	for	ADP
njb-1	87	19	the	the	DET
njb-1	87	20	peg	peg	NOUN
njb-1	87	21	group	group	NOUN
njb-1	87	22	in	in	ADP
njb-1	87	23	the	the	DET
njb-1	87	24	remission	remission	NOUN
njb-1	87	25	induction	induction	NOUN
njb-1	87	26	phases	phase	NOUN
njb-1	87	27	[	[	X
njb-1	87	28	20	20	NUM
njb-1	87	29	]	]	PUNCT
njb-1	87	30	.	.	PUNCT
njb-1	88	1	in	in	ADP
njb-1	88	2	a	a	DET
njb-1	88	3	study	study	NOUN
njb-1	88	4	,	,	PUNCT
njb-1	88	5	the	the	DET
njb-1	88	6	therapeutic	therapeutic	ADJ
njb-1	88	7	peg	peg	PROPN
njb-1	88	8	e.	e.	PROPN
njb-1	88	9	coli	coli	PROPN
njb-1	88	10	asparaginase	asparaginase	NOUN
njb-1	88	11	activity	activity	NOUN
njb-1	88	12	was	be	AUX
njb-1	88	13	observed	observe	VERB
njb-1	88	14	to	to	PART
njb-1	88	15	be	be	AUX
njb-1	88	16	0.234	0.234	NUM
njb-1	88	17	iu	iu	PROPN
njb-1	88	18	/	/	SYM
njb-1	88	19	ml	ml	NOUN
njb-1	88	20	among	among	ADP
njb-1	88	21	86	86	NUM
njb-1	88	22	%	%	NOUN
njb-1	88	23	of	of	ADP
njb-1	88	24	surviving	survive	VERB
njb-1	88	25	patients	patient	NOUN
njb-1	88	26	[	[	X
njb-1	88	27	17	17	NUM
njb-1	88	28	]	]	PUNCT
njb-1	88	29	.	.	PUNCT
njb-1	89	1	in	in	ADP
njb-1	89	2	another	another	DET
njb-1	89	3	study	study	NOUN
njb-1	89	4	by	by	ADP
njb-1	89	5	pieters	pieter	NOUN
njb-1	89	6	et	et	PROPN
njb-1	89	7	al	al	PROPN
njb-1	89	8	.	.	PROPN
njb-1	89	9	median	median	ADJ
njb-1	89	10	asparaginase	asparaginase	NOUN
njb-1	89	11	activity	activity	NOUN
njb-1	89	12	for	for	ADP
njb-1	89	13	native	native	PROPN
njb-1	89	14	e.	e.	PROPN
njb-1	89	15	coli	coli	PROPN
njb-1	89	16	asparaginase	asparaginase	NOUN
njb-1	89	17	was	be	AUX
njb-1	89	18	found	find	VERB
njb-1	89	19	to	to	PART
njb-1	89	20	be	be	AUX
njb-1	89	21	0.19	0.19	NUM
njb-1	89	22	iu	iu	NOUN
njb-1	89	23	/	/	SYM
njb-1	89	24	ml	ml	X
njb-1	89	25	while	while	SCONJ
njb-1	89	26	recombinant	recombinant	ADJ
njb-1	89	27	asparaginase	asparaginase	NOUN
njb-1	89	28	showed	show	VERB
njb-1	89	29	an	an	DET
njb-1	89	30	activity	activity	NOUN
njb-1	89	31	of	of	ADP
njb-1	89	32	0.14	0.14	NUM
njb-1	89	33	iu	iu	PROPN
njb-1	89	34	/	/	SYM
njb-1	89	35	ml	ml	PROPN
njb-1	89	36	(	(	PUNCT
njb-1	89	37	pieters	pieter	NOUN
njb-1	89	38	et	et	PROPN
njb-1	89	39	al	al	PROPN
njb-1	89	40	.	.	PROPN
njb-1	89	41	2008	2008	NUM
njb-1	89	42	)	)	PUNCT
njb-1	89	43	.	.	PUNCT
njb-1	90	1	moreover	moreover	ADV
njb-1	90	2	,	,	PUNCT
njb-1	90	3	van	van	PROPN
njb-1	90	4	der	der	PROPN
njb-1	90	5	sluis	sluis	PROPN
njb-1	90	6	et	et	PROPN
njb-1	90	7	al	al	PROPN
njb-1	90	8	.	.	PROPN
njb-1	90	9	reported	report	VERB
njb-1	90	10	the	the	DET
njb-1	90	11	serum	serum	NOUN
njb-1	90	12	asparaginase	asparaginase	NOUN
njb-1	90	13	activities	activity	NOUN
njb-1	90	14	of	of	ADP
njb-1	90	15	recombinant	recombinant	ADJ
njb-1	90	16	e.	e.	PROPN
njb-1	90	17	coli	coli	PROPN
njb-1	90	18	asparaginase	asparaginase	NOUN
njb-1	90	19	to	to	PART
njb-1	90	20	be	be	AUX
njb-1	90	21	>	>	X
njb-1	90	22	0.10	0.10	NUM
njb-1	90	23	iu	iu	PROPN
njb-1	90	24	/	/	SYM
njb-1	90	25	ml	ml	NOUN
njb-1	90	26	in	in	ADP
njb-1	90	27	74	74	NUM
njb-1	90	28	%	%	NOUN
njb-1	90	29	patients	patient	NOUN
njb-1	90	30	and	and	CCONJ
njb-1	90	31	was	be	AUX
njb-1	90	32	0.13	0.13	NUM
njb-1	90	33	iu	iu	NOUN
njb-1	90	34	/	/	SYM
njb-1	90	35	ml	ml	NOUN
njb-1	90	36	of	of	ADP
njb-1	90	37	all	all	DET
njb-1	90	38	measured	measure	VERB
njb-1	90	39	samples	sample	NOUN
njb-1	90	40	respectively	respectively	ADV
njb-1	90	41	[	[	X
njb-1	90	42	12	12	NUM
njb-1	90	43	]	]	PUNCT
njb-1	90	44	.	.	PUNCT
njb-1	91	1	in	in	ADP
njb-1	91	2	rau	rau	PROPN
njb-1	91	3	et	et	PROPN
njb-1	91	4	al	al	PROPN
njb-1	91	5	.	.	PUNCT
njb-1	92	1	none	none	NOUN
njb-1	92	2	of	of	ADP
njb-1	92	3	the	the	DET
njb-1	92	4	study	study	NOUN
njb-1	92	5	population	population	NOUN
njb-1	92	6	completed	complete	VERB
njb-1	92	7	the	the	DET
njb-1	92	8	trail	trail	NOUN
njb-1	92	9	and	and	CCONJ
njb-1	92	10	only	only	ADV
njb-1	92	11	one	one	NUM
njb-1	92	12	patient	patient	NOUN
njb-1	92	13	had	have	AUX
njb-1	92	14	tolerated	tolerate	VERB
njb-1	92	15	the	the	DET
njb-1	92	16	peg	peg	PROPN
njb-1	92	17	e.	e.	PROPN
njb-1	92	18	chrysanthemi	chrysanthemi	PROPN
njb-1	92	19	asparaginase	asparaginase	PROPN
njb-1	92	20	with	with	ADP
njb-1	92	21	activity	activity	NOUN
njb-1	92	22	>	>	X
njb-1	92	23	0.1	0.1	NUM
njb-1	92	24	iu	iu	NOUN
njb-1	92	25	/	/	SYM
njb-1	92	26	ml	ml	X
njb-1	93	1	[	[	X
njb-1	93	2	21	21	NUM
njb-1	93	3	]	]	PUNCT
njb-1	93	4	.	.	PUNCT
njb-1	94	1	significantly	significantly	ADV
njb-1	94	2	shorter	short	ADJ
njb-1	94	3	serum	serum	NOUN
njb-1	94	4	half	half	ADJ
njb-1	94	5	-	-	PUNCT
njb-1	94	6	life	life	NOUN
njb-1	94	7	of	of	ADP
njb-1	94	8	0.65	0.65	NUM
njb-1	94	9	days	day	NOUN
njb-1	94	10	was	be	AUX
njb-1	94	11	observed	observe	VERB
njb-1	94	12	for	for	ADP
njb-1	94	13	e.	e.	PROPN
njb-1	94	14	chrysanthemi	chrysanthemi	PROPN
njb-1	94	15	asparaginase	asparaginase	NOUN
njb-1	94	16	enzyme	enzyme	NOUN
njb-1	94	17	compared	compare	VERB
njb-1	94	18	to	to	ADP
njb-1	94	19	1.24	1.24	NUM
njb-1	94	20	days	day	NOUN
njb-1	94	21	for	for	ADP
njb-1	94	22	e	e	NOUN
njb-1	94	23	coli	coli	NOUN
njb-1	94	24	asparaginase	asparaginase	NOUN
njb-1	94	25	in	in	ADP
njb-1	94	26	a	a	DET
njb-1	94	27	study	study	NOUN
njb-1	94	28	by	by	ADP
njb-1	94	29	duval	duval	NOUN
njb-1	94	30	et	et	PROPN
njb-1	94	31	al	al	PROPN
njb-1	94	32	.	.	PUNCT
njb-1	95	1	[	[	X
njb-1	95	2	15	15	NUM
njb-1	95	3	]	]	X
njb-1	95	4	(	(	PUNCT
njb-1	95	5	table	table	NOUN
njb-1	95	6	2	2	NUM
njb-1	95	7	)	)	PUNCT
njb-1	95	8	.	.	PUNCT
njb-1	96	1	as	as	SCONJ
njb-1	96	2	stated	state	VERB
njb-1	96	3	earlier	early	ADV
njb-1	96	4	,	,	PUNCT
njb-1	96	5	asparaginase	asparaginase	NOUN
njb-1	96	6	activity	activity	NOUN
njb-1	96	7	in	in	ADP
njb-1	96	8	-	-	PUNCT
njb-1	96	9	vivo	vivo	NOUN
njb-1	96	10	was	be	AUX
njb-1	96	11	standardized	standardize	VERB
njb-1	96	12	to	to	PART
njb-1	96	13	be	be	AUX
njb-1	96	14	less	less	ADJ
njb-1	96	15	than	than	ADP
njb-1	96	16	0.1	0.1	NUM
njb-1	96	17	iu	iu	NOUN
njb-1	96	18	/	/	SYM
njb-1	96	19	ml	ml	NOUN
njb-1	96	20	during	during	ADP
njb-1	96	21	the	the	DET
njb-1	96	22	therapy	therapy	NOUN
njb-1	96	23	,	,	PUNCT
njb-1	96	24	but	but	CCONJ
njb-1	96	25	it	it	PRON
njb-1	96	26	happens	happen	VERB
njb-1	96	27	to	to	PART
njb-1	96	28	be	be	AUX
njb-1	96	29	between	between	ADP
njb-1	96	30	0.13	0.13	NUM
njb-1	96	31	-	-	SYM
njb-1	96	32	0.70	0.70	NUM
njb-1	96	33	iu	iu	PROPN
njb-1	96	34	/	/	SYM
njb-1	96	35	ml	ml	X
njb-1	96	36	(	(	PUNCT
njb-1	96	37	table	table	NOUN
njb-1	96	38	3	3	NUM
njb-1	96	39	)	)	PUNCT
njb-1	96	40	.	.	PUNCT
njb-1	97	1	this	this	PRON
njb-1	97	2	showcases	showcase	VERB
njb-1	97	3	that	that	SCONJ
njb-1	97	4	most	most	ADJ
njb-1	97	5	of	of	ADP
njb-1	97	6	the	the	DET
njb-1	97	7	individuals	individual	NOUN
njb-1	97	8	,	,	PUNCT
njb-1	97	9	who	who	PRON
njb-1	97	10	were	be	AUX
njb-1	97	11	under	under	ADP
njb-1	97	12	therapy	therapy	NOUN
njb-1	97	13	achieved	achieve	VERB
njb-1	97	14	the	the	DET
njb-1	97	15	threshold	threshold	NOUN
njb-1	97	16	.	.	PUNCT
njb-1	98	1	toxicity	toxicity	NOUN
njb-1	98	2	:	:	PUNCT
njb-1	98	3	in	in	ADP
njb-1	98	4	a	a	DET
njb-1	98	5	therapy	therapy	NOUN
njb-1	98	6	involving	involve	VERB
njb-1	98	7	asparaginase	asparaginase	NOUN
njb-1	98	8	,	,	PUNCT
njb-1	98	9	toxicity	toxicity	NOUN
njb-1	98	10	is	be	AUX
njb-1	98	11	directly	directly	ADV
njb-1	98	12	table	table	ADJ
njb-1	98	13	3	3	NUM
njb-1	98	14	.	.	PUNCT
njb-1	99	1	average	average	ADJ
njb-1	99	2	range	range	NOUN
njb-1	99	3	of	of	ADP
njb-1	99	4	asparaginase	asparaginase	NOUN
njb-1	99	5	activity	activity	NOUN
njb-1	99	6	in	in	ADP
njb-1	99	7	treated	treat	VERB
njb-1	99	8	patients	patient	NOUN
njb-1	99	9	from	from	ADP
njb-1	99	10	all	all	DET
njb-1	99	11	the	the	DET
njb-1	99	12	studied	study	VERB
njb-1	99	13	trials	trial	NOUN
njb-1	99	14	.	.	PUNCT
njb-1	100	1	type	type	NOUN
njb-1	100	2	of	of	ADP
njb-1	100	3	asparaginase	asparaginase	NOUN
njb-1	100	4	average	average	ADJ
njb-1	100	5	activity	activity	NOUN
njb-1	100	6	range	range	NOUN
njb-1	100	7	(	(	PUNCT
njb-1	100	8	iu	iu	X
njb-1	100	9	/	/	SYM
njb-1	100	10	ml	ml	PROPN
njb-1	100	11	)	)	PUNCT
njb-1	100	12	from	from	ADP
njb-1	100	13	all	all	DET
njb-1	100	14	trials	trial	NOUN
njb-1	100	15	native	native	ADJ
njb-1	100	16	escherichia	escherichia	NOUN
njb-1	100	17	coli	coli	PROPN
njb-1	100	18	0.13	0.13	NUM
njb-1	100	19	-	-	SYM
njb-1	100	20	0.19	0.19	NUM
njb-1	100	21	peg	peg	NOUN
njb-1	100	22	escherichia	escherichia	NOUN
njb-1	100	23	coli	coli	NOUN
njb-1	100	24	0.23	0.23	NUM
njb-1	100	25	-	-	SYM
njb-1	100	26	0.70	0.70	NUM
njb-1	100	27	erwinia	erwinia	PROPN
njb-1	100	28	chrysanthemi	chrysanthemi	PROPN
njb-1	100	29	0.13	0.13	NUM
njb-1	100	30	-	-	SYM
njb-1	100	31	0.58	0.58	NUM
njb-1	100	32	recombinant	recombinant	ADJ
njb-1	100	33	escherichia	escherichia	NOUN
njb-1	100	34	coli	coli	NOUN
njb-1	100	35	0.13	0.13	NUM
njb-1	100	36	-	-	SYM
njb-1	100	37	0.17	0.17	NUM
njb-1	100	38	related	relate	VERB
njb-1	100	39	to	to	ADP
njb-1	100	40	the	the	DET
njb-1	100	41	dose	dose	NOUN
njb-1	100	42	administered	administer	VERB
njb-1	100	43	.	.	PUNCT
njb-1	101	1	this	this	PRON
njb-1	101	2	is	be	AUX
njb-1	101	3	why	why	SCONJ
njb-1	101	4	controlled	control	VERB
njb-1	101	5	administration	administration	NOUN
njb-1	101	6	of	of	ADP
njb-1	101	7	quantity	quantity	NOUN
njb-1	101	8	is	be	AUX
njb-1	101	9	a	a	DET
njb-1	101	10	must	must	NOUN
njb-1	101	11	.	.	PUNCT
njb-1	102	1	a	a	DET
njb-1	102	2	trial	trial	NOUN
njb-1	102	3	reported	report	VERB
njb-1	102	4	that	that	SCONJ
njb-1	102	5	e.	e.	PROPN
njb-1	102	6	chrysanthemi	chrysanthemi	PROPN
njb-1	102	7	asparaginase	asparaginase	PROPN
njb-1	102	8	hypersensitivity	hypersensitivity	NOUN
njb-1	102	9	reaction	reaction	NOUN
njb-1	102	10	(	(	PUNCT
njb-1	102	11	urticaria	urticaria	PROPN
njb-1	102	12	)	)	PUNCT
njb-1	102	13	of	of	ADP
njb-1	102	14	grade	grade	NOUN
njb-1	102	15	1	1	NUM
njb-1	102	16	-	-	SYM
njb-1	102	17	2	2	NUM
njb-1	102	18	were	be	AUX
njb-1	102	19	seen	see	VERB
njb-1	102	20	in	in	ADP
njb-1	102	21	2(8	2(8	NUM
njb-1	102	22	%	%	NOUN
njb-1	102	23	)	)	PUNCT
njb-1	102	24	of	of	ADP
njb-1	102	25	patients	patient	NOUN
njb-1	102	26	,	,	PUNCT
njb-1	102	27	pancreatitis	pancreatitis	NOUN
njb-1	102	28	of	of	ADP
njb-1	102	29	grade	grade	NOUN
njb-1	102	30	1	1	NUM
njb-1	102	31	-	-	SYM
njb-1	102	32	3	3	NUM
njb-1	102	33	in	in	ADP
njb-1	102	34	3(12	3(12	NUM
njb-1	102	35	%	%	NOUN
njb-1	102	36	)	)	PUNCT
njb-1	102	37	of	of	ADP
njb-1	102	38	the	the	DET
njb-1	102	39	patients	patient	NOUN
njb-1	102	40	,	,	PUNCT
njb-1	102	41	and	and	CCONJ
njb-1	102	42	hyperglycemia	hyperglycemia	NOUN
njb-1	102	43	of	of	ADP
njb-1	102	44	grade	grade	NOUN
njb-1	102	45	1	1	NUM
njb-1	102	46	-	-	SYM
njb-1	102	47	2	2	NUM
njb-1	102	48	in	in	ADP
njb-1	102	49	5	5	NUM
njb-1	102	50	(	(	PUNCT
njb-1	102	51	20	20	NUM
njb-1	102	52	%	%	NOUN
njb-1	102	53	)	)	PUNCT
njb-1	102	54	of	of	ADP
njb-1	102	55	the	the	DET
njb-1	102	56	patients	patient	NOUN
njb-1	102	57	[	[	X
njb-1	102	58	8	8	NUM
njb-1	102	59	]	]	PUNCT
njb-1	102	60	.	.	PUNCT
njb-1	103	1	similarly	similarly	ADV
njb-1	103	2	,	,	PUNCT
njb-1	103	3	hypersensitivity	hypersensitivity	NOUN
njb-1	103	4	reaction	reaction	NOUN
njb-1	103	5	of	of	ADP
njb-1	103	6	grade	grade	NOUN
njb-1	103	7	3	3	NUM
njb-1	103	8	-	-	SYM
njb-1	103	9	4	4	NUM
njb-1	103	10	was	be	AUX
njb-1	103	11	seen	see	VERB
njb-1	103	12	in	in	ADP
njb-1	103	13	7(12	7(12	NUM
njb-1	103	14	%	%	NOUN
njb-1	103	15	)	)	PUNCT
njb-1	103	16	patients	patient	NOUN
njb-1	103	17	in	in	ADP
njb-1	103	18	native	native	PROPN
njb-1	103	19	e.	e.	PROPN
njb-1	103	20	coli	coli	PROPN
njb-1	103	21	asparaginase	asparaginase	NOUN
njb-1	103	22	treated	treat	VERB
njb-1	103	23	group	group	NOUN
njb-1	103	24	,	,	PUNCT
njb-1	103	25	3	3	NUM
njb-1	103	26	(	(	PUNCT
njb-1	103	27	6	6	NUM
njb-1	103	28	%	%	NOUN
njb-1	103	29	)	)	PUNCT
njb-1	103	30	in	in	ADP
njb-1	103	31	peg	peg	PROPN
njb-1	103	32	e.	e.	PROPN
njb-1	103	33	coli	coli	PROPN
njb-1	103	34	asparaginase	asparaginase	NOUN
njb-1	103	35	treated	treat	VERB
njb-1	103	36	group	group	NOUN
njb-1	103	37	,	,	PUNCT
njb-1	103	38	hyperglycemia	hyperglycemia	NOUN
njb-1	103	39	of	of	ADP
njb-1	103	40	grade	grade	NOUN
njb-1	103	41	3	3	NUM
njb-1	103	42	-	-	SYM
njb-1	103	43	4	4	NUM
njb-1	103	44	was	be	AUX
njb-1	103	45	seen	see	VERB
njb-1	103	46	in	in	ADP
njb-1	103	47	2(4	2(4	NUM
njb-1	103	48	%	%	NOUN
njb-1	103	49	)	)	PUNCT
njb-1	103	50	patients	patient	NOUN
njb-1	103	51	in	in	ADP
njb-1	103	52	native	native	PROPN
njb-1	103	53	e.	e.	PROPN
njb-1	103	54	coli	coli	PROPN
njb-1	103	55	asparaginase	asparaginase	NOUN
njb-1	103	56	treated	treat	VERB
njb-1	103	57	group	group	NOUN
njb-1	103	58	and	and	CCONJ
njb-1	103	59	in	in	ADP
njb-1	103	60	1(2	1(2	NUM
njb-1	103	61	%	%	NOUN
njb-1	103	62	)	)	PUNCT
njb-1	103	63	patient	patient	NOUN
njb-1	103	64	in	in	ADP
njb-1	103	65	peg	peg	PROPN
njb-1	103	66	e.	e.	PROPN
njb-1	103	67	coli	coli	PROPN
njb-1	103	68	asparaginase	asparaginase	NOUN
njb-1	103	69	group	group	NOUN
njb-1	104	1	[	[	X
njb-1	104	2	16	16	NUM
njb-1	104	3	]	]	PUNCT
njb-1	104	4	.	.	PUNCT
njb-1	105	1	later	later	ADV
njb-1	105	2	,	,	PUNCT
njb-1	105	3	van	van	PROPN
njb-1	105	4	der	der	PROPN
njb-1	105	5	sluis	sluis	NOUN
njb-1	105	6	et	et	PROPN
njb-1	105	7	al	al	PROPN
njb-1	105	8	reported	report	VERB
njb-1	105	9	that	that	SCONJ
njb-1	105	10	hypersensitivity	hypersensitivity	NOUN
njb-1	105	11	reaction	reaction	NOUN
njb-1	105	12	was	be	AUX
njb-1	105	13	seen	see	VERB
njb-1	105	14	in	in	ADP
njb-1	105	15	2(2.1	2(2.1	NUM
njb-1	105	16	%	%	NOUN
njb-1	105	17	)	)	PUNCT
njb-1	105	18	of	of	ADP
njb-1	105	19	the	the	DET
njb-1	105	20	patients	patient	NOUN
njb-1	105	21	in	in	ADP
njb-1	105	22	recombinant	recombinant	PROPN
njb-1	105	23	e.	e.	PROPN
njb-1	105	24	coli	coli	PROPN
njb-1	105	25	asparaginase	asparaginase	NOUN
njb-1	105	26	group	group	NOUN
njb-1	105	27	and	and	CCONJ
njb-1	105	28	5(5	5(5	NUM
njb-1	105	29	%	%	NOUN
njb-1	105	30	)	)	PUNCT
njb-1	105	31	in	in	ADP
njb-1	105	32	native	native	PROPN
njb-1	105	33	e.	e.	PROPN
njb-1	105	34	coli	coli	PROPN
njb-1	105	35	asparaginase	asparaginase	NOUN
njb-1	105	36	group	group	NOUN
njb-1	105	37	,	,	PUNCT
njb-1	105	38	pancreatitis	pancreatitis	NOUN
njb-1	105	39	of	of	ADP
njb-1	105	40	grade	grade	NOUN
njb-1	105	41	≥	≥	NOUN
njb-1	105	42	2	2	NUM
njb-1	105	43	was	be	AUX
njb-1	105	44	seen	see	VERB
njb-1	105	45	in	in	ADP
njb-1	105	46	1	1	NUM
njb-1	105	47	(	(	PUNCT
njb-1	105	48	1	1	NUM
njb-1	105	49	%	%	NOUN
njb-1	105	50	)	)	PUNCT
njb-1	105	51	of	of	ADP
njb-1	105	52	patient	patient	NOUN
njb-1	105	53	in	in	ADP
njb-1	105	54	native	native	PROPN
njb-1	105	55	e.	e.	PROPN
njb-1	105	56	coli	coli	PROPN
njb-1	105	57	asparaginase	asparaginase	NOUN
njb-1	105	58	group	group	NOUN
njb-1	106	1	[	[	X
njb-1	106	2	16	16	NUM
njb-1	106	3	]	]	PUNCT
njb-1	106	4	.	.	PUNCT
njb-1	107	1	also	also	ADV
njb-1	107	2	the	the	DET
njb-1	107	3	hypersensitivity	hypersensitivity	NOUN
njb-1	107	4	reaction	reaction	NOUN
njb-1	107	5	of	of	ADP
njb-1	107	6	grade	grade	NOUN
njb-1	107	7	1	1	NUM
njb-1	107	8	-	-	SYM
njb-1	107	9	4	4	NUM
njb-1	107	10	was	be	AUX
njb-1	107	11	seen	see	VERB
njb-1	107	12	in	in	ADP
njb-1	107	13	28(12	28(12	NUM
njb-1	107	14	%	%	NOUN
njb-1	107	15	)	)	PUNCT
njb-1	107	16	of	of	ADP
njb-1	107	17	patients	patient	NOUN
njb-1	107	18	receiving	receive	VERB
njb-1	107	19	peg	peg	NOUN
njb-1	107	20	e.	e.	PROPN
njb-1	107	21	coli	coli	PROPN
njb-1	107	22	asparaginase	asparaginase	NOUN
njb-1	107	23	and	and	CCONJ
njb-1	107	24	in	in	ADP
njb-1	107	25	21(9	21(9	NUM
njb-1	107	26	%	%	NOUN
njb-1	107	27	)	)	PUNCT
njb-1	107	28	in	in	ADP
njb-1	107	29	native	native	PROPN
njb-1	107	30	e.	e.	PROPN
njb-1	107	31	coli	coli	PROPN
njb-1	107	32	asparaginase	asparaginase	NOUN
njb-1	107	33	receiving	receive	VERB
njb-1	107	34	group	group	NOUN
njb-1	107	35	.	.	PUNCT
njb-1	108	1	pancreatitis	pancreatitis	PROPN
njb-1	108	2	of	of	ADP
njb-1	108	3	grade	grade	NOUN
njb-1	108	4	≥	≥	NOUN
njb-1	108	5	2	2	NUM
njb-1	108	6	was	be	AUX
njb-1	108	7	seen	see	VERB
njb-1	108	8	in	in	ADP
njb-1	108	9	27	27	NUM
njb-1	108	10	(	(	PUNCT
njb-1	108	11	12	12	NUM
njb-1	108	12	%	%	NOUN
njb-1	108	13	)	)	PUNCT
njb-1	108	14	of	of	ADP
njb-1	108	15	the	the	DET
njb-1	108	16	patients	patient	NOUN
njb-1	108	17	receiving	receive	VERB
njb-1	108	18	peg	peg	NOUN
njb-1	108	19	asparaginase	asparaginase	NOUN
njb-1	108	20	and	and	CCONJ
njb-1	108	21	22(10	22(10	NUM
njb-1	108	22	%	%	NOUN
njb-1	108	23	)	)	PUNCT
njb-1	108	24	receiving	receive	VERB
njb-1	108	25	native	native	ADJ
njb-1	108	26	e.	e.	PROPN
njb-1	108	27	coli	coli	PROPN
njb-1	108	28	asparaginase	asparaginase	NOUN
njb-1	108	29	group	group	NOUN
njb-1	109	1	[	[	X
njb-1	109	2	19	19	NUM
njb-1	109	3	]	]	PUNCT
njb-1	109	4	.	.	PUNCT
njb-1	110	1	in	in	ADP
njb-1	110	2	1999	1999	NUM
njb-1	110	3	,	,	PUNCT
njb-1	110	4	in	in	ADP
njb-1	110	5	a	a	DET
njb-1	110	6	study	study	NOUN
njb-1	110	7	by	by	ADP
njb-1	110	8	liang	liang	PROPN
njb-1	110	9	et	et	PROPN
njb-1	110	10	al	al	PROPN
njb-1	110	11	.	.	PROPN
njb-1	111	1	10,000	10,000	NUM
njb-1	111	2	iu	iu	PROPN
njb-1	111	3	/	/	SYM
njb-1	111	4	m2	m2	PROPN
njb-1	111	5	dose	dose	NOUN
njb-1	111	6	escherichia	escherichia	NOUN
njb-1	111	7	coli	coli	NOUN
njb-1	111	8	asparaginase	asparaginase	NOUN
njb-1	111	9	was	be	AUX
njb-1	111	10	used	use	VERB
njb-1	111	11	during	during	ADP
njb-1	111	12	the	the	DET
njb-1	111	13	remission	remission	NOUN
njb-1	111	14	induction	induction	NOUN
njb-1	111	15	therapy	therapy	NOUN
njb-1	111	16	on	on	ADP
njb-1	111	17	93	93	NUM
njb-1	111	18	children	child	NOUN
njb-1	111	19	with	with	ADP
njb-1	111	20	table	table	NOUN
njb-1	111	21	2	2	NUM
njb-1	111	22	.	.	PUNCT
njb-1	111	23	average	average	ADJ
njb-1	111	24	asparaginase	asparaginase	NOUN
njb-1	111	25	activity	activity	NOUN
njb-1	111	26	from	from	ADP
njb-1	111	27	individual	individual	ADJ
njb-1	111	28	trials	trial	NOUN
njb-1	111	29	in	in	ADP
njb-1	111	30	treated	treat	VERB
njb-1	111	31	patients	patient	NOUN
njb-1	111	32	clinical	clinical	ADJ
njb-1	111	33	trial	trial	NOUN
njb-1	111	34	type	type	NOUN
njb-1	111	35	of	of	ADP
njb-1	111	36	asparaginase	asparaginase	NOUN
njb-1	111	37	average	average	ADJ
njb-1	111	38	activity	activity	NOUN
njb-1	111	39	(	(	PUNCT
njb-1	111	40	iu	iu	PROPN
njb-1	111	41	/	/	SYM
njb-1	111	42	ml	ml	PROPN
njb-1	111	43	)	)	PUNCT
njb-1	112	1	[	[	PUNCT
njb-1	112	2	8	8	NUM
njb-1	112	3	]	]	PUNCT
njb-1	112	4	erwinia	erwinia	PROPN
njb-1	112	5	chrysanthemi	chrysanthemi	PROPN
njb-1	112	6	0.36	0.36	NUM
njb-1	113	1	[	[	PUNCT
njb-1	113	2	16	16	NUM
njb-1	113	3	]	]	PUNCT
njb-1	113	4	native	native	ADJ
njb-1	113	5	escherichia	escherichia	NOUN
njb-1	113	6	coli	coli	NOUN
njb-1	113	7	0.13	0.13	NUM
njb-1	114	1	[	[	PUNCT
njb-1	114	2	16	16	NUM
njb-1	114	3	]	]	X
njb-1	114	4	peg	peg	NOUN
njb-1	114	5	escherichia	escherichia	NOUN
njb-1	114	6	coli	coli	NOUN
njb-1	114	7	0.30	0.30	NUM
njb-1	115	1	[	[	PUNCT
njb-1	115	2	10	10	NUM
njb-1	115	3	]	]	PUNCT
njb-1	115	4	native	native	ADJ
njb-1	115	5	escherichia	escherichia	NOUN
njb-1	115	6	coli	coli	NOUN
njb-1	115	7	(	(	PUNCT
njb-1	115	8	asparaginase	asparaginase	NOUN
njb-1	115	9	medac	medac	PROPN
njb-1	115	10	)	)	PUNCT
njb-1	115	11	0.16	0.16	NUM
njb-1	116	1	[	[	PUNCT
njb-1	116	2	10	10	NUM
njb-1	116	3	]	]	PUNCT
njb-1	116	4	recombinant	recombinant	ADJ
njb-1	116	5	escherichia	escherichia	NOUN
njb-1	116	6	coli	coli	NOUN
njb-1	116	7	0.17	0.17	NUM
njb-1	116	8	[	[	PUNCT
njb-1	116	9	19	19	NUM
njb-1	116	10	]	]	PUNCT
njb-1	116	11	native	native	ADJ
njb-1	116	12	escherichia	escherichia	NOUN
njb-1	116	13	coli	coli	NOUN
njb-1	116	14	0.1-<0.2	0.1-<0.2	PUNCT
njb-1	117	1	[	[	X
njb-1	117	2	19	19	NUM
njb-1	117	3	]	]	X
njb-1	117	4	peg	peg	NOUN
njb-1	117	5	escherichia	escherichia	NOUN
njb-1	117	6	coli	coli	NOUN
njb-1	117	7	0.70	0.70	NUM
njb-1	118	1	[	[	PUNCT
njb-1	118	2	17	17	NUM
njb-1	118	3	]	]	PUNCT
njb-1	118	4	native	native	ADJ
njb-1	118	5	escherichia	escherichia	NOUN
njb-1	118	6	coli	coli	NOUN
njb-1	118	7	(	(	PUNCT
njb-1	118	8	asparaginase	asparaginase	NOUN
njb-1	118	9	medac	medac	PROPN
njb-1	118	10	)	)	PUNCT
njb-1	118	11	0.19	0.19	NUM
njb-1	119	1	[	[	PUNCT
njb-1	119	2	17	17	NUM
njb-1	119	3	]	]	PUNCT
njb-1	119	4	recombinant	recombinant	ADJ
njb-1	119	5	escherichia	escherichia	NOUN
njb-1	119	6	coli	coli	NOUN
njb-1	119	7	0.14	0.14	NUM
njb-1	120	1	[	[	PUNCT
njb-1	120	2	12	12	NUM
njb-1	120	3	]	]	PUNCT
njb-1	120	4	recombinant	recombinant	ADJ
njb-1	120	5	escherichia	escherichia	NOUN
njb-1	120	6	coli	coli	NOUN
njb-1	120	7	0.13	0.13	NUM
njb-1	120	8	nepal	nepal	PROPN
njb-1	120	9	j	j	PROPN
njb-1	120	10	biotechnol	biotechnol	PROPN
njb-1	120	11	.	.	PUNCT
njb-1	121	1	2	2	NUM
njb-1	121	2	0	0	NUM
njb-1	121	3	2	2	NUM
njb-1	121	4	1	1	NUM
njb-1	121	5	d	d	X
njb-1	121	6	e	e	X
njb-1	121	7	c	c	PROPN
njb-1	121	8	.	.	PUNCT
njb-1	122	1	9	9	NUM
njb-1	122	2	(	(	PUNCT
njb-1	122	3	2	2	NUM
njb-1	122	4	):	):	PUNCT
njb-1	122	5	39	39	NUM
njb-1	122	6	-	-	SYM
njb-1	122	7	47	47	NUM
njb-1	122	8	baral	baral	ADJ
njb-1	122	9	et	et	PROPN
njb-1	122	10	al	al	PROPN
njb-1	122	11	.	.	PUNCT
njb-1	123	1	©	©	PROPN
njb-1	123	2	njb	njb	PROPN
njb-1	123	3	,	,	PUNCT
njb-1	123	4	bsn	bsn	PROPN
njb-1	123	5	42	42	NUM
njb-1	123	6	standard	standard	ADJ
njb-1	123	7	-	-	PUNCT
njb-1	123	8	risk	risk	NOUN
njb-1	123	9	or	or	CCONJ
njb-1	123	10	sr	sr	PROPN
njb-1	123	11	(	(	PUNCT
njb-1	123	12	spontaneous	spontaneous	ADJ
njb-1	123	13	remission	remission	NOUN
njb-1	123	14	)	)	PUNCT
njb-1	123	15	all	all	PRON
njb-1	123	16	.	.	PUNCT
njb-1	124	1	they	they	PRON
njb-1	124	2	found	find	VERB
njb-1	124	3	that	that	SCONJ
njb-1	124	4	26.8	26.8	NUM
njb-1	124	5	%	%	NOUN
njb-1	124	6	or	or	CCONJ
njb-1	124	7	25	25	NUM
njb-1	124	8	of	of	ADP
njb-1	124	9	the	the	DET
njb-1	124	10	participants	participant	NOUN
njb-1	124	11	showed	show	VERB
njb-1	124	12	signs	sign	NOUN
njb-1	124	13	of	of	ADP
njb-1	124	14	toxicity	toxicity	NOUN
njb-1	124	15	.	.	PUNCT
njb-1	125	1	of	of	ADP
njb-1	125	2	them	they	PRON
njb-1	125	3	,	,	PUNCT
njb-1	125	4	15	15	NUM
njb-1	125	5	or	or	CCONJ
njb-1	125	6	16	16	NUM
njb-1	125	7	%	%	NOUN
njb-1	125	8	showed	show	VERB
njb-1	125	9	signs	sign	NOUN
njb-1	125	10	of	of	ADP
njb-1	125	11	sepsis	sepsis	NOUN
njb-1	125	12	,	,	PUNCT
njb-1	125	13	2	2	NUM
njb-1	125	14	or	or	CCONJ
njb-1	125	15	2	2	NUM
njb-1	125	16	%	%	NOUN
njb-1	125	17	had	have	VERB
njb-1	125	18	pneumonia	pneumonia	NOUN
njb-1	125	19	,	,	PUNCT
njb-1	125	20	6	6	NUM
njb-1	125	21	or	or	CCONJ
njb-1	125	22	6	6	NUM
njb-1	125	23	%	%	NOUN
njb-1	125	24	showed	show	VERB
njb-1	125	25	signs	sign	NOUN
njb-1	125	26	of	of	ADP
njb-1	125	27	hyperglycemia	hyperglycemia	NOUN
njb-1	125	28	,	,	PUNCT
njb-1	125	29	and	and	CCONJ
njb-1	125	30	6	6	NUM
njb-1	125	31	or	or	CCONJ
njb-1	125	32	6	6	NUM
njb-1	125	33	%	%	NOUN
njb-1	125	34	had	have	VERB
njb-1	125	35	hemorrhage	hemorrhage	NOUN
njb-1	125	36	.	.	PUNCT
njb-1	126	1	during	during	ADP
njb-1	126	2	remission	remission	NOUN
njb-1	126	3	induction	induction	NOUN
njb-1	126	4	,	,	PUNCT
njb-1	126	5	19	19	NUM
njb-1	126	6	of	of	ADP
njb-1	126	7	93	93	NUM
njb-1	126	8	or	or	CCONJ
njb-1	126	9	20.4	20.4	NUM
njb-1	126	10	%	%	NOUN
njb-1	126	11	of	of	ADP
njb-1	126	12	patients	patient	NOUN
njb-1	126	13	developed	develop	VERB
njb-1	126	14	a	a	DET
njb-1	126	15	severe	severe	ADJ
njb-1	126	16	infection	infection	NOUN
njb-1	126	17	.	.	PUNCT
njb-1	127	1	death	death	NOUN
njb-1	127	2	during	during	ADP
njb-1	127	3	induction	induction	NOUN
njb-1	127	4	occurred	occur	VERB
njb-1	127	5	in	in	ADP
njb-1	127	6	6	6	NUM
njb-1	127	7	patients	patient	NOUN
njb-1	127	8	[	[	X
njb-1	127	9	22	22	NUM
njb-1	127	10	]	]	PUNCT
njb-1	127	11	.	.	PUNCT
njb-1	128	1	a	a	DET
njb-1	128	2	phase	phase	NOUN
njb-1	128	3	ii	ii	PROPN
njb-1	128	4	clinical	clinical	ADJ
njb-1	128	5	trial	trial	NOUN
njb-1	128	6	was	be	AUX
njb-1	128	7	conducted	conduct	VERB
njb-1	128	8	by	by	ADP
njb-1	128	9	dinndorf	dinndorf	PROPN
njb-1	128	10	et	et	PROPN
njb-1	128	11	al	al	PROPN
njb-1	128	12	.	.	PUNCT
njb-1	129	1	for	for	ADP
njb-1	129	2	the	the	DET
njb-1	129	3	peg	peg	NOUN
njb-1	129	4	escherichia	escherichia	NOUN
njb-1	129	5	coli	coli	NOUN
njb-1	129	6	asparaginase	asparaginase	NOUN
njb-1	129	7	oncaspa	oncaspa	NOUN
njb-1	129	8	®	®	NOUN
njb-1	129	9	by	by	ADP
njb-1	129	10	enzon	enzon	ADJ
njb-1	129	11	pharmaceuticals	pharmaceutical	NOUN
njb-1	129	12	in	in	ADP
njb-1	129	13	118	118	NUM
njb-1	129	14	children	child	NOUN
njb-1	129	15	aged	age	VERB
njb-1	129	16	1	1	NUM
njb-1	129	17	to	to	PART
njb-1	129	18	9	9	NUM
njb-1	129	19	years	year	NOUN
njb-1	129	20	.	.	PUNCT
njb-1	130	1	it	it	PRON
njb-1	130	2	was	be	AUX
njb-1	130	3	a	a	DET
njb-1	130	4	comparative	comparative	ADJ
njb-1	130	5	study	study	NOUN
njb-1	130	6	between	between	ADP
njb-1	130	7	a	a	DET
njb-1	130	8	native	native	ADJ
njb-1	130	9	e.	e.	PROPN
njb-1	130	10	coli	coli	PROPN
njb-1	130	11	asparaginase	asparaginase	NOUN
njb-1	130	12	and	and	CCONJ
njb-1	130	13	the	the	DET
njb-1	130	14	peg	peg	PROPN
njb-1	130	15	e.	e.	PROPN
njb-1	130	16	coli	coli	PROPN
njb-1	130	17	asparaginase	asparaginase	NOUN
njb-1	130	18	.	.	PUNCT
njb-1	131	1	they	they	PRON
njb-1	131	2	concluded	conclude	VERB
njb-1	131	3	,	,	PUNCT
njb-1	131	4	14	14	NUM
njb-1	131	5	of	of	ADP
njb-1	131	6	the	the	DET
njb-1	131	7	58	58	NUM
njb-1	131	8	patients	patient	NOUN
njb-1	131	9	in	in	ADP
njb-1	131	10	the	the	DET
njb-1	131	11	peg	peg	NOUN
njb-1	131	12	asparaginase	asparaginase	NOUN
njb-1	131	13	group	group	NOUN
njb-1	131	14	compared	compare	VERB
njb-1	131	15	to	to	ADP
njb-1	131	16	18	18	NUM
njb-1	131	17	of	of	ADP
njb-1	131	18	the	the	DET
njb-1	131	19	59	59	NUM
njb-1	131	20	patients	patient	NOUN
njb-1	131	21	in	in	ADP
njb-1	131	22	the	the	DET
njb-1	131	23	native	native	ADJ
njb-1	131	24	escherichia	escherichia	PROPN
njb-1	131	25	coli	coli	NOUN
njb-1	131	26	group	group	NOUN
njb-1	131	27	suffered	suffer	VERB
njb-1	131	28	from	from	ADP
njb-1	131	29	toxic	toxic	ADJ
njb-1	131	30	effects	effect	NOUN
njb-1	131	31	.	.	PUNCT
njb-1	132	1	hyperglycemia	hyperglycemia	NOUN
njb-1	132	2	was	be	AUX
njb-1	132	3	much	much	ADV
njb-1	132	4	more	more	ADV
njb-1	132	5	common	common	ADJ
njb-1	132	6	in	in	ADP
njb-1	132	7	the	the	DET
njb-1	132	8	peg	peg	NOUN
njb-1	132	9	escherichia	escherichia	NOUN
njb-1	132	10	coli	coli	NOUN
njb-1	132	11	asparaginase	asparaginase	NOUN
njb-1	132	12	group	group	NOUN
njb-1	132	13	with	with	ADP
njb-1	132	14	5	5	NUM
njb-1	132	15	%	%	NOUN
njb-1	132	16	or	or	CCONJ
njb-1	132	17	3	3	NUM
njb-1	132	18	patients	patient	NOUN
njb-1	132	19	suffering	suffer	VERB
njb-1	132	20	from	from	ADP
njb-1	132	21	it	it	PRON
njb-1	132	22	and	and	CCONJ
njb-1	132	23	abnormal	abnormal	ADJ
njb-1	132	24	liver	liver	NOUN
njb-1	132	25	conditions	condition	NOUN
njb-1	132	26	were	be	AUX
njb-1	132	27	much	much	ADV
njb-1	132	28	more	more	ADV
njb-1	132	29	common	common	ADJ
njb-1	132	30	in	in	ADP
njb-1	132	31	the	the	DET
njb-1	132	32	native	native	ADJ
njb-1	132	33	escherichia	escherichia	PROPN
njb-1	132	34	coli	coli	NOUN
njb-1	132	35	asparaginase	asparaginase	NOUN
njb-1	132	36	group	group	NOUN
njb-1	132	37	,	,	PUNCT
njb-1	132	38	10	10	NUM
njb-1	132	39	patients	patient	NOUN
njb-1	132	40	with	with	ADP
njb-1	132	41	abnormal	abnormal	ADJ
njb-1	132	42	liver	liver	NOUN
njb-1	132	43	tests	test	NOUN
njb-1	132	44	compared	compare	VERB
njb-1	132	45	to	to	ADP
njb-1	132	46	6	6	NUM
njb-1	132	47	in	in	ADP
njb-1	132	48	the	the	DET
njb-1	132	49	peg	peg	NOUN
njb-1	132	50	escherichia	escherichia	NOUN
njb-1	132	51	coli	coli	NOUN
njb-1	132	52	asparaginase	asparaginase	NOUN
njb-1	132	53	group	group	NOUN
njb-1	133	1	[	[	X
njb-1	133	2	20	20	NUM
njb-1	133	3	]	]	PUNCT
njb-1	133	4	.	.	PUNCT
njb-1	134	1	another	another	DET
njb-1	134	2	study	study	NOUN
njb-1	134	3	conducted	conduct	VERB
njb-1	134	4	on	on	ADP
njb-1	134	5	144	144	NUM
njb-1	134	6	patients	patient	NOUN
njb-1	134	7	aged	age	VERB
njb-1	134	8	below	below	ADP
njb-1	134	9	22	22	NUM
njb-1	134	10	years	year	NOUN
njb-1	134	11	to	to	PART
njb-1	134	12	study	study	VERB
njb-1	134	13	the	the	DET
njb-1	134	14	effect	effect	NOUN
njb-1	134	15	of	of	ADP
njb-1	134	16	weekly	weekly	ADJ
njb-1	134	17	vs.	vs.	ADP
njb-1	134	18	bi	bi	ADJ
njb-1	134	19	-	-	ADJ
njb-1	134	20	weekly	weekly	ADJ
njb-1	134	21	dosing	dosing	NOUN
njb-1	134	22	regimens	regimen	NOUN
njb-1	134	23	with	with	ADP
njb-1	134	24	peg	peg	PROPN
njb-1	134	25	e.	e.	PROPN
njb-1	134	26	coli	coli	PROPN
njb-1	134	27	asparaginase	asparaginase	NOUN
njb-1	134	28	and	and	CCONJ
njb-1	134	29	native	native	PROPN
njb-1	134	30	e.	e.	PROPN
njb-1	134	31	coli	coli	PROPN
njb-1	134	32	asparaginase	asparaginase	NOUN
njb-1	134	33	in	in	ADP
njb-1	134	34	patients	patient	NOUN
njb-1	134	35	with	with	ADP
njb-1	134	36	first	first	ADJ
njb-1	134	37	relapses	relapse	NOUN
njb-1	134	38	of	of	ADP
njb-1	134	39	all	all	PRON
njb-1	134	40	in	in	ADP
njb-1	134	41	reinduction	reinduction	NOUN
njb-1	134	42	therapy	therapy	NOUN
njb-1	134	43	,	,	PUNCT
njb-1	134	44	found	find	VERB
njb-1	134	45	that	that	SCONJ
njb-1	134	46	out	out	ADP
njb-1	134	47	of	of	ADP
njb-1	134	48	the	the	DET
njb-1	134	49	143	143	ADJ
njb-1	134	50	patients	patient	NOUN
njb-1	134	51	whose	whose	DET
njb-1	134	52	data	datum	NOUN
njb-1	134	53	was	be	AUX
njb-1	134	54	evaluated	evaluate	VERB
njb-1	134	55	72	72	NUM
njb-1	134	56	or	or	CCONJ
njb-1	134	57	50	50	NUM
njb-1	134	58	%	%	NOUN
njb-1	134	59	of	of	ADP
njb-1	134	60	them	they	PRON
njb-1	134	61	suffered	suffer	VERB
njb-1	134	62	from	from	ADP
njb-1	134	63	severe	severe	ADJ
njb-1	134	64	infections	infection	NOUN
njb-1	134	65	.	.	PUNCT
njb-1	135	1	29	29	NUM
njb-1	135	2	of	of	ADP
njb-1	135	3	them	they	PRON
njb-1	135	4	had	have	VERB
njb-1	135	5	hypoalbuminemia	hypoalbuminemia	NOUN
njb-1	135	6	,	,	PUNCT
njb-1	135	7	32	32	NUM
njb-1	135	8	of	of	ADP
njb-1	135	9	them	they	PRON
njb-1	135	10	had	have	VERB
njb-1	135	11	low	low	ADJ
njb-1	135	12	fibrinogen	fibrinogen	NOUN
njb-1	135	13	and	and	CCONJ
njb-1	135	14	9	9	NUM
njb-1	135	15	of	of	ADP
njb-1	135	16	them	they	PRON
njb-1	135	17	showed	show	VERB
njb-1	135	18	weight	weight	NOUN
njb-1	135	19	loss	loss	NOUN
njb-1	135	20	.	.	PUNCT
njb-1	136	1	there	there	PRON
njb-1	136	2	were	be	VERB
njb-1	136	3	also	also	ADV
njb-1	136	4	specific	specific	ADJ
njb-1	136	5	toxicities	toxicity	NOUN
njb-1	136	6	seen	see	VERB
njb-1	136	7	in	in	ADP
njb-1	136	8	the	the	DET
njb-1	136	9	group	group	NOUN
njb-1	136	10	given	give	VERB
njb-1	136	11	peg	peg	PROPN
njb-1	136	12	e.	e.	PROPN
njb-1	136	13	coli	coli	PROPN
njb-1	136	14	asparaginase	asparaginase	NOUN
njb-1	136	15	.	.	PUNCT
njb-1	137	1	only	only	ADV
njb-1	137	2	6	6	NUM
njb-1	137	3	of	of	ADP
njb-1	137	4	the	the	DET
njb-1	137	5	144	144	NUM
njb-1	137	6	tested	tested	PROPN
njb-1	137	7	showed	show	VERB
njb-1	137	8	peg	peg	NOUN
njb-1	137	9	-	-	PUNCT
njb-1	137	10	asparaginase	asparaginase	NOUN
njb-1	137	11	hypersensitivity	hypersensitivity	NOUN
njb-1	137	12	,	,	PUNCT
njb-1	137	13	4	4	NUM
njb-1	137	14	of	of	ADP
njb-1	137	15	whom	whom	PRON
njb-1	137	16	only	only	ADV
njb-1	137	17	showed	show	VERB
njb-1	137	18	grade	grade	NOUN
njb-1	137	19	i	i	PRON
njb-1	137	20	allergic	allergic	ADJ
njb-1	137	21	reaction	reaction	NOUN
njb-1	137	22	.	.	PUNCT
njb-1	138	1	the	the	DET
njb-1	138	2	other	other	ADJ
njb-1	138	3	2	2	NUM
njb-1	138	4	had	have	VERB
njb-1	138	5	grade	grade	NOUN
njb-1	138	6	iii	iii	NUM
njb-1	138	7	hypersensitivity	hypersensitivity	NOUN
njb-1	138	8	and	and	CCONJ
njb-1	138	9	were	be	AUX
njb-1	138	10	given	give	VERB
njb-1	138	11	alternative	alternative	PROPN
njb-1	138	12	e.	e.	PROPN
njb-1	138	13	chrysanthemi	chrysanthemi	PROPN
njb-1	138	14	asparaginase	asparaginase	PROPN
njb-1	138	15	instead	instead	ADV
njb-1	138	16	[	[	X
njb-1	138	17	23	23	NUM
njb-1	138	18	]	]	PUNCT
njb-1	138	19	.	.	PUNCT
njb-1	139	1	additionally	additionally	ADV
njb-1	139	2	,	,	PUNCT
njb-1	139	3	in	in	ADP
njb-1	139	4	the	the	DET
njb-1	139	5	e.	e.	PROPN
njb-1	139	6	coli	coli	PROPN
njb-1	139	7	asparaginase	asparaginase	NOUN
njb-1	139	8	5000	5000	NUM
njb-1	139	9	arm	arm	NOUN
njb-1	139	10	9	9	NUM
njb-1	139	11	(	(	PUNCT
njb-1	139	12	2.7	2.7	NUM
njb-1	139	13	%	%	NOUN
njb-1	139	14	)	)	PUNCT
njb-1	139	15	deaths	death	NOUN
njb-1	139	16	were	be	AUX
njb-1	139	17	observed	observe	VERB
njb-1	139	18	,	,	PUNCT
njb-1	139	19	whereas	whereas	SCONJ
njb-1	139	20	in	in	ADP
njb-1	139	21	e.	e.	PROPN
njb-1	139	22	coli	coli	PROPN
njb-1	139	23	asparaginase	asparaginase	NOUN
njb-1	139	24	10000	10000	NUM
njb-1	139	25	arm	arm	NOUN
njb-1	139	26	23	23	NUM
njb-1	139	27	(	(	PUNCT
njb-1	139	28	6.5	6.5	NUM
njb-1	139	29	%	%	NOUN
njb-1	139	30	)	)	PUNCT
njb-1	139	31	deaths	death	NOUN
njb-1	139	32	were	be	AUX
njb-1	139	33	observed	observe	VERB
njb-1	139	34	.	.	PUNCT
njb-1	140	1	pneumonia	pneumonia	NOUN
njb-1	140	2	was	be	AUX
njb-1	140	3	seen	see	VERB
njb-1	140	4	in	in	ADP
njb-1	140	5	about	about	ADV
njb-1	140	6	50	50	NUM
njb-1	140	7	%	%	NOUN
njb-1	140	8	of	of	ADP
njb-1	140	9	patients	patient	NOUN
njb-1	140	10	and	and	CCONJ
njb-1	140	11	hypersensitivity	hypersensitivity	NOUN
njb-1	140	12	reaction	reaction	NOUN
njb-1	140	13	was	be	AUX
njb-1	140	14	reported	report	VERB
njb-1	140	15	in	in	ADP
njb-1	140	16	4.5	4.5	NUM
njb-1	140	17	%	%	NOUN
njb-1	140	18	(	(	PUNCT
njb-1	140	19	n=31	n=31	PROPN
njb-1	140	20	)	)	PUNCT
njb-1	140	21	patients	patient	NOUN
njb-1	140	22	in	in	ADP
njb-1	140	23	e.	e.	PROPN
njb-1	140	24	coli	coli	PROPN
njb-1	140	25	asparaginase	asparaginase	NOUN
njb-1	140	26	10000	10000	NUM
njb-1	140	27	arm	arm	NOUN
njb-1	140	28	.	.	PUNCT
njb-1	141	1	in	in	ADP
njb-1	141	2	e.	e.	PROPN
njb-1	141	3	coli	coli	PROPN
njb-1	141	4	5000	5000	NUM
njb-1	141	5	arm	arm	NOUN
njb-1	141	6	1.8	1.8	NUM
njb-1	141	7	%	%	NOUN
njb-1	141	8	(	(	PUNCT
njb-1	141	9	n=13	n=13	PROPN
njb-1	141	10	)	)	PUNCT
njb-1	141	11	patients	patient	NOUN
njb-1	141	12	showed	show	VERB
njb-1	141	13	hypersensitive	hypersensitive	ADJ
njb-1	141	14	reaction	reaction	NOUN
njb-1	141	15	[	[	X
njb-1	141	16	24	24	NUM
njb-1	141	17	]	]	PUNCT
njb-1	141	18	.	.	PUNCT
njb-1	142	1	later	later	ADV
njb-1	142	2	,	,	PUNCT
njb-1	142	3	15	15	NUM
njb-1	142	4	out	out	ADP
njb-1	142	5	of	of	ADP
njb-1	142	6	16	16	NUM
njb-1	142	7	deaths	death	NOUN
njb-1	142	8	were	be	AUX
njb-1	142	9	for	for	ADP
njb-1	142	10	patients	patient	NOUN
njb-1	142	11	over	over	ADP
njb-1	142	12	40	40	NUM
njb-1	142	13	years	year	NOUN
njb-1	142	14	.	.	PUNCT
njb-1	143	1	sepsis	sepsis	NOUN
njb-1	143	2	together	together	ADV
njb-1	143	3	with	with	ADP
njb-1	143	4	hepatotoxicity	hepatotoxicity	NOUN
njb-1	143	5	occurred	occur	VERB
njb-1	143	6	in	in	ADP
njb-1	143	7	50	50	NUM
njb-1	143	8	%	%	NOUN
njb-1	143	9	of	of	ADP
njb-1	143	10	the	the	DET
njb-1	143	11	dead	dead	ADJ
njb-1	143	12	patients	patient	NOUN
njb-1	143	13	.	.	PUNCT
njb-1	144	1	among	among	ADP
njb-1	144	2	surviving	survive	VERB
njb-1	144	3	people	people	NOUN
njb-1	144	4	treated	treat	VERB
njb-1	144	5	with	with	ADP
njb-1	144	6	peg	peg	PROPN
njb-1	144	7	e.	e.	PROPN
njb-1	144	8	coli	coli	PROPN
njb-1	144	9	asparaginase	asparaginase	NOUN
njb-1	144	10	pancreatitis	pancreatitis	NOUN
njb-1	144	11	and	and	CCONJ
njb-1	144	12	hypoalbuminaemia	hypoalbuminaemia	NOUN
njb-1	144	13	of	of	ADP
njb-1	144	14	grade	grade	NOUN
njb-1	144	15	3	3	NUM
njb-1	144	16	+	+	NUM
njb-1	144	17	were	be	AUX
njb-1	144	18	recorded	record	VERB
njb-1	144	19	on	on	ADP
njb-1	144	20	2	2	NUM
njb-1	144	21	patients	patient	NOUN
njb-1	144	22	(	(	PUNCT
njb-1	144	23	3	3	NUM
njb-1	144	24	%	%	NOUN
njb-1	144	25	)	)	PUNCT
njb-1	145	1	[	[	X
njb-1	145	2	17	17	NUM
njb-1	145	3	]	]	PUNCT
njb-1	145	4	.	.	PUNCT
njb-1	146	1	pieters	pieter	NOUN
njb-1	146	2	et	et	PROPN
njb-1	146	3	al	al	PROPN
njb-1	146	4	.	.	PROPN
njb-1	146	5	reported	report	VERB
njb-1	146	6	no	no	DET
njb-1	146	7	death	death	NOUN
njb-1	146	8	during	during	ADP
njb-1	146	9	the	the	DET
njb-1	146	10	trail	trail	NOUN
njb-1	146	11	but	but	CCONJ
njb-1	146	12	recorded	record	VERB
njb-1	146	13	deep	deep	ADJ
njb-1	146	14	venous	venous	ADJ
njb-1	146	15	thrombosis	thrombosis	NOUN
njb-1	146	16	and	and	CCONJ
njb-1	146	17	severe	severe	ADJ
njb-1	146	18	hyperglycemia	hyperglycemia	NOUN
njb-1	146	19	in	in	ADP
njb-1	146	20	two	two	NUM
njb-1	146	21	separate	separate	ADJ
njb-1	146	22	patients	patient	NOUN
njb-1	146	23	given	give	VERB
njb-1	146	24	with	with	ADP
njb-1	146	25	recombinant	recombinant	ADJ
njb-1	146	26	asparaginase	asparaginase	NOUN
njb-1	146	27	and	and	CCONJ
njb-1	146	28	similarly	similarly	ADV
njb-1	146	29	,	,	PUNCT
njb-1	146	30	deep	deep	ADJ
njb-1	146	31	venous	venous	ADJ
njb-1	146	32	thrombosis	thrombosis	NOUN
njb-1	146	33	and	and	CCONJ
njb-1	146	34	severe	severe	ADJ
njb-1	146	35	neutropenia	neutropenia	NOUN
njb-1	146	36	in	in	ADP
njb-1	146	37	two	two	NUM
njb-1	146	38	different	different	ADJ
njb-1	146	39	patients	patient	NOUN
njb-1	146	40	treated	treat	VERB
njb-1	146	41	with	with	ADP
njb-1	146	42	native	native	PROPN
njb-1	146	43	e.	e.	PROPN
njb-1	146	44	coli	coli	PROPN
njb-1	146	45	asparaginase	asparaginase	NOUN
njb-1	146	46	[	[	PUNCT
njb-1	146	47	11	11	NUM
njb-1	146	48	]	]	PUNCT
njb-1	146	49	.	.	PUNCT
njb-1	147	1	a	a	DET
njb-1	147	2	study	study	NOUN
njb-1	147	3	conducted	conduct	VERB
njb-1	147	4	by	by	ADP
njb-1	147	5	van	van	PROPN
njb-1	147	6	der	der	PROPN
njb-1	147	7	sluis	sluis	PROPN
njb-1	147	8	et	et	PROPN
njb-1	147	9	al	al	PROPN
njb-1	147	10	.	.	PROPN
njb-1	147	11	found	find	VERB
njb-1	147	12	that	that	SCONJ
njb-1	147	13	12	12	NUM
njb-1	147	14	patients	patient	NOUN
njb-1	147	15	under	under	ADP
njb-1	147	16	treatment	treatment	NOUN
njb-1	147	17	showed	show	VERB
njb-1	147	18	hemorrhage	hemorrhage	NOUN
njb-1	147	19	,	,	PUNCT
njb-1	147	20	nose	nose	NOUN
njb-1	147	21	bleeding	bleeding	NOUN
njb-1	147	22	,	,	PUNCT
njb-1	147	23	thrombosis	thrombosis	NOUN
njb-1	147	24	of	of	ADP
njb-1	147	25	the	the	DET
njb-1	147	26	superior	superior	ADJ
njb-1	147	27	vena	vena	NOUN
njb-1	147	28	cava	cava	NOUN
njb-1	147	29	and	and	CCONJ
njb-1	147	30	increased	increase	VERB
njb-1	147	31	alanine	alanine	NOUN
njb-1	147	32	aminotransferase	aminotransferase	PROPN
njb-1	147	33	ctc	ctc	PROPN
njb-1	147	34	grade	grade	PROPN
njb-1	147	35	iii	iii	NUM
njb-1	148	1	[	[	PUNCT
njb-1	148	2	12	12	NUM
njb-1	148	3	]	]	PUNCT
njb-1	148	4	.	.	PUNCT
njb-1	149	1	rau	rau	PROPN
njb-1	149	2	et	et	PROPN
njb-1	149	3	al	al	PROPN
njb-1	149	4	.	.	PROPN
njb-1	149	5	reported	report	VERB
njb-1	149	6	complications	complication	NOUN
njb-1	149	7	of	of	ADP
njb-1	149	8	chest	chest	NOUN
njb-1	149	9	tightness	tightness	NOUN
njb-1	149	10	and	and	CCONJ
njb-1	149	11	facial	facial	ADJ
njb-1	149	12	erythema	erythema	NOUN
njb-1	149	13	with	with	ADP
njb-1	149	14	mild	mild	ADJ
njb-1	149	15	swelling	swelling	NOUN
njb-1	149	16	and	and	CCONJ
njb-1	149	17	anaphylaxis	anaphylaxis	ADJ
njb-1	149	18	in	in	ADP
njb-1	149	19	three	three	NUM
njb-1	149	20	patients	patient	NOUN
njb-1	149	21	[	[	X
njb-1	149	22	21	21	NUM
njb-1	149	23	]	]	PUNCT
njb-1	149	24	.	.	PUNCT
njb-1	150	1	albertsen	albertsen	PROPN
njb-1	150	2	et	et	PROPN
njb-1	150	3	al	al	PROPN
njb-1	150	4	.	.	PROPN
njb-1	151	1	in	in	ADP
njb-1	151	2	2019	2019	NUM
njb-1	151	3	,	,	PUNCT
njb-1	151	4	demonstrated	demonstrate	VERB
njb-1	151	5	that	that	SCONJ
njb-1	151	6	60	60	NUM
njb-1	151	7	(	(	PUNCT
njb-1	151	8	9.6	9.6	NUM
njb-1	151	9	%	%	NOUN
njb-1	151	10	)	)	PUNCT
njb-1	151	11	patients	patient	NOUN
njb-1	151	12	experienced	experience	VERB
njb-1	151	13	toxicity	toxicity	NOUN
njb-1	151	14	during	during	ADP
njb-1	151	15	peg	peg	PROPN
njb-1	151	16	e.	e.	PROPN
njb-1	151	17	coli	coli	PROPN
njb-1	151	18	asparaginase	asparaginase	NOUN
njb-1	151	19	treatment	treatment	NOUN
njb-1	151	20	and	and	CCONJ
njb-1	151	21	23	23	NUM
njb-1	151	22	(	(	PUNCT
njb-1	151	23	3.7	3.7	NUM
njb-1	151	24	%	%	NOUN
njb-1	151	25	)	)	PUNCT
njb-1	151	26	after	after	ADP
njb-1	151	27	the	the	DET
njb-1	151	28	last	last	ADJ
njb-1	151	29	dose	dose	NOUN
njb-1	151	30	.	.	PUNCT
njb-1	152	1	among	among	ADP
njb-1	152	2	those	those	DET
njb-1	152	3	showing	show	VERB
njb-1	152	4	symptoms	symptom	NOUN
njb-1	152	5	,	,	PUNCT
njb-1	152	6	hypersensitivity	hypersensitivity	NOUN
njb-1	152	7	was	be	AUX
njb-1	152	8	seen	see	VERB
njb-1	152	9	in	in	ADP
njb-1	152	10	13	13	NUM
njb-1	152	11	(	(	PUNCT
njb-1	152	12	2	2	NUM
njb-1	152	13	%	%	NOUN
njb-1	152	14	)	)	PUNCT
njb-1	152	15	,	,	PUNCT
njb-1	152	16	osteonecrosis	osteonecrosis	NOUN
njb-1	152	17	in	in	ADP
njb-1	152	18	29	29	NUM
njb-1	152	19	(	(	PUNCT
njb-1	152	20	4.6	4.6	NUM
njb-1	152	21	%	%	NOUN
njb-1	152	22	)	)	PUNCT
njb-1	152	23	,	,	PUNCT
njb-1	152	24	pancreatitis	pancreatitis	PROPN
njb-1	152	25	was	be	AUX
njb-1	152	26	seen	see	VERB
njb-1	152	27	in	in	ADP
njb-1	152	28	24	24	NUM
njb-1	152	29	(	(	PUNCT
njb-1	152	30	3.84	3.84	NUM
njb-1	152	31	%	%	NOUN
njb-1	152	32	)	)	PUNCT
njb-1	152	33	and	and	CCONJ
njb-1	152	34	thromboembolisms	thromboembolism	NOUN
njb-1	152	35	in	in	ADP
njb-1	152	36	17	17	NUM
njb-1	152	37	(	(	PUNCT
njb-1	152	38	2.72	2.72	NUM
njb-1	152	39	%	%	NOUN
njb-1	152	40	)	)	PUNCT
njb-1	152	41	.	.	PUNCT
njb-1	153	1	in	in	ADP
njb-1	153	2	a	a	DET
njb-1	153	3	3	3	NUM
njb-1	153	4	-	-	PUNCT
njb-1	153	5	year	year	NOUN
njb-1	153	6	period	period	NOUN
njb-1	153	7	of	of	ADP
njb-1	153	8	observation	observation	NOUN
njb-1	153	9	,	,	PUNCT
njb-1	153	10	incidence	incidence	NOUN
njb-1	153	11	of	of	ADP
njb-1	153	12	any	any	DET
njb-1	153	13	form	form	NOUN
njb-1	153	14	of	of	ADP
njb-1	153	15	toxicity	toxicity	NOUN
njb-1	153	16	associated	associate	VERB
njb-1	153	17	with	with	ADP
njb-1	153	18	first	first	ADJ
njb-1	153	19	asparaginase	asparaginase	NOUN
njb-1	153	20	treatment	treatment	NOUN
njb-1	153	21	after	after	SCONJ
njb-1	153	22	randomization	randomization	NOUN
njb-1	153	23	was	be	AUX
njb-1	153	24	found	find	VERB
njb-1	153	25	to	to	PART
njb-1	153	26	be	be	AUX
njb-1	153	27	much	much	ADV
njb-1	153	28	higher	high	ADJ
njb-1	153	29	in	in	ADP
njb-1	153	30	children	child	NOUN
njb-1	153	31	of	of	ADP
njb-1	153	32	age	age	NOUN
njb-1	153	33	10	10	NUM
njb-1	153	34	years	year	NOUN
njb-1	153	35	or	or	CCONJ
njb-1	153	36	older	old	ADJ
njb-1	153	37	compared	compare	VERB
njb-1	153	38	to	to	ADP
njb-1	153	39	children	child	NOUN
njb-1	153	40	younger	young	ADJ
njb-1	153	41	than	than	ADP
njb-1	153	42	10	10	NUM
njb-1	153	43	years	year	NOUN
njb-1	153	44	,	,	PUNCT
njb-1	153	45	but	but	CCONJ
njb-1	153	46	did	do	AUX
njb-1	153	47	not	not	PART
njb-1	153	48	differ	differ	VERB
njb-1	153	49	between	between	ADP
njb-1	153	50	boys	boy	NOUN
njb-1	153	51	and	and	CCONJ
njb-1	153	52	girls	girl	NOUN
njb-1	153	53	or	or	CCONJ
njb-1	153	54	between	between	ADP
njb-1	153	55	patients	patient	NOUN
njb-1	153	56	at	at	ADP
njb-1	153	57	intermediate	intermediate	ADJ
njb-1	153	58	risk	risk	NOUN
njb-1	153	59	or	or	CCONJ
njb-1	153	60	standard	standard	ADJ
njb-1	153	61	risk	risk	NOUN
njb-1	153	62	[	[	X
njb-1	153	63	13	13	NUM
njb-1	153	64	]	]	PUNCT
njb-1	153	65	.	.	PUNCT
njb-1	154	1	additionally	additionally	ADV
njb-1	154	2	in	in	ADP
njb-1	154	3	another	another	DET
njb-1	154	4	study	study	NOUN
njb-1	154	5	comparing	compare	VERB
njb-1	154	6	native	native	ADJ
njb-1	154	7	e.	e.	PROPN
njb-1	154	8	coli	coli	PROPN
njb-1	154	9	asparaginase	asparaginase	NOUN
njb-1	154	10	with	with	ADP
njb-1	154	11	e.	e.	PROPN
njb-1	154	12	chrysanthemi	chrysanthemi	PROPN
njb-1	154	13	asparaginase	asparaginase	PROPN
njb-1	154	14	,	,	PUNCT
njb-1	154	15	e.	e.	PROPN
njb-1	154	16	coli	coli	PROPN
njb-1	154	17	asparaginase	asparaginase	NOUN
njb-1	154	18	arm	arm	NOUN
njb-1	154	19	had	have	VERB
njb-1	154	20	more	more	ADJ
njb-1	154	21	instances	instance	NOUN
njb-1	154	22	of	of	ADP
njb-1	154	23	coagulation	coagulation	NOUN
njb-1	154	24	abnormalities	abnormality	NOUN
njb-1	154	25	(	(	PUNCT
njb-1	154	26	30.2	30.2	NUM
njb-1	154	27	%	%	NOUN
njb-1	154	28	)	)	PUNCT
njb-1	154	29	compared	compare	VERB
njb-1	154	30	to	to	ADP
njb-1	154	31	e.	e.	PROPN
njb-1	154	32	chrysanthemi	chrysanthemi	PROPN
njb-1	154	33	asparaginase	asparaginase	PROPN
njb-1	154	34	arm	arm	NOUN
njb-1	154	35	(	(	PUNCT
njb-1	154	36	11.8	11.8	NUM
njb-1	154	37	%	%	NOUN
njb-1	154	38	)	)	PUNCT
njb-1	155	1	[	[	X
njb-1	155	2	15	15	NUM
njb-1	155	3	]	]	PUNCT
njb-1	155	4	.	.	PUNCT
njb-1	156	1	another	another	DET
njb-1	156	2	trial	trial	NOUN
njb-1	156	3	conducted	conduct	VERB
njb-1	156	4	in	in	ADP
njb-1	156	5	spain	spain	PROPN
njb-1	156	6	by	by	ADP
njb-1	156	7	ribera	ribera	PROPN
njb-1	156	8	et	et	PROPN
njb-1	156	9	al	al	PROPN
njb-1	156	10	concluded	conclude	VERB
njb-1	156	11	that	that	SCONJ
njb-1	156	12	during	during	ADP
njb-1	156	13	induction	induction	NOUN
njb-1	156	14	therapy	therapy	NOUN
njb-1	156	15	,	,	PUNCT
njb-1	156	16	percentage	percentage	NOUN
njb-1	156	17	of	of	ADP
njb-1	156	18	patients	patient	NOUN
njb-1	156	19	with	with	ADP
njb-1	156	20	detectable	detectable	ADJ
njb-1	156	21	infection	infection	NOUN
njb-1	156	22	,	,	PUNCT
njb-1	156	23	hypersensitivity	hypersensitivity	NOUN
njb-1	156	24	,	,	PUNCT
njb-1	156	25	thrombosis	thrombosis	NOUN
njb-1	156	26	,	,	PUNCT
njb-1	156	27	hepatic	hepatic	ADJ
njb-1	156	28	toxicity	toxicity	NOUN
njb-1	156	29	,	,	PUNCT
njb-1	156	30	pancreatitis	pancreatitis	PROPN
njb-1	156	31	and	and	CCONJ
njb-1	156	32	coagulopathy	coagulopathy	NOUN
njb-1	156	33	(	(	PUNCT
njb-1	156	34	all	all	PRON
njb-1	156	35	of	of	ADP
njb-1	156	36	them	they	PRON
njb-1	156	37	within	within	ADP
njb-1	156	38	grade	grade	NOUN
njb-1	156	39	3	3	NUM
njb-1	156	40	-	-	SYM
njb-1	156	41	4	4	NUM
njb-1	156	42	)	)	PUNCT
njb-1	156	43	for	for	ADP
njb-1	156	44	native	native	PROPN
njb-1	156	45	e.	e.	PROPN
njb-1	156	46	coli	coli	PROPN
njb-1	156	47	asparaginase	asparaginase	NOUN
njb-1	156	48	was	be	AUX
njb-1	156	49	56	56	NUM
njb-1	156	50	%	%	NOUN
njb-1	156	51	,	,	PUNCT
njb-1	156	52	1	1	NUM
njb-1	156	53	%	%	NOUN
njb-1	156	54	,	,	PUNCT
njb-1	156	55	6	6	NUM
njb-1	156	56	%	%	NOUN
njb-1	156	57	,	,	PUNCT
njb-1	156	58	21	21	NUM
njb-1	156	59	%	%	NOUN
njb-1	156	60	,	,	PUNCT
njb-1	156	61	1	1	NUM
njb-1	156	62	%	%	NOUN
njb-1	156	63	,	,	PUNCT
njb-1	156	64	11	11	NUM
njb-1	156	65	%	%	NOUN
njb-1	156	66	respectively	respectively	ADV
njb-1	156	67	while	while	SCONJ
njb-1	156	68	for	for	ADP
njb-1	156	69	peg	peg	PROPN
njb-1	156	70	e.	e.	PROPN
njb-1	156	71	coli	coli	PROPN
njb-1	156	72	asparaginase	asparaginase	NOUN
njb-1	156	73	was	be	AUX
njb-1	156	74	45	45	NUM
njb-1	156	75	,	,	PUNCT
njb-1	156	76	0	0	NUM
njb-1	156	77	,	,	PUNCT
njb-1	156	78	9	9	NUM
njb-1	156	79	,	,	PUNCT
njb-1	156	80	38	38	NUM
njb-1	156	81	,	,	PUNCT
njb-1	156	82	3	3	NUM
njb-1	156	83	,	,	PUNCT
njb-1	156	84	18	18	NUM
njb-1	156	85	respectively	respectively	ADV
njb-1	156	86	.	.	PUNCT
njb-1	157	1	similarly	similarly	ADV
njb-1	157	2	during	during	ADP
njb-1	157	3	consolidation	consolidation	NOUN
njb-1	157	4	therapy	therapy	NOUN
njb-1	157	5	,	,	PUNCT
njb-1	157	6	percentage	percentage	NOUN
njb-1	157	7	of	of	ADP
njb-1	157	8	patients	patient	NOUN
njb-1	157	9	with	with	ADP
njb-1	157	10	detectable	detectable	ADJ
njb-1	157	11	infection	infection	NOUN
njb-1	157	12	,	,	PUNCT
njb-1	157	13	hypersensitivity	hypersensitivity	NOUN
njb-1	157	14	,	,	PUNCT
njb-1	157	15	thrombosis	thrombosis	NOUN
njb-1	157	16	,	,	PUNCT
njb-1	157	17	hepatic	hepatic	ADJ
njb-1	157	18	toxicity	toxicity	NOUN
njb-1	157	19	,	,	PUNCT
njb-1	157	20	pancreatitis	pancreatitis	PROPN
njb-1	157	21	and	and	CCONJ
njb-1	157	22	coagulopathy	coagulopathy	NOUN
njb-1	157	23	(	(	PUNCT
njb-1	157	24	all	all	PRON
njb-1	157	25	within	within	ADP
njb-1	157	26	grade	grade	NOUN
njb-1	157	27	3	3	NUM
njb-1	157	28	-	-	SYM
njb-1	157	29	4	4	NUM
njb-1	157	30	)	)	PUNCT
njb-1	157	31	for	for	ADP
njb-1	157	32	native	native	PROPN
njb-1	157	33	e.	e.	PROPN
njb-1	157	34	coli	coli	PROPN
njb-1	157	35	asparaginase	asparaginase	NOUN
njb-1	157	36	was	be	AUX
njb-1	157	37	16	16	NUM
njb-1	157	38	%	%	NOUN
njb-1	157	39	,	,	PUNCT
njb-1	157	40	1	1	NUM
njb-1	157	41	%	%	NOUN
njb-1	157	42	,	,	PUNCT
njb-1	157	43	0.4	0.4	NUM
njb-1	157	44	%	%	NOUN
njb-1	157	45	,	,	PUNCT
njb-1	157	46	3	3	NUM
njb-1	157	47	%	%	NOUN
njb-1	157	48	,	,	PUNCT
njb-1	157	49	0	0	NUM
njb-1	157	50	%	%	NOUN
njb-1	157	51	,	,	PUNCT
njb-1	157	52	0.4	0.4	NUM
njb-1	157	53	%	%	NOUN
njb-1	157	54	respectively	respectively	ADV
njb-1	157	55	while	while	SCONJ
njb-1	157	56	for	for	ADP
njb-1	157	57	peg	peg	PROPN
njb-1	157	58	e.	e.	PROPN
njb-1	157	59	coli	coli	PROPN
njb-1	157	60	asparaginase	asparaginase	NOUN
njb-1	157	61	was	be	AUX
njb-1	157	62	13	13	NUM
njb-1	157	63	%	%	NOUN
njb-1	157	64	,	,	PUNCT
njb-1	157	65	1	1	NUM
njb-1	157	66	%	%	NOUN
njb-1	157	67	,	,	PUNCT
njb-1	157	68	0	0	NUM
njb-1	157	69	%	%	NOUN
njb-1	157	70	,	,	PUNCT
njb-1	157	71	11	11	NUM
njb-1	157	72	%	%	NOUN
njb-1	157	73	,	,	PUNCT
njb-1	157	74	0	0	NUM
njb-1	157	75	%	%	NOUN
njb-1	157	76	,	,	PUNCT
njb-1	157	77	5	5	NUM
njb-1	157	78	%	%	NOUN
njb-1	157	79	respectively	respectively	ADV
njb-1	157	80	[	[	X
njb-1	157	81	25	25	NUM
njb-1	157	82	]	]	PUNCT
njb-1	157	83	.	.	PUNCT
njb-1	158	1	toxicities	toxicity	NOUN
njb-1	158	2	caused	cause	VERB
njb-1	158	3	by	by	ADP
njb-1	158	4	different	different	ADJ
njb-1	158	5	forms	form	NOUN
njb-1	158	6	are	be	AUX
njb-1	158	7	asparaginases	asparaginase	NOUN
njb-1	158	8	are	be	AUX
njb-1	158	9	relatively	relatively	ADV
njb-1	158	10	similar	similar	ADJ
njb-1	158	11	in	in	ADP
njb-1	158	12	every	every	DET
njb-1	158	13	patient	patient	NOUN
njb-1	158	14	group	group	NOUN
njb-1	158	15	(	(	PUNCT
njb-1	158	16	table	table	NOUN
njb-1	158	17	4	4	NUM
njb-1	158	18	)	)	PUNCT
njb-1	158	19	.	.	PUNCT
njb-1	159	1	nepal	nepal	PROPN
njb-1	159	2	j	j	PROPN
njb-1	159	3	biotechnol	biotechnol	PROPN
njb-1	159	4	.	.	PUNCT
njb-1	160	1	2	2	NUM
njb-1	160	2	0	0	NUM
njb-1	160	3	2	2	NUM
njb-1	160	4	1	1	NUM
njb-1	160	5	d	d	X
njb-1	160	6	e	e	X
njb-1	160	7	c	c	PROPN
njb-1	160	8	.	.	PUNCT
njb-1	161	1	9	9	NUM
njb-1	161	2	(	(	PUNCT
njb-1	161	3	2	2	NUM
njb-1	161	4	):	):	PUNCT
njb-1	161	5	39	39	NUM
njb-1	161	6	-	-	SYM
njb-1	161	7	47	47	NUM
njb-1	161	8	baral	baral	ADJ
njb-1	161	9	et	et	PROPN
njb-1	161	10	al	al	PROPN
njb-1	161	11	.	.	PUNCT
njb-1	162	1	©	©	PROPN
njb-1	162	2	njb	njb	PROPN
njb-1	162	3	,	,	PUNCT
njb-1	162	4	bsn	bsn	PROPN
njb-1	162	5	43	43	NUM
njb-1	162	6	event	event	NOUN
njb-1	162	7	-	-	PUNCT
njb-1	162	8	free	free	ADJ
njb-1	162	9	survival	survival	NOUN
njb-1	162	10	(	(	PUNCT
njb-1	162	11	efs	ef	NOUN
njb-1	162	12	):	):	PUNCT
njb-1	162	13	following	follow	VERB
njb-1	162	14	initial	initial	ADJ
njb-1	162	15	treatment	treatment	NOUN
njb-1	162	16	for	for	ADP
njb-1	162	17	cancer	cancer	NOUN
njb-1	162	18	,	,	PUNCT
njb-1	162	19	patients	patient	NOUN
njb-1	162	20	generally	generally	ADV
njb-1	162	21	remain	remain	VERB
njb-1	162	22	free	free	ADJ
njb-1	162	23	of	of	ADP
njb-1	162	24	any	any	DET
njb-1	162	25	complications	complication	NOUN
njb-1	162	26	or	or	CCONJ
njb-1	162	27	symptoms	symptom	NOUN
njb-1	162	28	that	that	PRON
njb-1	162	29	were	be	AUX
njb-1	162	30	intended	intend	VERB
njb-1	162	31	to	to	PART
njb-1	162	32	delay	delay	VERB
njb-1	162	33	or	or	CCONJ
njb-1	162	34	prevent	prevent	VERB
njb-1	162	35	their	their	PRON
njb-1	162	36	treatment	treatment	NOUN
njb-1	162	37	.	.	PUNCT
njb-1	163	1	this	this	PRON
njb-1	163	2	is	be	AUX
njb-1	163	3	known	know	VERB
njb-1	163	4	as	as	ADP
njb-1	163	5	an	an	DET
njb-1	163	6	event	event	NOUN
njb-1	163	7	-	-	PUNCT
njb-1	163	8	free	free	ADJ
njb-1	163	9	survival	survival	NOUN
njb-1	163	10	.	.	PUNCT
njb-1	164	1	vyas	vyas	PROPN
njb-1	164	2	et	et	PROPN
njb-1	164	3	al	al	PROPN
njb-1	164	4	.	.	PROPN
njb-1	164	5	reported	report	VERB
njb-1	164	6	that	that	SCONJ
njb-1	164	7	2	2	NUM
njb-1	164	8	-	-	PUNCT
njb-1	164	9	years	year	NOUN
njb-1	164	10	event	event	NOUN
njb-1	164	11	-	-	PUNCT
njb-1	164	12	free	free	ADJ
njb-1	164	13	survival	survival	NOUN
njb-1	164	14	of	of	ADP
njb-1	164	15	patients	patient	NOUN
njb-1	164	16	treated	treat	VERB
njb-1	164	17	with	with	ADP
njb-1	164	18	peg	peg	PROPN
njb-1	164	19	e.	e.	PROPN
njb-1	164	20	coli	coli	PROPN
njb-1	164	21	was	be	AUX
njb-1	164	22	84	84	NUM
njb-1	164	23	%	%	NOUN
njb-1	164	24	and	and	CCONJ
njb-1	164	25	treated	treat	VERB
njb-1	164	26	with	with	ADP
njb-1	164	27	native	native	PROPN
njb-1	164	28	e.	e.	PROPN
njb-1	164	29	coli	coli	PROPN
njb-1	164	30	asparaginase	asparaginase	NOUN
njb-1	164	31	was	be	AUX
njb-1	164	32	80.7	80.7	NUM
njb-1	164	33	%	%	NOUN
njb-1	164	34	[	[	PUNCT
njb-1	164	35	16	16	NUM
njb-1	164	36	]	]	PUNCT
njb-1	164	37	.	.	PUNCT
njb-1	165	1	place	place	PROPN
njb-1	165	2	et	et	PROPN
njb-1	165	3	al	al	PROPN
njb-1	165	4	evaluated	evaluate	VERB
njb-1	165	5	5years	5year	NOUN
njb-1	165	6	of	of	ADP
njb-1	165	7	event	event	NOUN
njb-1	165	8	-	-	PUNCT
njb-1	165	9	free	free	ADJ
njb-1	165	10	survival	survival	NOUN
njb-1	165	11	of	of	ADP
njb-1	165	12	patients	patient	NOUN
njb-1	165	13	to	to	PART
njb-1	165	14	be	be	AUX
njb-1	165	15	90	90	NUM
njb-1	165	16	%	%	NOUN
njb-1	165	17	in	in	ADP
njb-1	165	18	peg	peg	PROPN
njb-1	165	19	e.	e.	PROPN
njb-1	165	20	coli	coli	PROPN
njb-1	165	21	asparaginase	asparaginase	NOUN
njb-1	165	22	treated	treat	VERB
njb-1	165	23	group	group	NOUN
njb-1	165	24	and	and	CCONJ
njb-1	165	25	89	89	NUM
njb-1	165	26	%	%	NOUN
njb-1	165	27	native	native	PROPN
njb-1	165	28	e.	e.	PROPN
njb-1	165	29	coli	coli	PROPN
njb-1	165	30	asparaginase	asparaginase	NOUN
njb-1	165	31	treated	treat	VERB
njb-1	165	32	group[19	group[19	NOUN
njb-1	165	33	]	]	PUNCT
njb-1	165	34	.	.	PUNCT
njb-1	166	1	pession	pession	NOUN
njb-1	166	2	et	et	PROPN
njb-1	166	3	al	al	PROPN
njb-1	166	4	.	.	PROPN
njb-1	167	1	study	study	PROPN
njb-1	167	2	found	find	VERB
njb-1	167	3	that	that	SCONJ
njb-1	167	4	5	5	NUM
njb-1	167	5	year	year	NOUN
njb-1	167	6	and	and	CCONJ
njb-1	167	7	10	10	NUM
njb-1	167	8	year	year	NOUN
njb-1	167	9	eventfree	eventfree	NOUN
njb-1	167	10	survival	survival	NOUN
njb-1	167	11	(	(	PUNCT
njb-1	167	12	efs	efs	PROPN
njb-1	167	13	)	)	PUNCT
njb-1	167	14	of	of	ADP
njb-1	167	15	native	native	PROPN
njb-1	167	16	e.	e.	PROPN
njb-1	167	17	coli	coli	PROPN
njb-1	167	18	asparaginase	asparaginase	NOUN
njb-1	167	19	group	group	NOUN
njb-1	167	20	was	be	AUX
njb-1	167	21	84.6	84.6	NUM
njb-1	167	22	%	%	NOUN
njb-1	167	23	and	and	CCONJ
njb-1	167	24	82.5	82.5	NUM
njb-1	167	25	%	%	NOUN
njb-1	167	26	for	for	ADP
njb-1	167	27	the	the	DET
njb-1	167	28	494	494	NUM
njb-1	167	29	patients	patient	NOUN
njb-1	167	30	enrolled	enrol	VERB
njb-1	167	31	in	in	ADP
njb-1	167	32	the	the	DET
njb-1	167	33	trial	trial	NOUN
njb-1	167	34	.	.	PUNCT
njb-1	168	1	58	58	NUM
njb-1	168	2	cases	case	NOUN
njb-1	168	3	failed	fail	VERB
njb-1	168	4	to	to	PART
njb-1	168	5	achieve	achieve	VERB
njb-1	168	6	event	event	NOUN
njb-1	168	7	-	-	PUNCT
njb-1	168	8	free	free	ADJ
njb-1	168	9	status	status	NOUN
njb-1	168	10	with	with	ADP
njb-1	168	11	1	1	NUM
njb-1	168	12	case	case	NOUN
njb-1	168	13	of	of	ADP
njb-1	168	14	second	second	ADJ
njb-1	168	15	malignancy	malignancy	NOUN
njb-1	168	16	and	and	CCONJ
njb-1	168	17	22	22	NUM
njb-1	168	18	relapses	relapse	NOUN
njb-1	168	19	.	.	PUNCT
njb-1	169	1	the	the	DET
njb-1	169	2	study	study	NOUN
njb-1	169	3	by	by	ADP
njb-1	169	4	liang	liang	PROPN
njb-1	169	5	et	et	PROPN
njb-1	169	6	al	al	PROPN
njb-1	169	7	.	.	PROPN
njb-1	169	8	was	be	AUX
njb-1	169	9	a	a	DET
njb-1	169	10	comparison	comparison	NOUN
njb-1	169	11	between	between	ADP
njb-1	169	12	the	the	DET
njb-1	169	13	use	use	NOUN
njb-1	169	14	of	of	ADP
njb-1	169	15	native	native	PROPN
njb-1	169	16	e.	e.	PROPN
njb-1	169	17	coli	coli	PROPN
njb-1	169	18	asparaginase	asparaginase	NOUN
njb-1	169	19	and	and	CCONJ
njb-1	169	20	epidoxorubicin	epidoxorubicin	PROPN
njb-1	169	21	in	in	ADP
njb-1	169	22	the	the	DET
njb-1	169	23	treatment	treatment	NOUN
njb-1	169	24	of	of	ADP
njb-1	169	25	sr	sr	PROPN
njb-1	169	26	all	all	PRON
njb-1	169	27	in	in	ADP
njb-1	169	28	the	the	DET
njb-1	169	29	remission	remission	NOUN
njb-1	169	30	induction	induction	NOUN
njb-1	169	31	therapy	therapy	NOUN
njb-1	169	32	.	.	PUNCT
njb-1	170	1	they	they	PRON
njb-1	170	2	also	also	ADV
njb-1	170	3	saw	see	VERB
njb-1	170	4	5	5	NUM
njb-1	170	5	relapses	relapse	NOUN
njb-1	170	6	in	in	ADP
njb-1	170	7	their	their	PRON
njb-1	170	8	asparaginase	asparaginase	NOUN
njb-1	170	9	arm	arm	NOUN
njb-1	170	10	of	of	ADP
njb-1	170	11	the	the	DET
njb-1	170	12	study	study	NOUN
njb-1	170	13	group	group	NOUN
njb-1	170	14	.	.	PUNCT
njb-1	171	1	they	they	PRON
njb-1	171	2	estimated	estimate	VERB
njb-1	171	3	an	an	DET
njb-1	171	4	efs	ef	NOUN
njb-1	171	5	at	at	ADP
njb-1	171	6	3	3	NUM
njb-1	171	7	years	year	NOUN
njb-1	171	8	to	to	PART
njb-1	171	9	be	be	AUX
njb-1	171	10	72%[22	72%[22	NUM
njb-1	171	11	]	]	PUNCT
njb-1	171	12	.	.	PUNCT
njb-1	172	1	the	the	DET
njb-1	172	2	fda	fda	PROPN
njb-1	172	3	phase	phase	PROPN
njb-1	172	4	ii	ii	PROPN
njb-1	172	5	trial	trial	NOUN
njb-1	172	6	study	study	NOUN
njb-1	172	7	by	by	ADP
njb-1	172	8	dinndorf	dinndorf	PROPN
njb-1	172	9	et	et	PROPN
njb-1	172	10	al	al	PROPN
njb-1	172	11	.	.	PROPN
njb-1	172	12	did	do	AUX
njb-1	172	13	not	not	PART
njb-1	172	14	attempt	attempt	VERB
njb-1	172	15	to	to	PART
njb-1	172	16	find	find	VERB
njb-1	172	17	long	long	ADJ
njb-1	172	18	-	-	PUNCT
njb-1	172	19	term	term	NOUN
njb-1	172	20	efs	ef	NOUN
njb-1	172	21	.	.	PUNCT
njb-1	173	1	they	they	PRON
njb-1	173	2	estimated	estimate	VERB
njb-1	173	3	an	an	DET
njb-1	173	4	80	80	NUM
njb-1	173	5	%	%	NOUN
njb-1	173	6	efs	ef	NOUN
njb-1	173	7	for	for	ADP
njb-1	173	8	both	both	CCONJ
njb-1	173	9	their	their	PRON
njb-1	173	10	erwinia	erwinia	PROPN
njb-1	173	11	asparaginase	asparaginase	NOUN
njb-1	173	12	group	group	NOUN
njb-1	173	13	and	and	CCONJ
njb-1	173	14	peg	peg	NOUN
njb-1	173	15	asparaginase	asparaginase	NOUN
njb-1	173	16	group	group	NOUN
njb-1	173	17	.	.	PUNCT
njb-1	174	1	karachunskiy	karachunskiy	PROPN
njb-1	174	2	et	et	PROPN
njb-1	174	3	al	al	PROPN
njb-1	174	4	.	.	PROPN
njb-1	174	5	conducted	conduct	VERB
njb-1	174	6	a	a	DET
njb-1	174	7	study	study	NOUN
njb-1	174	8	on	on	ADP
njb-1	174	9	event	event	NOUN
njb-1	174	10	-	-	PUNCT
njb-1	174	11	free	free	ADJ
njb-1	174	12	survival	survival	NOUN
njb-1	174	13	rates	rate	NOUN
njb-1	174	14	and	and	CCONJ
njb-1	174	15	found	find	VERB
njb-1	174	16	that	that	SCONJ
njb-1	174	17	at	at	ADP
njb-1	174	18	10	10	NUM
njb-1	174	19	years	year	NOUN
njb-1	174	20	the	the	DET
njb-1	174	21	probabilities	probability	NOUN
njb-1	174	22	of	of	ADP
njb-1	174	23	event	event	NOUN
njb-1	174	24	-	-	PUNCT
njb-1	174	25	free	free	ADJ
njb-1	174	26	survival	survival	NOUN
njb-1	174	27	rates	rate	NOUN
njb-1	174	28	for	for	ADP
njb-1	174	29	escherichia	escherichia	NOUN
njb-1	174	30	coli	coli	NOUN
njb-1	174	31	5000	5000	NUM
njb-1	174	32	arm	arm	NOUN
njb-1	174	33	(	(	PUNCT
njb-1	174	34	79	79	NUM
njb-1	174	35	±	±	NOUN
njb-1	174	36	2	2	NUM
njb-1	174	37	%	%	NOUN
njb-1	174	38	)	)	PUNCT
njb-1	174	39	were	be	AUX
njb-1	174	40	not	not	PART
njb-1	174	41	significantly	significantly	ADV
njb-1	174	42	different	different	ADJ
njb-1	174	43	from	from	ADP
njb-1	174	44	escherichia	escherichia	NOUN
njb-1	174	45	coli	coli	NOUN
njb-1	174	46	10000	10000	NUM
njb-1	174	47	arm	arm	NOUN
njb-1	174	48	(	(	PUNCT
njb-1	174	49	75	75	NUM
njb-1	174	50	±	±	NOUN
njb-1	174	51	2	2	NUM
njb-1	174	52	%	%	NOUN
njb-1	174	53	)	)	PUNCT
njb-1	175	1	[	[	X
njb-1	175	2	24	24	NUM
njb-1	175	3	]	]	PUNCT
njb-1	175	4	.	.	PUNCT
njb-1	176	1	while	while	SCONJ
njb-1	176	2	comparing	compare	VERB
njb-1	176	3	native	native	ADJ
njb-1	176	4	e.	e.	PROPN
njb-1	176	5	coli	coli	PROPN
njb-1	176	6	asparaginase	asparaginase	NOUN
njb-1	176	7	with	with	ADP
njb-1	176	8	e.	e.	PROPN
njb-1	176	9	chrysanthemi	chrysanthemi	PROPN
njb-1	176	10	asparaginase	asparaginase	PROPN
njb-1	176	11	,	,	PUNCT
njb-1	176	12	event	event	NOUN
njb-1	176	13	-	-	PUNCT
njb-1	176	14	free	free	ADJ
njb-1	176	15	survival	survival	NOUN
njb-1	176	16	predicted	predict	VERB
njb-1	176	17	was	be	AUX
njb-1	176	18	6	6	NUM
njb-1	176	19	years	year	NOUN
njb-1	176	20	and	and	CCONJ
njb-1	176	21	percentage	percentage	NOUN
njb-1	176	22	patient	patient	ADJ
njb-1	176	23	survival	survival	NOUN
njb-1	176	24	was	be	AUX
njb-1	176	25	73.4	73.4	NUM
njb-1	176	26	%	%	NOUN
njb-1	176	27	versus	versus	ADP
njb-1	176	28	59.8	59.8	NUM
njb-1	176	29	%	%	NOUN
njb-1	177	1	[	[	PUNCT
njb-1	177	2	15	15	NUM
njb-1	177	3	]	]	PUNCT
njb-1	177	4	(	(	PUNCT
njb-1	177	5	table	table	NOUN
njb-1	177	6	5	5	NUM
njb-1	177	7	)	)	PUNCT
njb-1	177	8	.	.	PUNCT
njb-1	178	1	by	by	ADP
njb-1	178	2	observing	observe	VERB
njb-1	178	3	years	year	NOUN
njb-1	178	4	of	of	ADP
njb-1	178	5	event	event	NOUN
njb-1	178	6	free	free	ADJ
njb-1	178	7	survival	survival	NOUN
njb-1	178	8	ranges	range	VERB
njb-1	178	9	,	,	PUNCT
njb-1	178	10	it	it	PRON
njb-1	178	11	can	can	AUX
njb-1	178	12	be	be	AUX
njb-1	178	13	discerned	discern	VERB
njb-1	178	14	that	that	SCONJ
njb-1	178	15	peg	peg	PROPN
njb-1	178	16	e.	e.	PROPN
njb-1	178	17	coli	coli	PROPN
njb-1	178	18	asparaginase	asparaginase	NOUN
njb-1	178	19	gives	give	VERB
njb-1	178	20	low	low	ADJ
njb-1	178	21	degree	degree	NOUN
njb-1	178	22	of	of	ADP
njb-1	178	23	disease	disease	NOUN
njb-1	178	24	reoccurrence	reoccurrence	NOUN
njb-1	178	25	(	(	PUNCT
njb-1	178	26	table	table	NOUN
njb-1	178	27	6	6	NUM
njb-1	178	28	)	)	PUNCT
njb-1	178	29	.	.	PUNCT
njb-1	179	1	follow	follow	VERB
njb-1	179	2	up	up	ADP
njb-1	179	3	period	period	NOUN
njb-1	179	4	for	for	ADP
njb-1	179	5	event	event	NOUN
njb-1	179	6	free	free	ADJ
njb-1	179	7	survival	survival	NOUN
njb-1	179	8	patients	patient	NOUN
njb-1	179	9	were	be	AUX
njb-1	179	10	reported	report	VERB
njb-1	179	11	for	for	ADP
njb-1	179	12	10	10	NUM
njb-1	179	13	years	year	NOUN
njb-1	179	14	for	for	ADP
njb-1	179	15	native	native	PROPN
njb-1	179	16	e.	e.	PROPN
njb-1	179	17	coli	coli	PROPN
njb-1	179	18	(	(	PUNCT
njb-1	179	19	10	10	NUM
njb-1	179	20	years	year	NOUN
njb-1	179	21	)	)	PUNCT
njb-1	179	22	,	,	PUNCT
njb-1	179	23	6	6	NUM
njb-1	179	24	years	year	NOUN
njb-1	179	25	for	for	ADP
njb-1	179	26	peg	peg	PROPN
njb-1	179	27	e.	e.	PROPN
njb-1	179	28	coli	coli	PROPN
njb-1	179	29	and	and	CCONJ
njb-1	179	30	6	6	NUM
njb-1	179	31	years	year	NOUN
njb-1	179	32	for	for	ADP
njb-1	179	33	e.	e.	PROPN
njb-1	179	34	chrysanthemi	chrysanthemi	PROPN
njb-1	179	35	asparaginases	asparaginases	PROPN
njb-1	179	36	.	.	PUNCT
njb-1	180	1	overall	overall	ADJ
njb-1	180	2	survival	survival	NOUN
njb-1	180	3	:	:	PUNCT
njb-1	180	4	a	a	DET
njb-1	180	5	clinical	clinical	ADJ
njb-1	180	6	trial	trial	NOUN
njb-1	180	7	reported	report	VERB
njb-1	180	8	2	2	NUM
njb-1	180	9	-	-	PUNCT
njb-1	180	10	year	year	NOUN
njb-1	180	11	event	event	NOUN
njb-1	180	12	-	-	PUNCT
njb-1	180	13	free	free	ADJ
njb-1	180	14	survival	survival	NOUN
njb-1	180	15	of	of	ADP
njb-1	180	16	patients	patient	NOUN
njb-1	180	17	at	at	ADP
njb-1	180	18	93	93	NUM
njb-1	180	19	%	%	NOUN
njb-1	180	20	treated	treat	VERB
njb-1	180	21	with	with	ADP
njb-1	180	22	peg	peg	PROPN
njb-1	180	23	e.	e.	PROPN
njb-1	180	24	coli	coli	PROPN
njb-1	180	25	asparaginase	asparaginase	NOUN
njb-1	180	26	table	table	NOUN
njb-1	180	27	5	5	NUM
njb-1	180	28	:	:	PUNCT
njb-1	180	29	time	time	NOUN
njb-1	180	30	period	period	NOUN
njb-1	180	31	of	of	ADP
njb-1	180	32	event	event	NOUN
njb-1	180	33	-	-	PUNCT
njb-1	180	34	free	free	ADJ
njb-1	180	35	survival	survival	NOUN
njb-1	180	36	in	in	ADP
njb-1	180	37	treated	treat	VERB
njb-1	180	38	patients	patient	NOUN
njb-1	180	39	from	from	ADP
njb-1	180	40	individual	individual	ADJ
njb-1	180	41	trials	trial	NOUN
njb-1	180	42	.	.	PUNCT
njb-1	181	1	clinical	clinical	ADJ
njb-1	181	2	trial	trial	NOUN
njb-1	181	3	type	type	NOUN
njb-1	181	4	of	of	ADP
njb-1	181	5	asparaginase	asparaginase	NOUN
njb-1	181	6	event	event	NOUN
njb-1	181	7	free	free	ADJ
njb-1	181	8	survival	survival	NOUN
njb-1	181	9	year	year	NOUN
njb-1	181	10	%	%	NOUN
njb-1	181	11	of	of	ADP
njb-1	181	12	patients	patient	NOUN
njb-1	181	13	survived	survive	VERB
njb-1	181	14	follow	follow	VERB
njb-1	181	15	up	up	ADP
njb-1	181	16	period	period	NOUN
njb-1	181	17	(	(	PUNCT
njb-1	181	18	years	year	NOUN
njb-1	181	19	)	)	PUNCT
njb-1	182	1	[	[	X
njb-1	182	2	16	16	NUM
njb-1	182	3	]	]	PUNCT
njb-1	182	4	native	native	ADJ
njb-1	182	5	escherichia	escherichia	PROPN
njb-1	182	6	coli	coli	NOUN
njb-1	182	7	2	2	NUM
njb-1	182	8	80.7	80.7	NUM
njb-1	182	9	2	2	NUM
njb-1	182	10	peg	peg	NOUN
njb-1	182	11	escherichia	escherichia	NOUN
njb-1	182	12	coli	coli	NOUN
njb-1	182	13	2	2	NUM
njb-1	182	14	84	84	NUM
njb-1	183	1	[	[	PUNCT
njb-1	183	2	19	19	NUM
njb-1	183	3	]	]	PUNCT
njb-1	183	4	native	native	ADJ
njb-1	183	5	escherichia	escherichia	PROPN
njb-1	183	6	coli	coli	NOUN
njb-1	183	7	5	5	NUM
njb-1	183	8	89	89	NUM
njb-1	183	9	6	6	NUM
njb-1	183	10	peg	peg	NOUN
njb-1	183	11	escherichia	escherichia	NOUN
njb-1	183	12	coli	coli	NOUN
njb-1	183	13	5	5	NUM
njb-1	183	14	90	90	NUM
njb-1	183	15	[	[	PUNCT
njb-1	183	16	26	26	NUM
njb-1	183	17	]	]	PUNCT
njb-1	183	18	native	native	ADJ
njb-1	183	19	escherichia	escherichia	PROPN
njb-1	183	20	coli	coli	NOUN
njb-1	183	21	5	5	NUM
njb-1	183	22	84.6	84.6	NUM
njb-1	183	23	10	10	NUM
njb-1	183	24	native	native	ADJ
njb-1	183	25	escherichia	escherichia	NOUN
njb-1	183	26	coli	coli	NOUN
njb-1	183	27	10	10	NUM
njb-1	183	28	82.5	82.5	NUM
njb-1	184	1	[	[	PUNCT
njb-1	184	2	24	24	NUM
njb-1	184	3	]	]	PUNCT
njb-1	184	4	native	native	ADJ
njb-1	184	5	escherichia	escherichia	NOUN
njb-1	184	6	coli	coli	PROPN
njb-1	184	7	10	10	NUM
njb-1	184	8	73	73	NUM
njb-1	184	9	-	-	SYM
njb-1	184	10	81	81	NUM
njb-1	184	11	10	10	NUM
njb-1	184	12	[	[	PUNCT
njb-1	184	13	15	15	NUM
njb-1	184	14	]	]	PUNCT
njb-1	184	15	native	native	ADJ
njb-1	184	16	escherichia	escherichia	NOUN
njb-1	184	17	coli	coli	NOUN
njb-1	184	18	6	6	NUM
njb-1	184	19	73.4	73.4	NUM
njb-1	184	20	6	6	NUM
njb-1	184	21	erwinia	erwinia	NOUN
njb-1	184	22	chrysanthemi	chrysanthemi	PROPN
njb-1	184	23	6	6	NUM
njb-1	184	24	60	60	NUM
njb-1	184	25	[	[	PUNCT
njb-1	184	26	22	22	NUM
njb-1	184	27	]	]	PUNCT
njb-1	184	28	native	native	ADJ
njb-1	184	29	escherichia	escherichia	PROPN
njb-1	184	30	coli	coli	NOUN
njb-1	184	31	3	3	NUM
njb-1	184	32	72	72	NUM
njb-1	184	33	3	3	NUM
njb-1	184	34	table	table	NOUN
njb-1	184	35	6	6	NUM
njb-1	184	36	:	:	PUNCT
njb-1	184	37	average	average	ADJ
njb-1	184	38	year	year	NOUN
njb-1	184	39	range	range	NOUN
njb-1	184	40	of	of	ADP
njb-1	184	41	event	event	NOUN
njb-1	184	42	-	-	PUNCT
njb-1	184	43	free	free	ADJ
njb-1	184	44	survival	survival	NOUN
njb-1	184	45	in	in	ADP
njb-1	184	46	treated	treat	VERB
njb-1	184	47	patients	patient	NOUN
njb-1	184	48	from	from	ADP
njb-1	184	49	all	all	DET
njb-1	184	50	the	the	DET
njb-1	184	51	studied	study	VERB
njb-1	184	52	trials	trial	NOUN
njb-1	184	53	.	.	PUNCT
njb-1	185	1	type	type	NOUN
njb-1	185	2	of	of	ADP
njb-1	185	3	asparaginase	asparaginase	NOUN
njb-1	185	4	average	average	ADJ
njb-1	185	5	year	year	NOUN
njb-1	185	6	range	range	NOUN
njb-1	185	7	of	of	ADP
njb-1	185	8	eventfree	eventfree	ADJ
njb-1	185	9	survival	survival	NOUN
njb-1	185	10	year	year	NOUN
njb-1	185	11	(	(	PUNCT
njb-1	185	12	%	%	NOUN
njb-1	185	13	range	range	NOUN
njb-1	185	14	)	)	PUNCT
njb-1	185	15	native	native	ADJ
njb-1	185	16	escherichia	escherichia	NOUN
njb-1	185	17	coli	coli	NOUN
njb-1	185	18	5(84%-89%)-10	5(84%-89%)-10	NUM
njb-1	185	19	(	(	PUNCT
njb-1	185	20	75%-82	75%-82	NUM
njb-1	185	21	%	%	NOUN
njb-1	185	22	)	)	PUNCT
njb-1	185	23	peg	peg	NOUN
njb-1	185	24	escherichia	escherichia	NOUN
njb-1	185	25	coli	coli	NOUN
njb-1	185	26	5(90	5(90	NUM
njb-1	185	27	%	%	NOUN
njb-1	185	28	)	)	PUNCT
njb-1	185	29	erwinia	erwinia	PROPN
njb-1	185	30	chrysanthemi	chrysanthemi	PROPN
njb-1	185	31	6	6	NUM
njb-1	185	32	(	(	PUNCT
njb-1	185	33	59	59	NUM
njb-1	185	34	%	%	NOUN
njb-1	185	35	)	)	PUNCT
njb-1	185	36	and	and	CCONJ
njb-1	185	37	84	84	NUM
njb-1	185	38	%	%	NOUN
njb-1	185	39	treated	treat	VERB
njb-1	185	40	with	with	ADP
njb-1	185	41	native	native	PROPN
njb-1	185	42	e.	e.	PROPN
njb-1	185	43	coli	coli	PROPN
njb-1	185	44	asparaginase	asparaginase	NOUN
njb-1	185	45	[	[	PUNCT
njb-1	185	46	16	16	NUM
njb-1	185	47	]	]	PUNCT
njb-1	185	48	and	and	CCONJ
njb-1	185	49	another	another	DET
njb-1	185	50	trial	trial	NOUN
njb-1	185	51	evaluated	evaluate	VERB
njb-1	185	52	5	5	NUM
njb-1	185	53	-	-	PUNCT
njb-1	185	54	years	year	NOUN
njb-1	185	55	of	of	ADP
njb-1	185	56	overall	overall	ADJ
njb-1	185	57	survival	survival	NOUN
njb-1	185	58	of	of	ADP
njb-1	185	59	patients	patient	NOUN
njb-1	185	60	.	.	PUNCT
njb-1	186	1	the	the	DET
njb-1	186	2	statistics	statistic	NOUN
njb-1	186	3	was	be	AUX
njb-1	186	4	96	96	NUM
njb-1	186	5	%	%	NOUN
njb-1	186	6	treated	treat	VERB
njb-1	186	7	with	with	ADP
njb-1	186	8	pegasparaginase	pegasparaginase	NOUN
njb-1	186	9	and	and	CCONJ
njb-1	186	10	94	94	NUM
njb-1	186	11	%	%	NOUN
njb-1	186	12	treated	treat	VERB
njb-1	186	13	with	with	ADP
njb-1	186	14	escherichia	escherichia	NOUN
njb-1	186	15	coli	coli	NOUN
njb-1	186	16	asparaginase	asparaginase	NOUN
njb-1	186	17	[	[	PUNCT
njb-1	186	18	19	19	NUM
njb-1	186	19	]	]	PUNCT
njb-1	186	20	.	.	PUNCT
njb-1	187	1	likewise	likewise	ADV
njb-1	187	2	,	,	PUNCT
njb-1	187	3	karachunskiy	karachunskiy	PROPN
njb-1	187	4	et	et	PROPN
njb-1	187	5	al	al	PROPN
njb-1	187	6	.	.	PROPN
njb-1	187	7	reported	report	VERB
njb-1	187	8	that	that	SCONJ
njb-1	187	9	patients	patient	NOUN
njb-1	187	10	of	of	ADP
njb-1	187	11	e.	e.	PROPN
njb-1	187	12	coli	coli	PROPN
njb-1	187	13	asparaginase	asparaginase	NOUN
njb-1	187	14	5000	5000	NUM
njb-1	187	15	arm	arm	NOUN
njb-1	187	16	(	(	PUNCT
njb-1	187	17	86	86	NUM
njb-1	187	18	±	±	NOUN
njb-1	187	19	2	2	NUM
njb-1	187	20	%	%	NOUN
njb-1	187	21	)	)	PUNCT
njb-1	187	22	had	have	VERB
njb-1	187	23	slightly	slightly	ADV
njb-1	187	24	superior	superior	ADJ
njb-1	187	25	probability	probability	NOUN
njb-1	187	26	of	of	ADP
njb-1	187	27	overall	overall	ADJ
njb-1	187	28	survival	survival	NOUN
njb-1	187	29	at	at	ADP
njb-1	187	30	10	10	NUM
njb-1	187	31	years	year	NOUN
njb-1	187	32	compared	compare	VERB
njb-1	187	33	to	to	ADP
njb-1	187	34	e.	e.	PROPN
njb-1	187	35	coli	coli	PROPN
njb-1	187	36	asparaginase	asparaginase	NOUN
njb-1	187	37	10000	10000	NUM
njb-1	187	38	arm	arm	NOUN
njb-1	187	39	(	(	PUNCT
njb-1	187	40	82	82	NUM
njb-1	187	41	±	±	NOUN
njb-1	187	42	2	2	NUM
njb-1	187	43	%	%	NOUN
njb-1	187	44	)	)	PUNCT
njb-1	188	1	[	[	X
njb-1	188	2	24	24	NUM
njb-1	188	3	]	]	PUNCT
njb-1	188	4	.	.	PUNCT
njb-1	189	1	overall	overall	ADJ
njb-1	189	2	survival	survival	NOUN
njb-1	189	3	estimated	estimate	VERB
njb-1	189	4	at	at	ADP
njb-1	189	5	5	5	NUM
njb-1	189	6	and	and	CCONJ
njb-1	189	7	10	10	NUM
njb-1	189	8	years	year	NOUN
njb-1	189	9	was	be	AUX
njb-1	189	10	94.4	94.4	NUM
njb-1	189	11	%	%	NOUN
njb-1	189	12	and	and	CCONJ
njb-1	189	13	93.7	93.7	NUM
njb-1	189	14	%	%	NOUN
njb-1	189	15	in	in	ADP
njb-1	189	16	the	the	DET
njb-1	189	17	group	group	NOUN
njb-1	189	18	with	with	ADP
njb-1	189	19	asparaginase	asparaginase	NOUN
njb-1	189	20	versus	versus	ADP
njb-1	189	21	89.8	89.8	NUM
njb-1	189	22	%	%	NOUN
njb-1	189	23	and	and	CCONJ
njb-1	189	24	88.6	88.6	NUM
njb-1	189	25	%	%	NOUN
njb-1	189	26	in	in	ADP
njb-1	189	27	the	the	DET
njb-1	189	28	group	group	NOUN
njb-1	189	29	without	without	ADP
njb-1	189	30	asparaginase	asparaginase	NOUN
njb-1	189	31	,	,	PUNCT
njb-1	189	32	respectively	respectively	ADV
njb-1	189	33	[	[	X
njb-1	189	34	26	26	NUM
njb-1	189	35	]	]	PUNCT
njb-1	189	36	(	(	PUNCT
njb-1	189	37	table	table	NOUN
njb-1	189	38	7	7	NUM
njb-1	189	39	)	)	PUNCT
njb-1	189	40	.	.	PUNCT
njb-1	190	1	moreover	moreover	ADV
njb-1	190	2	,	,	PUNCT
njb-1	190	3	study	study	NOUN
njb-1	190	4	conducted	conduct	VERB
njb-1	190	5	in	in	ADP
njb-1	190	6	2002	2002	NUM
njb-1	190	7	demonstrated	demonstrate	VERB
njb-1	190	8	that	that	SCONJ
njb-1	190	9	6	6	NUM
njb-1	190	10	year	year	NOUN
njb-1	190	11	survival	survival	NOUN
njb-1	190	12	rate	rate	NOUN
njb-1	190	13	using	use	VERB
njb-1	190	14	native	native	PROPN
njb-1	190	15	e.	e.	PROPN
njb-1	190	16	coli	coli	PROPN
njb-1	190	17	asparaginase	asparaginase	NOUN
njb-1	190	18	was	be	AUX
njb-1	190	19	greater	great	ADJ
njb-1	190	20	than	than	ADP
njb-1	190	21	using	use	VERB
njb-1	190	22	e.	e.	PROPN
njb-1	190	23	chrysanthemi	chrysanthemi	PROPN
njb-1	190	24	asparaginase	asparaginase	PROPN
njb-1	190	25	(	(	PUNCT
njb-1	190	26	83.9	83.9	NUM
njb-1	190	27	%	%	NOUN
njb-1	190	28	vs	vs	ADP
njb-1	190	29	75.1	75.1	NUM
njb-1	190	30	%	%	NOUN
njb-1	190	31	)	)	PUNCT
njb-1	191	1	[	[	X
njb-1	191	2	15	15	NUM
njb-1	191	3	]	]	SYM
njb-1	191	4	.	.	PUNCT
njb-1	191	5	table	table	NOUN
njb-1	191	6	4	4	NUM
njb-1	191	7	.	.	PUNCT
njb-1	192	1	average	average	ADJ
njb-1	192	2	range	range	NOUN
njb-1	192	3	of	of	ADP
njb-1	192	4	occurring	occur	VERB
njb-1	192	5	toxicity	toxicity	NOUN
njb-1	192	6	in	in	ADP
njb-1	192	7	treated	treat	VERB
njb-1	192	8	patients	patient	NOUN
njb-1	192	9	from	from	ADP
njb-1	192	10	all	all	DET
njb-1	192	11	the	the	DET
njb-1	192	12	studies	study	NOUN
njb-1	192	13	trials	trial	NOUN
njb-1	192	14	.	.	PUNCT
njb-1	193	1	asparaginase	asparaginase	NOUN
njb-1	193	2	types	type	VERB
njb-1	193	3	toxicity	toxicity	NOUN
njb-1	193	4	escherichia	escherichia	NOUN
njb-1	193	5	coli	coli	NOUN
njb-1	193	6	asparaginase	asparaginase	NOUN
njb-1	193	7	(	(	PUNCT
njb-1	193	8	%	%	INTJ
njb-1	193	9	)	)	PUNCT
njb-1	193	10	pegescherichia	pegescherichia	NOUN
njb-1	193	11	coli	coli	NOUN
njb-1	193	12	asparaginase	asparaginase	NOUN
njb-1	193	13	(	(	PUNCT
njb-1	193	14	%	%	INTJ
njb-1	193	15	)	)	PUNCT
njb-1	193	16	erwinia	erwinia	PROPN
njb-1	193	17	chrysanthemi	chrysanthemi	PROPN
njb-1	193	18	asparaginase	asparaginase	PROPN
njb-1	193	19	(	(	PUNCT
njb-1	193	20	%	%	INTJ
njb-1	193	21	)	)	PUNCT
njb-1	193	22	recombinant	recombinant	ADJ
njb-1	193	23	escherichia	escherichia	NOUN
njb-1	193	24	coli	coli	NOUN
njb-1	193	25	asparaginase	asparaginase	NOUN
njb-1	193	26	(	(	PUNCT
njb-1	193	27	%	%	INTJ
njb-1	193	28	)	)	PUNCT
njb-1	193	29	hypersensitivity	hypersensitivity	NOUN
njb-1	193	30	1.8	1.8	NUM
njb-1	193	31	–	–	PUNCT
njb-1	193	32	12	12	NUM
njb-1	193	33	2	2	NUM
njb-1	193	34	–	–	PUNCT
njb-1	193	35	12	12	NUM
njb-1	193	36	1.3	1.3	NUM
njb-1	193	37	–	–	PUNCT
njb-1	193	38	12	12	NUM
njb-1	193	39	2.1	2.1	NUM
njb-1	193	40	pancreatitis	pancreatitis	NOUN
njb-1	193	41	1	1	NUM
njb-1	193	42	–	–	PUNCT
njb-1	193	43	10	10	NUM
njb-1	193	44	3	3	NUM
njb-1	193	45	-	-	SYM
njb-1	193	46	12	12	NUM
njb-1	193	47	na	na	ADP
njb-1	193	48	na	na	X
njb-1	193	49	hyperglycemia	hyperglycemia	NOUN
njb-1	193	50	4	4	NUM
njb-1	193	51	–	–	PUNCT
njb-1	193	52	6	6	NUM
njb-1	193	53	2	2	NUM
njb-1	193	54	5	5	NUM
njb-1	193	55	–	–	PUNCT
njb-1	193	56	20	20	NUM
njb-1	193	57	na	na	ADP
njb-1	193	58	the	the	DET
njb-1	193	59	range	range	NOUN
njb-1	193	60	of	of	ADP
njb-1	193	61	toxicities	toxicity	NOUN
njb-1	193	62	are	be	AUX
njb-1	193	63	of	of	ADP
njb-1	193	64	1	1	NUM
njb-1	193	65	-	-	SYM
njb-1	193	66	4	4	NUM
njb-1	193	67	grade	grade	NOUN
njb-1	193	68	from	from	ADP
njb-1	193	69	all	all	DET
njb-1	193	70	the	the	DET
njb-1	193	71	trials	trial	NOUN
njb-1	193	72	.	.	PUNCT
njb-1	194	1	nepal	nepal	PROPN
njb-1	194	2	j	j	PROPN
njb-1	194	3	biotechnol	biotechnol	PROPN
njb-1	194	4	.	.	PUNCT
njb-1	195	1	2	2	NUM
njb-1	195	2	0	0	NUM
njb-1	195	3	2	2	NUM
njb-1	195	4	1	1	NUM
njb-1	195	5	d	d	X
njb-1	195	6	e	e	X
njb-1	195	7	c	c	PROPN
njb-1	195	8	.	.	PUNCT
njb-1	196	1	9	9	NUM
njb-1	196	2	(	(	PUNCT
njb-1	196	3	2	2	NUM
njb-1	196	4	):	):	PUNCT
njb-1	196	5	39	39	NUM
njb-1	196	6	-	-	SYM
njb-1	196	7	47	47	NUM
njb-1	196	8	baral	baral	ADJ
njb-1	196	9	et	et	PROPN
njb-1	196	10	al	al	PROPN
njb-1	196	11	.	.	PUNCT
njb-1	197	1	©	©	PROPN
njb-1	197	2	njb	njb	PROPN
njb-1	197	3	,	,	PUNCT
njb-1	197	4	bsn	bsn	PROPN
njb-1	197	5	44	44	NUM
njb-1	197	6	in	in	ADP
njb-1	197	7	terms	term	NOUN
njb-1	197	8	of	of	ADP
njb-1	197	9	overall	overall	ADJ
njb-1	197	10	survival	survival	NOUN
njb-1	197	11	peg	peg	NOUN
njb-1	197	12	asparaginase	asparaginase	PROPN
njb-1	197	13	from	from	ADP
njb-1	197	14	escherichia	escherichia	NOUN
njb-1	197	15	coli	coli	NOUN
njb-1	197	16	showed	show	VERB
njb-1	197	17	better	well	ADJ
njb-1	197	18	result	result	NOUN
njb-1	197	19	than	than	ADP
njb-1	197	20	other	other	ADJ
njb-1	197	21	forms	form	NOUN
njb-1	197	22	of	of	ADP
njb-1	197	23	asparaginases	asparaginase	NOUN
njb-1	197	24	(	(	PUNCT
njb-1	197	25	table	table	NOUN
njb-1	197	26	8)	8)	NUM
njb-1	197	27	table	table	NOUN
njb-1	197	28	8	8	NUM
njb-1	197	29	.	.	PUNCT
njb-1	198	1	average	average	ADJ
njb-1	198	2	year	year	NOUN
njb-1	198	3	range	range	NOUN
njb-1	198	4	of	of	ADP
njb-1	198	5	overall	overall	ADJ
njb-1	198	6	survival	survival	NOUN
njb-1	198	7	in	in	ADP
njb-1	198	8	treated	treat	VERB
njb-1	198	9	patients	patient	NOUN
njb-1	198	10	from	from	ADP
njb-1	198	11	all	all	DET
njb-1	198	12	the	the	DET
njb-1	198	13	studied	study	VERB
njb-1	198	14	trials	trial	NOUN
njb-1	198	15	.	.	PUNCT
njb-1	199	1	type	type	NOUN
njb-1	199	2	of	of	ADP
njb-1	199	3	asparaginase	asparaginase	NOUN
njb-1	199	4	average	average	ADJ
njb-1	199	5	year	year	NOUN
njb-1	199	6	range	range	NOUN
njb-1	199	7	of	of	ADP
njb-1	199	8	overall	overall	ADJ
njb-1	199	9	survival	survival	NOUN
njb-1	199	10	year	year	NOUN
njb-1	199	11	(	(	PUNCT
njb-1	199	12	%	%	NOUN
njb-1	199	13	range	range	NOUN
njb-1	199	14	)	)	PUNCT
njb-1	199	15	native	native	ADJ
njb-1	199	16	escherichia	escherichia	PROPN
njb-1	199	17	coli	coli	PROPN
njb-1	199	18	5	5	NUM
njb-1	199	19	(	(	PUNCT
njb-1	199	20	94	94	NUM
njb-1	199	21	%	%	NOUN
njb-1	199	22	)	)	PUNCT
njb-1	199	23	10	10	NUM
njb-1	199	24	(	(	PUNCT
njb-1	199	25	93	93	NUM
njb-1	199	26	%	%	NOUN
njb-1	199	27	)	)	PUNCT
njb-1	199	28	peg	peg	NOUN
njb-1	199	29	escherichia	escherichia	NOUN
njb-1	199	30	coli	coli	NOUN
njb-1	199	31	5	5	NUM
njb-1	199	32	(	(	PUNCT
njb-1	199	33	96	96	NUM
njb-1	199	34	%	%	NOUN
njb-1	199	35	)	)	PUNCT
njb-1	199	36	follow	follow	VERB
njb-1	199	37	up	up	ADP
njb-1	199	38	period	period	NOUN
njb-1	199	39	of	of	ADP
njb-1	199	40	overall	overall	ADJ
njb-1	199	41	survival	survival	NOUN
njb-1	199	42	of	of	ADP
njb-1	199	43	patients	patient	NOUN
njb-1	199	44	were	be	AUX
njb-1	199	45	reported	report	VERB
njb-1	199	46	for	for	ADP
njb-1	199	47	10	10	NUM
njb-1	199	48	years	year	NOUN
njb-1	199	49	for	for	ADP
njb-1	199	50	native	native	PROPN
njb-1	199	51	e.	e.	PROPN
njb-1	199	52	coli	coli	PROPN
njb-1	199	53	asparaginase	asparaginase	NOUN
njb-1	199	54	,	,	PUNCT
njb-1	199	55	6	6	NUM
njb-1	199	56	years	year	NOUN
njb-1	199	57	for	for	ADP
njb-1	199	58	peg	peg	PROPN
njb-1	199	59	e.	e.	PROPN
njb-1	199	60	coli	coli	PROPN
njb-1	199	61	asparaginase	asparaginase	NOUN
njb-1	199	62	and	and	CCONJ
njb-1	199	63	6	6	NUM
njb-1	199	64	years	year	NOUN
njb-1	199	65	for	for	ADP
njb-1	199	66	e.	e.	PROPN
njb-1	199	67	chrysanthemi	chrysanthemi	PROPN
njb-1	199	68	asparaginase	asparaginase	PROPN
njb-1	199	69	.	.	PUNCT
njb-1	200	1	anti	anti	ADJ
njb-1	200	2	-	-	ADJ
njb-1	200	3	asparaginase	asparaginase	ADJ
njb-1	200	4	antibody	antibody	NOUN
njb-1	200	5	(	(	PUNCT
njb-1	200	6	aaa	aaa	PROPN
njb-1	200	7	)	)	PUNCT
njb-1	200	8	the	the	DET
njb-1	200	9	most	most	ADV
njb-1	200	10	common	common	ADJ
njb-1	200	11	adverse	adverse	ADJ
njb-1	200	12	reactions	reaction	NOUN
njb-1	200	13	of	of	ADP
njb-1	200	14	asparaginase	asparaginase	NOUN
njb-1	200	15	in	in	ADP
njb-1	200	16	children	child	NOUN
njb-1	200	17	are	be	AUX
njb-1	200	18	produced	produce	VERB
njb-1	200	19	by	by	ADP
njb-1	200	20	anti	anti	ADJ
njb-1	200	21	-	-	ADJ
njb-1	200	22	asparaginase	asparaginase	ADJ
njb-1	200	23	antibodies	antibody	NOUN
njb-1	200	24	.	.	PUNCT
njb-1	201	1	these	these	DET
njb-1	201	2	adverse	adverse	ADJ
njb-1	201	3	reactions	reaction	NOUN
njb-1	201	4	can	can	AUX
njb-1	201	5	manifest	manifest	VERB
njb-1	201	6	as	as	ADV
njb-1	201	7	mild	mild	ADJ
njb-1	201	8	or	or	CCONJ
njb-1	201	9	severe	severe	ADJ
njb-1	201	10	allergic	allergic	ADJ
njb-1	201	11	reactions	reaction	NOUN
njb-1	201	12	.	.	PUNCT
njb-1	202	1	it	it	PRON
njb-1	202	2	was	be	AUX
njb-1	202	3	reported	report	VERB
njb-1	202	4	that	that	SCONJ
njb-1	202	5	10	10	NUM
njb-1	202	6	%	%	NOUN
njb-1	202	7	(	(	PUNCT
njb-1	202	8	9	9	NUM
njb-1	202	9	in	in	ADP
njb-1	202	10	native	native	PROPN
njb-1	202	11	e.	e.	PROPN
njb-1	202	12	coli	coli	PROPN
njb-1	202	13	asparaginase	asparaginase	NOUN
njb-1	202	14	and	and	CCONJ
njb-1	202	15	10	10	NUM
njb-1	202	16	in	in	ADP
njb-1	202	17	recombinant	recombinant	ADJ
njb-1	202	18	escherichia	escherichia	NOUN
njb-1	202	19	coli	coli	NOUN
njb-1	202	20	asparaginase	asparaginase	NOUN
njb-1	202	21	group	group	NOUN
njb-1	202	22	)	)	PUNCT
njb-1	202	23	patients	patient	NOUN
njb-1	202	24	were	be	AUX
njb-1	202	25	detected	detect	VERB
njb-1	202	26	positive	positive	ADJ
njb-1	202	27	for	for	ADP
njb-1	202	28	aaa	aaa	NOUN
njb-1	203	1	[	[	PUNCT
njb-1	203	2	10	10	NUM
njb-1	203	3	]	]	PUNCT
njb-1	203	4	.	.	PUNCT
njb-1	204	1	the	the	DET
njb-1	204	2	dinnodorf	dinnodorf	PROPN
njb-1	204	3	et	et	PROPN
njb-1	204	4	al	al	PROPN
njb-1	204	5	.	.	PUNCT
njb-1	205	1	fda	fda	PROPN
njb-1	205	2	study	study	NOUN
njb-1	205	3	found	find	VERB
njb-1	205	4	that	that	SCONJ
njb-1	205	5	16	16	NUM
njb-1	205	6	out	out	ADP
njb-1	205	7	of	of	ADP
njb-1	205	8	57	57	NUM
njb-1	205	9	or	or	CCONJ
njb-1	205	10	28	28	NUM
njb-1	205	11	%	%	NOUN
njb-1	205	12	of	of	ADP
njb-1	205	13	their	their	PRON
njb-1	205	14	patients	patient	NOUN
njb-1	205	15	treated	treat	VERB
njb-1	205	16	with	with	ADP
njb-1	205	17	native	native	PROPN
njb-1	205	18	e.	e.	PROPN
njb-1	205	19	coli	coli	PROPN
njb-1	205	20	asparaginase	asparaginase	NOUN
njb-1	205	21	had	have	VERB
njb-1	205	22	anti	anti	ADJ
njb-1	205	23	-	-	ADJ
njb-1	205	24	aparaginase	aparaginase	ADJ
njb-1	205	25	antibodies	antibody	NOUN
njb-1	205	26	at	at	ADP
njb-1	205	27	any	any	DET
njb-1	205	28	given	give	VERB
njb-1	205	29	time	time	NOUN
njb-1	205	30	in	in	ADP
njb-1	205	31	of	of	ADP
njb-1	205	32	the	the	DET
njb-1	205	33	treatment	treatment	NOUN
njb-1	205	34	.	.	PUNCT
njb-1	206	1	three	three	NUM
njb-1	206	2	subjects	subject	NOUN
njb-1	206	3	were	be	AUX
njb-1	206	4	known	know	VERB
njb-1	206	5	to	to	PART
njb-1	206	6	have	have	VERB
njb-1	206	7	pre	pre	VERB
njb-1	206	8	-	-	ADJ
njb-1	206	9	existing	exist	VERB
njb-1	206	10	antiaparaginase	antiaparaginase	NOUN
njb-1	206	11	antibodies	antibody	NOUN
njb-1	206	12	.	.	PUNCT
njb-1	207	1	in	in	ADP
njb-1	207	2	the	the	DET
njb-1	207	3	patients	patient	NOUN
njb-1	207	4	treated	treat	VERB
njb-1	207	5	with	with	ADP
njb-1	207	6	the	the	DET
njb-1	207	7	peg	peg	PROPN
njb-1	207	8	e.	e.	PROPN
njb-1	207	9	coli	coli	PROPN
njb-1	207	10	asparaginase	asparaginase	NOUN
njb-1	207	11	11	11	NUM
njb-1	207	12	%	%	NOUN
njb-1	207	13	of	of	ADP
njb-1	207	14	the	the	DET
njb-1	207	15	55	55	NUM
njb-1	207	16	or	or	CCONJ
njb-1	207	17	6	6	NUM
njb-1	207	18	of	of	ADP
njb-1	207	19	them	they	PRON
njb-1	207	20	had	have	VERB
njb-1	207	21	asparaginase	asparaginase	NOUN
njb-1	207	22	antibodies	antibody	NOUN
njb-1	207	23	.	.	PUNCT
njb-1	208	1	rau	rau	PROPN
njb-1	208	2	et	et	PROPN
njb-1	208	3	al	al	PROPN
njb-1	208	4	.	.	PROPN
njb-1	208	5	2018	2018	NUM
njb-1	208	6	reported	report	VERB
njb-1	208	7	very	very	ADV
njb-1	208	8	low	low	ADJ
njb-1	208	9	anti	anti	ADJ
njb-1	208	10	-	-	ADJ
njb-1	208	11	peg	peg	ADJ
njb-1	208	12	igm	igm	NOUN
njb-1	208	13	among	among	ADP
njb-1	208	14	three	three	NUM
njb-1	208	15	patients	patient	NOUN
njb-1	208	16	.	.	PUNCT
njb-1	209	1	anti	anti	ADJ
njb-1	209	2	-	-	ADJ
njb-1	209	3	peg	peg	ADJ
njb-1	209	4	igg	igg	PROPN
njb-1	209	5	was	be	AUX
njb-1	209	6	observed	observe	VERB
njb-1	209	7	in	in	ADP
njb-1	209	8	three	three	NUM
njb-1	209	9	patients	patient	NOUN
njb-1	209	10	except	except	SCONJ
njb-1	209	11	one	one	NUM
njb-1	209	12	after	after	ADP
njb-1	209	13	5.5	5.5	NUM
njb-1	209	14	-	-	PUNCT
njb-1	209	15	years	year	NOUN
njb-1	209	16	of	of	ADP
njb-1	209	17	exposure	exposure	NOUN
njb-1	209	18	to	to	PART
njb-1	209	19	peg	peg	PROPN
njb-1	209	20	e.	e.	PROPN
njb-1	209	21	coli	coli	PROPN
njb-1	209	22	asparaginase	asparaginase	NOUN
njb-1	209	23	[	[	X
njb-1	209	24	21	21	NUM
njb-1	209	25	]	]	PUNCT
njb-1	209	26	(	(	PUNCT
njb-1	209	27	table	table	NOUN
njb-1	209	28	9	9	NUM
njb-1	209	29	)	)	PUNCT
njb-1	209	30	.	.	PUNCT
njb-1	210	1	table	table	NOUN
njb-1	210	2	9	9	NUM
njb-1	210	3	.	.	PUNCT
njb-1	211	1	individual	individual	ADJ
njb-1	211	2	patients	patient	NOUN
njb-1	211	3	positive	positive	ADJ
njb-1	211	4	with	with	ADP
njb-1	211	5	anti	anti	ADJ
njb-1	211	6	-	-	ADJ
njb-1	211	7	asparaginase	asparaginase	ADJ
njb-1	211	8	antibody	antibody	NOUN
njb-1	211	9	(	(	PUNCT
njb-1	211	10	aaa	aaa	NOUN
njb-1	211	11	)	)	PUNCT
njb-1	211	12	from	from	ADP
njb-1	211	13	trials	trial	NOUN
njb-1	211	14	.	.	PUNCT
njb-1	212	1	clinical	clinical	ADJ
njb-1	212	2	trial	trial	NOUN
njb-1	212	3	type	type	NOUN
njb-1	212	4	of	of	ADP
njb-1	212	5	asparaginase	asparaginase	NOUN
njb-1	212	6	%	%	NOUN
njb-1	212	7	of	of	ADP
njb-1	212	8	patients	patient	NOUN
njb-1	212	9	positive	positive	ADJ
njb-1	212	10	for	for	ADP
njb-1	212	11	anti	anti	ADJ
njb-1	212	12	-	-	ADJ
njb-1	212	13	asparaginase	asparaginase	ADJ
njb-1	212	14	antibody	antibody	NOUN
njb-1	212	15	(	(	PUNCT
njb-1	212	16	aaa	aaa	NOUN
njb-1	212	17	)	)	PUNCT
njb-1	213	1	[	[	PUNCT
njb-1	213	2	10	10	NUM
njb-1	213	3	]	]	PUNCT
njb-1	213	4	recombinant	recombinant	ADJ
njb-1	213	5	escherichia	escherichia	NOUN
njb-1	213	6	coli	coli	NOUN
njb-1	213	7	10	10	NUM
njb-1	213	8	native	native	ADJ
njb-1	213	9	escherichia	escherichia	NOUN
njb-1	213	10	coli	coli	NOUN
njb-1	213	11	(	(	PUNCT
njb-1	213	12	asparaginase	asparaginase	NOUN
njb-1	213	13	medac	medac	PROPN
njb-1	213	14	)	)	PUNCT
njb-1	214	1	[	[	PUNCT
njb-1	214	2	20	20	NUM
njb-1	214	3	]	]	PUNCT
njb-1	214	4	native	native	ADJ
njb-1	214	5	escherichia	escherichia	NOUN
njb-1	214	6	coli	coli	NOUN
njb-1	214	7	28	28	NUM
njb-1	214	8	peg	peg	NOUN
njb-1	214	9	escherichia	escherichia	NOUN
njb-1	214	10	coli	coli	NOUN
njb-1	214	11	11	11	NUM
njb-1	214	12	peg	peg	NOUN
njb-1	214	13	asparaginase	asparaginase	NOUN
njb-1	214	14	from	from	ADP
njb-1	214	15	escherichia	escherichia	NOUN
njb-1	214	16	coli	coli	NOUN
njb-1	214	17	has	have	AUX
njb-1	214	18	shown	show	VERB
njb-1	214	19	promising	promising	ADJ
njb-1	214	20	advantages	advantage	NOUN
njb-1	214	21	over	over	ADP
njb-1	214	22	other	other	ADJ
njb-1	214	23	forms	form	NOUN
njb-1	214	24	of	of	ADP
njb-1	214	25	asparaginases	asparaginase	NOUN
njb-1	214	26	.	.	PUNCT
njb-1	215	1	anti	anti	ADJ
njb-1	215	2	-	-	ADJ
njb-1	215	3	asparaginase	asparaginase	ADJ
njb-1	215	4	antibodies	antibody	NOUN
njb-1	215	5	are	be	AUX
njb-1	215	6	found	find	VERB
njb-1	215	7	in	in	ADP
njb-1	215	8	lower	low	ADJ
njb-1	215	9	numbers	number	NOUN
njb-1	215	10	in	in	ADP
njb-1	215	11	peg	peg	NOUN
njb-1	215	12	asparaginase	asparaginase	NOUN
njb-1	215	13	.	.	PUNCT
njb-1	216	1	(	(	PUNCT
njb-1	216	2	table	table	NOUN
njb-1	216	3	10	10	NUM
njb-1	216	4	)	)	PUNCT
njb-1	216	5	.	.	PUNCT
njb-1	217	1	table	table	NOUN
njb-1	217	2	10	10	NUM
njb-1	217	3	.	.	PUNCT
njb-1	218	1	average	average	ADJ
njb-1	218	2	%	%	NOUN
njb-1	218	3	range	range	NOUN
njb-1	218	4	of	of	ADP
njb-1	218	5	patients	patient	NOUN
njb-1	218	6	positive	positive	ADJ
njb-1	218	7	for	for	ADP
njb-1	218	8	antiasparaginase	antiasparaginase	ADJ
njb-1	218	9	antibody	antibody	NOUN
njb-1	218	10	(	(	PUNCT
njb-1	218	11	aaa	aaa	NOUN
njb-1	218	12	)	)	PUNCT
njb-1	218	13	from	from	ADP
njb-1	218	14	all	all	DET
njb-1	218	15	the	the	DET
njb-1	218	16	studies	study	NOUN
njb-1	218	17	trials	trial	NOUN
njb-1	218	18	.	.	PUNCT
njb-1	219	1	type	type	NOUN
njb-1	219	2	of	of	ADP
njb-1	219	3	asparaginase	asparaginase	NOUN
njb-1	219	4	average	average	ADJ
njb-1	219	5	%	%	NOUN
njb-1	219	6	range	range	NOUN
njb-1	219	7	of	of	ADP
njb-1	219	8	patients	patient	NOUN
njb-1	219	9	positive	positive	ADJ
njb-1	219	10	for	for	ADP
njb-1	219	11	anti	anti	ADJ
njb-1	219	12	-	-	ADJ
njb-1	219	13	asparaginase	asparaginase	ADJ
njb-1	219	14	antibody	antibody	NOUN
njb-1	219	15	(	(	PUNCT
njb-1	219	16	aaa	aaa	PROPN
njb-1	219	17	)	)	PUNCT
njb-1	219	18	native	native	ADJ
njb-1	219	19	escherichia	escherichia	PROPN
njb-1	219	20	coli	coli	PROPN
njb-1	219	21	10%-28	10%-28	NUM
njb-1	219	22	%	%	NOUN
njb-1	219	23	peg	peg	NOUN
njb-1	219	24	escherichia	escherichia	NOUN
njb-1	219	25	coli	coli	NOUN
njb-1	219	26	11	11	NUM
njb-1	219	27	%	%	NOUN
njb-1	219	28	discussion	discussion	NOUN
njb-1	219	29	and	and	CCONJ
njb-1	219	30	conclusion	conclusion	NOUN
njb-1	219	31	data	datum	NOUN
njb-1	219	32	was	be	AUX
njb-1	219	33	obtained	obtain	VERB
njb-1	219	34	from	from	ADP
njb-1	219	35	various	various	ADJ
njb-1	219	36	clinical	clinical	ADJ
njb-1	219	37	trials	trial	NOUN
njb-1	219	38	(	(	PUNCT
njb-1	219	39	table	table	NOUN
njb-1	219	40	11	11	NUM
njb-1	219	41	)	)	PUNCT
njb-1	219	42	on	on	ADP
njb-1	219	43	asparaginase	asparaginase	NOUN
njb-1	219	44	activity	activity	NOUN
njb-1	219	45	,	,	PUNCT
njb-1	219	46	concentration	concentration	NOUN
njb-1	219	47	,	,	PUNCT
njb-1	219	48	and	and	CCONJ
njb-1	219	49	toxicity	toxicity	NOUN
njb-1	219	50	of	of	ADP
njb-1	219	51	the	the	DET
njb-1	219	52	three	three	NUM
njb-1	219	53	major	major	ADJ
njb-1	219	54	types	type	NOUN
njb-1	219	55	of	of	ADP
njb-1	219	56	asparaginases	asparaginase	NOUN
njb-1	219	57	used	use	VERB
njb-1	219	58	for	for	ADP
njb-1	219	59	all	all	DET
njb-1	219	60	therapies	therapy	NOUN
njb-1	219	61	:	:	PUNCT
njb-1	219	62	peg	peg	NOUN
njb-1	219	63	-	-	PUNCT
njb-1	219	64	asparaginase	asparaginase	NOUN
njb-1	219	65	,	,	PUNCT
njb-1	219	66	erwinia	erwinia	PROPN
njb-1	219	67	chrysanthemi	chrysanthemi	PROPN
njb-1	219	68	asparaginase	asparaginase	PROPN
njb-1	219	69	and	and	CCONJ
njb-1	219	70	native	native	ADJ
njb-1	219	71	escherichia	escherichia	NOUN
njb-1	219	72	coli	coli	PROPN
njb-1	219	73	asparaginase	asparaginase	NOUN
njb-1	219	74	.	.	PUNCT
njb-1	220	1	peg	peg	PROPN
njb-1	220	2	e.	e.	PROPN
njb-1	220	3	coli	coli	PROPN
njb-1	220	4	asparaginase	asparaginase	NOUN
njb-1	220	5	activity	activity	NOUN
njb-1	220	6	was	be	AUX
njb-1	220	7	seen	see	VERB
njb-1	220	8	to	to	PART
njb-1	220	9	be	be	AUX
njb-1	220	10	between	between	ADP
njb-1	220	11	0.3	0.3	NUM
njb-1	220	12	-	-	SYM
njb-1	220	13	0.7	0.7	NUM
njb-1	220	14	iu	iu	NOUN
njb-1	220	15	/	/	SYM
njb-1	220	16	ml	ml	PROPN
njb-1	220	17	,	,	PUNCT
njb-1	220	18	which	which	PRON
njb-1	220	19	is	be	AUX
njb-1	220	20	the	the	DET
njb-1	220	21	highest	high	ADJ
njb-1	220	22	in	in	ADP
njb-1	220	23	comparison	comparison	NOUN
njb-1	220	24	to	to	ADP
njb-1	220	25	others	other	NOUN
njb-1	220	26	(	(	PUNCT
njb-1	220	27	table	table	NOUN
njb-1	220	28	3	3	NUM
njb-1	220	29	)	)	PUNCT
njb-1	220	30	.	.	PUNCT
njb-1	221	1	in	in	ADP
njb-1	221	2	terms	term	NOUN
njb-1	221	3	of	of	ADP
njb-1	221	4	toxicity	toxicity	NOUN
njb-1	221	5	,	,	PUNCT
njb-1	221	6	all	all	DET
njb-1	221	7	three	three	NUM
njb-1	221	8	forms	form	NOUN
njb-1	221	9	of	of	ADP
njb-1	221	10	asparaginases	asparaginase	NOUN
njb-1	221	11	showed	show	VERB
njb-1	221	12	similar	similar	ADJ
njb-1	221	13	results	result	NOUN
njb-1	221	14	(	(	PUNCT
njb-1	221	15	table	table	NOUN
njb-1	221	16	4	4	NUM
njb-1	221	17	)	)	PUNCT
njb-1	221	18	.	.	PUNCT
njb-1	222	1	toxicities	toxicity	NOUN
njb-1	222	2	like	like	ADP
njb-1	222	3	hyperglycemia	hyperglycemia	NOUN
njb-1	222	4	and	and	CCONJ
njb-1	222	5	pancreatitis	pancreatitis	NOUN
njb-1	222	6	were	be	AUX
njb-1	222	7	seen	see	VERB
njb-1	222	8	in	in	ADP
njb-1	222	9	a	a	DET
njb-1	222	10	significant	significant	ADJ
njb-1	222	11	number	number	NOUN
njb-1	222	12	of	of	ADP
njb-1	222	13	cases	case	NOUN
njb-1	222	14	leading	lead	VERB
njb-1	222	15	to	to	ADP
njb-1	222	16	a	a	DET
njb-1	222	17	decrease	decrease	NOUN
njb-1	222	18	in	in	ADP
njb-1	222	19	the	the	DET
njb-1	222	20	effectiveness	effectiveness	NOUN
njb-1	222	21	of	of	ADP
njb-1	222	22	the	the	DET
njb-1	222	23	enzyme	enzyme	NOUN
njb-1	222	24	in	in	ADP
njb-1	222	25	the	the	DET
njb-1	222	26	treatment	treatment	NOUN
njb-1	222	27	of	of	ADP
njb-1	222	28	the	the	DET
njb-1	222	29	patients	patient	NOUN
njb-1	222	30	.	.	PUNCT
njb-1	223	1	in	in	ADP
njb-1	223	2	several	several	ADJ
njb-1	223	3	studies	study	NOUN
njb-1	223	4	,	,	PUNCT
njb-1	223	5	we	we	PRON
njb-1	223	6	can	can	AUX
njb-1	223	7	see	see	VERB
njb-1	223	8	that	that	DET
njb-1	223	9	incidence	incidence	NOUN
njb-1	223	10	of	of	ADP
njb-1	223	11	toxicity	toxicity	NOUN
njb-1	223	12	increases	increase	NOUN
njb-1	223	13	with	with	ADP
njb-1	223	14	the	the	DET
njb-1	223	15	dose	dose	NOUN
njb-1	223	16	of	of	ADP
njb-1	223	17	the	the	DET
njb-1	223	18	enzyme	enzyme	NOUN
njb-1	223	19	.	.	PUNCT
njb-1	224	1	another	another	DET
njb-1	224	2	minor	minor	ADJ
njb-1	224	3	conclusion	conclusion	NOUN
njb-1	224	4	that	that	SCONJ
njb-1	224	5	we	we	PRON
njb-1	224	6	can	can	AUX
njb-1	224	7	derive	derive	VERB
njb-1	224	8	from	from	ADP
njb-1	224	9	clinical	clinical	ADJ
njb-1	224	10	trials	trial	NOUN
njb-1	224	11	by	by	ADP
njb-1	224	12	place	place	NOUN
njb-1	224	13	et	et	PROPN
njb-1	224	14	al	al	PROPN
njb-1	224	15	and	and	CCONJ
njb-1	224	16	vyas	vyas	PROPN
njb-1	224	17	et	et	PROPN
njb-1	224	18	al	al	PROPN
njb-1	224	19	is	be	AUX
njb-1	224	20	that	that	SCONJ
njb-1	224	21	overall	overall	ADJ
njb-1	224	22	survival	survival	NOUN
njb-1	224	23	was	be	AUX
njb-1	224	24	slightly	slightly	ADV
njb-1	224	25	higher	high	ADJ
njb-1	224	26	for	for	ADP
njb-1	224	27	peg	peg	PROPN
njb-1	224	28	e.	e.	PROPN
njb-1	224	29	coli	coli	PROPN
njb-1	224	30	asparaginase	asparaginase	NOUN
njb-1	224	31	than	than	ADP
njb-1	224	32	native	native	ADJ
njb-1	224	33	e.	e.	PROPN
njb-1	224	34	coli	coli	PROPN
njb-1	224	35	asparaginase	asparaginase	NOUN
njb-1	224	36	(	(	PUNCT
njb-1	224	37	table	table	NOUN
njb-1	224	38	8)	8)	NUM
njb-1	224	39	.	.	PUNCT
njb-1	225	1	this	this	DET
njb-1	225	2	difference	difference	NOUN
njb-1	225	3	is	be	AUX
njb-1	225	4	very	very	ADV
njb-1	225	5	slight	slight	ADJ
njb-1	225	6	and	and	CCONJ
njb-1	225	7	the	the	DET
njb-1	225	8	results	result	NOUN
njb-1	225	9	stay	stay	VERB
njb-1	225	10	the	the	DET
njb-1	225	11	same	same	ADJ
njb-1	225	12	for	for	ADP
njb-1	225	13	event	event	NOUN
njb-1	225	14	free	free	ADJ
njb-1	225	15	survival	survival	NOUN
njb-1	225	16	making	make	VERB
njb-1	225	17	conclusions	conclusion	NOUN
njb-1	225	18	about	about	ADP
njb-1	225	19	the	the	DET
njb-1	225	20	higher	high	ADJ
njb-1	225	21	efficacy	efficacy	NOUN
njb-1	225	22	of	of	ADP
njb-1	225	23	one	one	NUM
njb-1	225	24	type	type	NOUN
njb-1	225	25	of	of	ADP
njb-1	225	26	asparaginase	asparaginase	NOUN
njb-1	225	27	over	over	ADP
njb-1	225	28	the	the	DET
njb-1	225	29	other	other	ADJ
njb-1	225	30	difficult	difficult	ADJ
njb-1	225	31	(	(	PUNCT
njb-1	225	32	table	table	NOUN
njb-1	225	33	6	6	NUM
njb-1	225	34	)	)	PUNCT
njb-1	225	35	.	.	PUNCT
njb-1	226	1	there	there	PRON
njb-1	226	2	were	be	VERB
njb-1	226	3	number	number	NOUN
njb-1	226	4	of	of	ADP
njb-1	226	5	other	other	ADJ
njb-1	226	6	studies	study	NOUN
njb-1	226	7	that	that	PRON
njb-1	226	8	did	do	AUX
njb-1	226	9	not	not	PART
njb-1	226	10	directly	directly	ADV
njb-1	226	11	evaluate	evaluate	VERB
njb-1	226	12	the	the	DET
njb-1	226	13	safety	safety	NOUN
njb-1	226	14	and	and	CCONJ
njb-1	226	15	efficacy	efficacy	NOUN
njb-1	226	16	of	of	ADP
njb-1	226	17	asparaginases	asparaginase	NOUN
njb-1	226	18	in	in	ADP
njb-1	226	19	clinical	clinical	ADJ
njb-1	226	20	trials	trial	NOUN
njb-1	226	21	for	for	ADP
njb-1	226	22	children	child	NOUN
njb-1	226	23	.	.	PUNCT
njb-1	227	1	since	since	SCONJ
njb-1	227	2	these	these	DET
njb-1	227	3	studies	study	NOUN
njb-1	227	4	were	be	AUX
njb-1	227	5	also	also	ADV
njb-1	227	6	included	include	VERB
njb-1	227	7	in	in	ADP
njb-1	227	8	this	this	DET
njb-1	227	9	review	review	NOUN
njb-1	227	10	,	,	PUNCT
njb-1	227	11	we	we	PRON
njb-1	227	12	will	will	AUX
njb-1	227	13	discuss	discuss	VERB
njb-1	227	14	the	the	DET
njb-1	227	15	findings	finding	NOUN
njb-1	227	16	of	of	ADP
njb-1	227	17	these	these	DET
njb-1	227	18	studies	study	NOUN
njb-1	227	19	.	.	PUNCT
njb-1	228	1	in	in	ADP
njb-1	228	2	the	the	DET
njb-1	228	3	study	study	NOUN
njb-1	228	4	by	by	ADP
njb-1	228	5	rau	rau	PROPN
njb-1	228	6	et	et	PROPN
njb-1	228	7	al	al	PROPN
njb-1	228	8	.	.	PROPN
njb-1	228	9	pegcrisantaspase	pegcrisantaspase	PROPN
njb-1	228	10	(	(	PUNCT
njb-1	228	11	erwinia	erwinia	PROPN
njb-1	228	12	chrysanthemi	chrysanthemi	PROPN
njb-1	228	13	pegylated	pegylate	VERB
njb-1	228	14	asparaginase	asparaginase	NOUN
njb-1	228	15	)	)	PUNCT
njb-1	228	16	treatment	treatment	NOUN
njb-1	228	17	also	also	ADV
njb-1	228	18	reported	report	VERB
njb-1	228	19	hypersensitivity	hypersensitivity	NOUN
njb-1	228	20	reaction	reaction	NOUN
njb-1	228	21	to	to	ADP
njb-1	228	22	the	the	DET
njb-1	228	23	patients	patient	NOUN
njb-1	228	24	table	table	NOUN
njb-1	228	25	7	7	NUM
njb-1	228	26	.	.	SYM
njb-1	228	27	time	time	NOUN
njb-1	228	28	period	period	NOUN
njb-1	228	29	of	of	ADP
njb-1	228	30	overall	overall	ADJ
njb-1	228	31	survival	survival	NOUN
njb-1	228	32	in	in	ADP
njb-1	228	33	treated	treat	VERB
njb-1	228	34	patients	patient	NOUN
njb-1	228	35	from	from	ADP
njb-1	228	36	individual	individual	ADJ
njb-1	228	37	trials	trial	NOUN
njb-1	228	38	.	.	PUNCT
njb-1	229	1	clinical	clinical	ADJ
njb-1	229	2	trial	trial	NOUN
njb-1	229	3	type	type	NOUN
njb-1	229	4	of	of	ADP
njb-1	229	5	asparaginase	asparaginase	NOUN
njb-1	229	6	overall	overall	ADJ
njb-1	229	7	surviva	surviva	NOUN
njb-1	229	8	l	l	PROPN
njb-1	229	9	year	year	NOUN
njb-1	229	10	%	%	NOUN
njb-1	229	11	of	of	ADP
njb-1	229	12	patients	patient	NOUN
njb-1	229	13	survived	survive	VERB
njb-1	229	14	follow	follow	VERB
njb-1	229	15	up	up	ADP
njb-1	229	16	period	period	NOUN
njb-1	229	17	(	(	PUNCT
njb-1	229	18	years	year	NOUN
njb-1	229	19	)	)	PUNCT
njb-1	230	1	[	[	X
njb-1	230	2	16	16	NUM
njb-1	230	3	]	]	PUNCT
njb-1	230	4	native	native	ADJ
njb-1	230	5	escherichia	escherichia	PROPN
njb-1	230	6	coli	coli	NOUN
njb-1	230	7	2	2	NUM
njb-1	230	8	84	84	NUM
njb-1	230	9	2	2	NUM
njb-1	230	10	peg	peg	NOUN
njb-1	230	11	escherichia	escherichia	NOUN
njb-1	230	12	coli	coli	NOUN
njb-1	230	13	2	2	NUM
njb-1	230	14	93	93	NUM
njb-1	231	1	[	[	PUNCT
njb-1	231	2	19	19	NUM
njb-1	231	3	]	]	PUNCT
njb-1	231	4	native	native	ADJ
njb-1	231	5	escherichia	escherichia	NOUN
njb-1	231	6	coli	coli	NOUN
njb-1	231	7	5	5	NUM
njb-1	231	8	94	94	NUM
njb-1	231	9	6	6	NUM
njb-1	231	10	peg	peg	NOUN
njb-1	231	11	escherichia	escherichia	NOUN
njb-1	231	12	coli	coli	NOUN
njb-1	231	13	5	5	NUM
njb-1	231	14	96	96	NUM
njb-1	232	1	[	[	PUNCT
njb-1	232	2	26	26	NUM
njb-1	232	3	]	]	PUNCT
njb-1	232	4	native	native	ADJ
njb-1	232	5	escherichia	escherichia	PROPN
njb-1	232	6	coli	coli	NOUN
njb-1	232	7	5	5	NUM
njb-1	232	8	94.4	94.4	NUM
njb-1	232	9	10	10	NUM
njb-1	232	10	native	native	ADJ
njb-1	232	11	escherichia	escherichia	NOUN
njb-1	232	12	coli	coli	NOUN
njb-1	232	13	10	10	NUM
njb-1	232	14	93.7	93.7	NUM
njb-1	233	1	[	[	PUNCT
njb-1	233	2	24	24	NUM
njb-1	233	3	]	]	PUNCT
njb-1	233	4	native	native	ADJ
njb-1	233	5	escherichia	escherichia	NOUN
njb-1	233	6	coli	coli	NOUN
njb-1	233	7	10	10	NUM
njb-1	233	8	80	80	NUM
njb-1	233	9	-	-	SYM
njb-1	233	10	88	88	NUM
njb-1	233	11	10	10	NUM
njb-1	233	12	[	[	PUNCT
njb-1	233	13	15	15	NUM
njb-1	233	14	]	]	PUNCT
njb-1	233	15	native	native	ADJ
njb-1	233	16	escherichia	escherichia	NOUN
njb-1	233	17	coli	coli	NOUN
njb-1	233	18	6	6	NUM
njb-1	233	19	84	84	NUM
njb-1	233	20	6	6	NUM
njb-1	233	21	erwinia	erwinia	NOUN
njb-1	233	22	chrysanthemi	chrysanthemi	PROPN
njb-1	233	23	6	6	NUM
njb-1	233	24	75	75	NUM
njb-1	233	25	nepal	nepal	PROPN
njb-1	233	26	j	j	PROPN
njb-1	233	27	biotechnol	biotechnol	NOUN
njb-1	233	28	.	.	PUNCT
njb-1	234	1	2	2	NUM
njb-1	234	2	0	0	NUM
njb-1	234	3	2	2	NUM
njb-1	234	4	1	1	NUM
njb-1	234	5	d	d	X
njb-1	234	6	e	e	X
njb-1	234	7	c	c	PROPN
njb-1	234	8	.	.	PUNCT
njb-1	235	1	9	9	NUM
njb-1	235	2	(	(	PUNCT
njb-1	235	3	2	2	NUM
njb-1	235	4	):	):	PUNCT
njb-1	235	5	39	39	NUM
njb-1	235	6	-	-	SYM
njb-1	235	7	47	47	NUM
njb-1	235	8	baral	baral	ADJ
njb-1	235	9	et	et	PROPN
njb-1	235	10	al	al	PROPN
njb-1	235	11	.	.	PUNCT
njb-1	236	1	©	©	PROPN
njb-1	236	2	njb	njb	PROPN
njb-1	236	3	,	,	PUNCT
njb-1	236	4	bsn	bsn	PROPN
njb-1	236	5	45	45	NUM
njb-1	236	6	with	with	ADP
njb-1	236	7	previously	previously	ADV
njb-1	236	8	showing	show	VERB
njb-1	236	9	hypersensitivity	hypersensitivity	NOUN
njb-1	236	10	reaction	reaction	NOUN
njb-1	236	11	to	to	PART
njb-1	236	12	peg	peg	VERB
njb-1	236	13	asparaginase	asparaginase	NOUN
njb-1	236	14	treatment	treatment	NOUN
njb-1	236	15	.	.	PUNCT
njb-1	237	1	table	table	NOUN
njb-1	237	2	11	11	NUM
njb-1	237	3	.	.	PUNCT
njb-1	238	1	general	general	ADJ
njb-1	238	2	data	datum	NOUN
njb-1	238	3	of	of	ADP
njb-1	238	4	selected	select	VERB
njb-1	238	5	studies	study	NOUN
njb-1	238	6	.	.	PUNCT
njb-1	239	1	author	author	NOUN
njb-1	239	2	,	,	PUNCT
njb-1	239	3	year	year	NOUN
njb-1	239	4	country	country	NOUN
njb-1	239	5	type	type	NOUN
njb-1	239	6	of	of	ADP
njb-1	239	7	enzyme	enzyme	NOUN
njb-1	239	8	(	(	PUNCT
njb-1	239	9	asparaginase	asparaginase	NOUN
njb-1	239	10	)	)	PUNCT
njb-1	239	11	route	route	NOUN
njb-1	239	12	of	of	ADP
njb-1	239	13	administration	administration	NOUN
njb-1	239	14	period	period	NOUN
njb-1	239	15	of	of	ADP
njb-1	239	16	treatment	treatment	NOUN
njb-1	239	17	of	of	ADP
njb-1	239	18	enzyme	enzyme	NOUN
njb-1	239	19	total	total	ADJ
njb-1	239	20	number	number	NOUN
njb-1	239	21	of	of	ADP
njb-1	239	22	participant	participant	ADJ
njb-1	239	23	study	study	NOUN
njb-1	239	24	group(age	group(age	NOUN
njb-1	239	25	)	)	PUNCT
njb-1	239	26	ogawa	ogawa	PROPN
njb-1	239	27	et	et	PROPN
njb-1	239	28	al	al	PROPN
njb-1	239	29	.	.	PROPN
njb-1	239	30	2017	2017	NUM
njb-1	240	1	japan	japan	PROPN
njb-1	240	2	erwinia	erwinia	PROPN
njb-1	240	3	chrysanthemi	chrysanthemi	PROPN
njb-1	240	4	intramuscular	intramuscular	ADJ
njb-1	240	5	2weeks	2weeks	NUM
njb-1	240	6	24	24	NUM
njb-1	240	7	2	2	NUM
njb-1	240	8	-	-	SYM
njb-1	240	9	16	16	NUM
njb-1	240	10	years	year	NOUN
njb-1	240	11	vyas	vyas	PROPN
njb-1	240	12	et	et	PROPN
njb-1	240	13	al	al	PROPN
njb-1	240	14	.	.	PROPN
njb-1	240	15	2018	2018	NUM
njb-1	240	16	india	india	PROPN
njb-1	240	17	native	native	PROPN
njb-1	240	18	escherichia	escherichia	PROPN
njb-1	240	19	coli	coli	PROPN
njb-1	240	20	)	)	PUNCT
njb-1	240	21	intramuscular	intramuscular	ADV
njb-1	240	22	10	10	NUM
njb-1	240	23	weeks	week	NOUN
njb-1	240	24	106	106	NUM
njb-1	240	25	less	less	ADJ
njb-1	240	26	than	than	ADP
njb-1	240	27	18	18	NUM
njb-1	240	28	years	year	NOUN
njb-1	240	29	generic	generic	ADJ
njb-1	240	30	peg	peg	NOUN
njb-1	240	31	escherichia	escherichia	NOUN
njb-1	240	32	coli	coli	NOUN
njb-1	240	33	)	)	PUNCT
njb-1	240	34	intravenous	intravenous	ADJ
njb-1	240	35	van	van	PROPN
njb-1	240	36	der	der	PROPN
njb-1	240	37	sluis	sluis	PROPN
njb-1	240	38	al	al	PROPN
njb-1	240	39	,	,	PUNCT
njb-1	240	40	2018	2018	NUM
njb-1	240	41	netherlands	netherland	VERB
njb-1	240	42	recombinant	recombinant	ADJ
njb-1	240	43	escherichia	escherichia	NOUN
njb-1	240	44	coli	coli	NOUN
njb-1	240	45	intravenous	intravenous	ADJ
njb-1	240	46	5	5	NUM
njb-1	240	47	weeks	week	NOUN
njb-1	240	48	199	199	NUM
njb-1	240	49	children	child	NOUN
njb-1	240	50	native	native	ADJ
njb-1	240	51	escherichia	escherichia	PROPN
njb-1	240	52	coli	coli	PROPN
njb-1	240	53	place	place	NOUN
njb-1	240	54	et	et	PROPN
njb-1	240	55	al	al	PROPN
njb-1	240	56	.	.	PROPN
njb-1	240	57	2015	2015	NUM
njb-1	240	58	usa	usa	PROPN
njb-1	240	59	and	and	CCONJ
njb-1	240	60	canada	canada	PROPN
njb-1	240	61	peg	peg	PROPN
njb-1	240	62	escherichia	escherichia	PROPN
njb-1	240	63	coli	coli	PROPN
njb-1	240	64	)	)	PUNCT
njb-1	240	65	intravenous	intravenous	ADJ
njb-1	240	66	30	30	NUM
njb-1	240	67	weeks	week	NOUN
njb-1	240	68	463	463	NUM
njb-1	240	69	1	1	NUM
njb-1	240	70	-	-	SYM
njb-1	240	71	18	18	NUM
njb-1	240	72	years	year	NOUN
njb-1	240	73	escherichia	escherichia	NOUN
njb-1	240	74	coli	coli	NOUN
njb-1	240	75	intramuscular	intramuscular	ADJ
njb-1	240	76	pession	pession	NOUN
njb-1	240	77	et	et	PROPN
njb-1	240	78	al	al	PROPN
njb-1	240	79	.	.	PROPN
njb-1	240	80	2005	2005	NUM
njb-1	241	1	italy	italy	PROPN
njb-1	241	2	90	90	NUM
njb-1	241	3	%	%	NOUN
njb-1	241	4	of	of	ADP
njb-1	241	5	the	the	DET
njb-1	241	6	patients	patient	NOUN
njb-1	241	7	received	receive	VERB
njb-1	241	8	erwinia	erwinia	PROPN
njb-1	241	9	chrysanthemi	chrysanthemi	PROPN
njb-1	241	10	10	10	NUM
njb-1	241	11	%	%	NOUN
njb-1	241	12	escherichia	escherichia	NOUN
njb-1	241	13	coli	coli	NOUN
njb-1	241	14	intramuscular	intramuscular	ADV
njb-1	241	15	24	24	NUM
njb-1	241	16	months	month	NOUN
njb-1	241	17	490	490	NUM
njb-1	241	18	1	1	NUM
njb-1	241	19	-	-	SYM
njb-1	241	20	15	15	NUM
njb-1	241	21	years	year	NOUN
njb-1	241	22	liang	liang	PROPN
njb-1	241	23	et	et	PROPN
njb-1	241	24	al	al	PROPN
njb-1	241	25	.	.	PROPN
njb-1	241	26	1999	1999	NUM
njb-1	241	27	taiwan	taiwan	PROPN
njb-1	241	28	escherichia	escherichia	NOUN
njb-1	241	29	coli	coli	NOUN
njb-1	241	30	intramuscular	intramuscular	ADV
njb-1	241	31	110	110	NUM
njb-1	241	32	weeks	week	NOUN
njb-1	241	33	201	201	NUM
njb-1	241	34	1	1	NUM
njb-1	241	35	-	-	SYM
njb-1	241	36	15	15	NUM
njb-1	241	37	years	year	NOUN
njb-1	241	38	dinndorf	dinndorf	PROPN
njb-1	241	39	et	et	PROPN
njb-1	241	40	al	al	PROPN
njb-1	241	41	.	.	PROPN
njb-1	241	42	2007	2007	NUM
njb-1	241	43	usa	usa	PROPN
njb-1	241	44	escherichia	escherichia	PROPN
njb-1	241	45	coli[elspar	coli[elspar	NOUN
njb-1	241	46	®	®	NOUN
njb-1	241	47	from	from	ADP
njb-1	241	48	merck	merck	PROPN
njb-1	241	49	]	]	X
njb-1	241	50	peg	peg	PROPN
njb-1	241	51	escherichia	escherichia	PROPN
njb-1	241	52	colioncaspa	colioncaspa	PROPN
njb-1	241	53	®	®	PROPN
njb-1	241	54	by	by	ADP
njb-1	241	55	enzon	enzon	ADJ
njb-1	241	56	pharmaceuticals	pharmaceutical	NOUN
njb-1	241	57	,	,	PUNCT
njb-1	241	58	inc	inc	PROPN
njb-1	241	59	both	both	DET
njb-1	241	60	intramuscular	intramuscular	ADJ
njb-1	241	61	12	12	NUM
njb-1	241	62	weeks	week	NOUN
njb-1	241	63	118	118	NUM
njb-1	241	64	1	1	NUM
njb-1	241	65	-	-	SYM
njb-1	241	66	9	9	NUM
njb-1	241	67	years	year	NOUN
njb-1	241	68	abshire	abshire	VERB
njb-1	241	69	et	et	PROPN
njb-1	241	70	al	al	PROPN
njb-1	241	71	.	.	PROPN
njb-1	241	72	2000	2000	NUM
njb-1	242	1	usa	usa	PROPN
njb-1	242	2	peg	peg	PROPN
njb-1	242	3	escherichia	escherichia	PROPN
njb-1	242	4	coli	coli	PROPN
njb-1	242	5	erwinia	erwinia	PROPN
njb-1	242	6	chrysanthemi	chrysanthemi	PROPN
njb-1	242	7	intramuscular	intramuscular	PROPN
njb-1	242	8	4	4	NUM
njb-1	242	9	weeks	week	NOUN
njb-1	242	10	144	144	NUM
njb-1	242	11	below	below	ADP
njb-1	242	12	22	22	NUM
njb-1	242	13	years	year	NOUN
njb-1	242	14	of	of	ADP
njb-1	242	15	age	age	NOUN
njb-1	242	16	karachunskiy	karachunskiy	NOUN
njb-1	242	17	et	et	PROPN
njb-1	242	18	al	al	PROPN
njb-1	242	19	moscow	moscow	PROPN
njb-1	242	20	–	–	PUNCT
njb-1	242	21	berlin	berlin	PROPN
njb-1	242	22	native	native	PROPN
njb-1	242	23	escherichia	escherichia	PROPN
njb-1	242	24	coli	coli	NOUN
njb-1	242	25	intramuscular	intramuscular	ADV
njb-1	242	26	200	200	NUM
njb-1	242	27	days	day	NOUN
njb-1	242	28	774	774	NUM
njb-1	242	29	1	1	NUM
njb-1	242	30	-	-	SYM
njb-1	242	31	19	19	NUM
njb-1	242	32	years	year	NOUN
njb-1	242	33	patel	patel	PROPN
njb-1	242	34	et	et	PROPN
njb-1	242	35	al	al	PROPN
njb-1	242	36	.	.	PROPN
njb-1	242	37	2017	2017	NUM
njb-1	242	38	uk	uk	PROPN
njb-1	242	39	peg	peg	PROPN
njb-1	242	40	escherichia	escherichia	PROPN
njb-1	242	41	coli	coli	PROPN
njb-1	242	42	8	8	NUM
njb-1	242	43	weeks	week	NOUN
njb-1	242	44	91	91	NUM
njb-1	242	45	25	25	NUM
njb-1	242	46	-	-	SYM
njb-1	242	47	65	65	NUM
njb-1	242	48	years	year	NOUN
njb-1	242	49	pieters	pieter	NOUN
njb-1	242	50	et	et	PROPN
njb-1	242	51	al	al	PROPN
njb-1	242	52	.	.	PUNCT
njb-1	243	1	netherlands	netherlands	PROPN
njb-1	243	2	recombinant	recombinant	ADJ
njb-1	243	3	escherichia	escherichia	NOUN
njb-1	243	4	coli	coli	NOUN
njb-1	243	5	asparaginase	asparaginase	NOUN
njb-1	243	6	asparaginase	asparaginase	NOUN
njb-1	243	7	medac	medac	VERB
njb-1	243	8	intravenous	intravenous	ADJ
njb-1	243	9	39	39	NUM
njb-1	243	10	days	day	NOUN
njb-1	243	11	32	32	NUM
njb-1	243	12	1	1	NUM
njb-1	243	13	-	-	SYM
njb-1	243	14	14	14	NUM
njb-1	243	15	years	year	NOUN
njb-1	243	16	van	van	PROPN
njb-1	243	17	der	der	PROPN
njb-1	243	18	sluis	sluis	PROPN
njb-1	243	19	et	et	X
njb-1	243	20	al	al	PROPN
njb-1	243	21	.	.	PROPN
njb-1	243	22	2013	2013	NUM
njb-1	243	23	netherlands	netherlands	PROPN
njb-1	243	24	and	and	CCONJ
njb-1	243	25	germany	germany	PROPN
njb-1	243	26	recombinant	recombinant	ADJ
njb-1	243	27	escherichia	escherichia	NOUN
njb-1	243	28	coli	coli	NOUN
njb-1	243	29	-asparaginase	-asparaginase	ADV
njb-1	243	30	39	39	NUM
njb-1	243	31	days	day	NOUN
njb-1	243	32	12	12	NUM
njb-1	243	33	below	below	ADP
njb-1	243	34	1	1	NUM
njb-1	243	35	years	year	NOUN
njb-1	243	36	rau	rau	PROPN
njb-1	243	37	et	et	PROPN
njb-1	243	38	al	al	PROPN
njb-1	243	39	.	.	PROPN
njb-1	243	40	2018	2018	NUM
njb-1	243	41	usa	usa	PROPN
njb-1	243	42	peg	peg	PROPN
njb-1	243	43	erwinia	erwinia	PROPN
njb-1	243	44	chrysanthemi	chrysanthemi	PROPN
njb-1	243	45	intravenous	intravenous	PROPN
njb-1	243	46	29	29	NUM
njb-1	243	47	days	day	NOUN
njb-1	243	48	4	4	NUM
njb-1	243	49	1	1	NUM
njb-1	243	50	-	-	SYM
njb-1	243	51	20	20	NUM
njb-1	243	52	years	year	NOUN
njb-1	243	53	albertsen	albertsen	PROPN
njb-1	243	54	et	et	PROPN
njb-1	243	55	al	al	PROPN
njb-1	243	56	.	.	PROPN
njb-1	243	57	2019	2019	NUM
njb-1	243	58	denmark	denmark	NOUN
njb-1	243	59	,	,	PUNCT
njb-1	243	60	finland	finland	PROPN
njb-1	243	61	,	,	PUNCT
njb-1	243	62	iceland	iceland	NOUN
njb-1	243	63	,	,	PUNCT
njb-1	243	64	norway	norway	PROPN
njb-1	243	65	,	,	PUNCT
njb-1	243	66	or	or	CCONJ
njb-1	243	67	sweden	sweden	PROPN
njb-1	243	68	pegescherichia	pegescherichia	NOUN
njb-1	243	69	coli	coli	NOUN
njb-1	243	70	intramuscular	intramuscular	ADV
njb-1	243	71	30	30	NUM
njb-1	243	72	-	-	SYM
njb-1	243	73	33	33	NUM
njb-1	243	74	weeks	week	NOUN
njb-1	243	75	625	625	NUM
njb-1	243	76	children	child	NOUN
njb-1	243	77	duval	duval	NOUN
njb-1	243	78	et	et	PROPN
njb-1	243	79	al	al	PROPN
njb-1	243	80	.	.	PROPN
njb-1	243	81	2002	2002	NUM
njb-1	243	82	belgium	belgium	PROPN
njb-1	243	83	,	,	PUNCT
njb-1	243	84	france	france	PROPN
njb-1	243	85	and	and	CCONJ
njb-1	243	86	portugal	portugal	PROPN
njb-1	243	87	escherichia	escherichia	PROPN
njb-1	243	88	coli	coli	PROPN
njb-1	243	89	intravenously	intravenously	ADV
njb-1	243	90	6	6	NUM
njb-1	243	91	weeks	week	NOUN
njb-1	243	92	700	700	NUM
njb-1	243	93	less	less	ADJ
njb-1	243	94	than	than	ADP
njb-1	243	95	18	18	NUM
njb-1	243	96	years	year	NOUN
njb-1	243	97	erwinia	erwinia	PROPN
njb-1	243	98	chrysanthemi	chrysanthemi	PROPN
njb-1	243	99	kurtzberg	kurtzberg	PROPN
njb-1	243	100	et	et	PROPN
njb-1	243	101	al	al	PROPN
njb-1	243	102	.	.	PROPN
njb-1	243	103	2011	2011	NUM
njb-1	243	104	usa	usa	PROPN
njb-1	243	105	,	,	PUNCT
njb-1	243	106	canada	canada	PROPN
njb-1	243	107	peg	peg	PROPN
njb-1	243	108	escherichia	escherichia	PROPN
njb-1	243	109	coli	coli	PROPN
njb-1	243	110	asparaginase	asparaginase	NOUN
njb-1	243	111	intramuscularly	intramuscularly	ADV
njb-1	243	112	4	4	NUM
njb-1	243	113	weeks	week	NOUN
njb-1	243	114	76	76	NUM
njb-1	243	115	less	less	ADJ
njb-1	243	116	than	than	ADP
njb-1	243	117	21	21	NUM
njb-1	243	118	years	year	NOUN
njb-1	243	119	native	native	ADJ
njb-1	243	120	escherichia	escherichia	NOUN
njb-1	243	121	coli	coli	PROPN
njb-1	243	122	ribera	ribera	NOUN
njb-1	243	123	et	et	PROPN
njb-1	243	124	al	al	PROPN
njb-1	243	125	.	.	PROPN
njb-1	243	126	2017	2017	NUM
njb-1	244	1	spain	spain	PROPN
njb-1	244	2	native	native	PROPN
njb-1	244	3	escherichia	escherichia	PROPN
njb-1	244	4	coli	coli	PROPN
njb-1	244	5	intravenously	intravenously	ADV
njb-1	244	6	4	4	NUM
njb-1	244	7	weeks	week	NOUN
njb-1	244	8	126	126	NUM
njb-1	244	9	18	18	NUM
njb-1	244	10	-	-	SYM
njb-1	244	11	60	60	NUM
njb-1	244	12	years	year	NOUN
njb-1	244	13	it	it	PRON
njb-1	244	14	is	be	AUX
njb-1	244	15	possible	possible	ADJ
njb-1	244	16	that	that	DET
njb-1	244	17	peg	peg	NOUN
njb-1	244	18	(	(	PUNCT
njb-1	244	19	poly	poly	ADJ
njb-1	244	20	ethylene	ethylene	NOUN
njb-1	244	21	glycol	glycol	PROPN
njb-1	244	22	)	)	PUNCT
njb-1	244	23	can	can	AUX
njb-1	244	24	be	be	AUX
njb-1	244	25	immunogenic	immunogenic	ADJ
njb-1	244	26	and	and	CCONJ
njb-1	244	27	anti	anti	ADJ
njb-1	244	28	-	-	ADJ
njb-1	244	29	peg	peg	ADJ
njb-1	244	30	igg	igg	NOUN
njb-1	244	31	antibodies	antibody	NOUN
njb-1	244	32	are	be	AUX
njb-1	244	33	formed	form	VERB
njb-1	244	34	during	during	ADP
njb-1	244	35	peg	peg	NOUN
njb-1	244	36	-	-	PUNCT
njb-1	244	37	asparaginase	asparaginase	NOUN
njb-1	244	38	treatment	treatment	NOUN
njb-1	244	39	.	.	PUNCT
njb-1	245	1	the	the	DET
njb-1	245	2	remaining	remain	VERB
njb-1	245	3	immunological	immunological	ADJ
njb-1	245	4	memory	memory	NOUN
njb-1	245	5	may	may	AUX
njb-1	245	6	mediate	mediate	VERB
njb-1	245	7	hypersensitivity	hypersensitivity	NOUN
njb-1	245	8	reaction	reaction	NOUN
njb-1	245	9	during	during	ADP
njb-1	245	10	pegcrisantaspase	pegcrisantaspase	NOUN
njb-1	245	11	treatment	treatment	NOUN
njb-1	245	12	.	.	PUNCT
njb-1	246	1	one	one	NUM
njb-1	246	2	of	of	ADP
njb-1	246	3	the	the	DET
njb-1	246	4	patients	patient	NOUN
njb-1	246	5	involved	involve	VERB
njb-1	246	6	in	in	ADP
njb-1	246	7	this	this	DET
njb-1	246	8	study	study	NOUN
njb-1	246	9	had	have	AUX
njb-1	246	10	not	not	PART
njb-1	246	11	been	be	AUX
njb-1	246	12	exposed	expose	VERB
njb-1	246	13	to	to	ADP
njb-1	246	14	pegaspargase	pegaspargase	NOUN
njb-1	246	15	for	for	ADP
njb-1	246	16	5.5	5.5	NUM
njb-1	246	17	years	year	NOUN
njb-1	246	18	.	.	PUNCT
njb-1	247	1	he	he	PRON
njb-1	247	2	did	do	AUX
njb-1	247	3	not	not	PART
njb-1	247	4	experience	experience	VERB
njb-1	247	5	a	a	DET
njb-1	247	6	pegcrisantaspase	pegcrisantaspase	NOUN
njb-1	247	7	hypersensitivity	hypersensitivity	NOUN
njb-1	247	8	reaction	reaction	NOUN
njb-1	247	9	.	.	PUNCT
njb-1	248	1	a	a	DET
njb-1	248	2	lack	lack	NOUN
njb-1	248	3	of	of	ADP
njb-1	248	4	a	a	DET
njb-1	248	5	durable	durable	ADJ
njb-1	248	6	immunologic	immunologic	ADJ
njb-1	248	7	memory	memory	NOUN
njb-1	248	8	from	from	ADP
njb-1	248	9	anti	anti	ADJ
njb-1	248	10	-	-	ADJ
njb-1	248	11	peg	peg	ADJ
njb-1	248	12	-	-	PUNCT
njb-1	248	13	mediated	mediate	VERB
njb-1	248	14	immune	immune	ADJ
njb-1	248	15	reactions	reaction	NOUN
njb-1	248	16	may	may	AUX
njb-1	248	17	be	be	AUX
njb-1	248	18	the	the	DET
njb-1	248	19	case	case	NOUN
njb-1	248	20	for	for	ADP
njb-1	248	21	this	this	DET
njb-1	248	22	patient	patient	NOUN
njb-1	248	23	.	.	PUNCT
njb-1	249	1	it	it	PRON
njb-1	249	2	is	be	AUX
njb-1	249	3	suggested	suggest	VERB
njb-1	249	4	that	that	SCONJ
njb-1	249	5	patients	patient	NOUN
njb-1	249	6	who	who	PRON
njb-1	249	7	have	have	AUX
njb-1	249	8	been	be	AUX
njb-1	249	9	recently	recently	ADV
njb-1	249	10	exposed	expose	VERB
njb-1	249	11	to	to	PART
njb-1	249	12	peg	peg	VERB
njb-1	249	13	in	in	ADP
njb-1	249	14	the	the	DET
njb-1	249	15	formulation	formulation	NOUN
njb-1	249	16	of	of	ADP
njb-1	249	17	other	other	ADJ
njb-1	249	18	medicine	medicine	NOUN
njb-1	249	19	in	in	ADP
njb-1	249	20	any	any	DET
njb-1	249	21	disease	disease	NOUN
njb-1	249	22	should	should	AUX
njb-1	249	23	not	not	PART
njb-1	249	24	use	use	VERB
njb-1	249	25	any	any	DET
njb-1	249	26	peg	peg	NOUN
njb-1	249	27	asparaginase	asparaginase	NOUN
njb-1	249	28	in	in	ADP
njb-1	249	29	any	any	DET
njb-1	249	30	form	form	NOUN
njb-1	249	31	.	.	PUNCT
njb-1	250	1	instead	instead	ADV
njb-1	250	2	,	,	PUNCT
njb-1	250	3	native	native	ADJ
njb-1	250	4	escherichia	escherichia	NOUN
njb-1	250	5	coli	coli	NOUN
njb-1	250	6	or	or	CCONJ
njb-1	250	7	erwinia	erwinia	PROPN
njb-1	250	8	chrysanthemi	chrysanthemi	PROPN
njb-1	250	9	asparaginase	asparaginase	PROPN
njb-1	250	10	should	should	AUX
njb-1	250	11	be	be	AUX
njb-1	250	12	used	use	VERB
njb-1	250	13	.	.	PUNCT
njb-1	251	1	in	in	ADP
njb-1	251	2	another	another	DET
njb-1	251	3	study	study	NOUN
njb-1	251	4	by	by	ADP
njb-1	251	5	patel	patel	PROPN
njb-1	251	6	et	et	PROPN
njb-1	251	7	al	al	PROPN
njb-1	251	8	.	.	PUNCT
njb-1	252	1	it	it	PRON
njb-1	252	2	was	be	AUX
njb-1	252	3	shown	show	VERB
njb-1	252	4	that	that	SCONJ
njb-1	252	5	asparaginase	asparaginase	NOUN
njb-1	252	6	toxicity	toxicity	NOUN
njb-1	252	7	can	can	AUX
njb-1	252	8	be	be	AUX
njb-1	252	9	substantial	substantial	ADJ
njb-1	252	10	in	in	ADP
njb-1	252	11	older	old	ADJ
njb-1	252	12	patients	patient	NOUN
njb-1	252	13	,	,	PUNCT
njb-1	252	14	making	make	VERB
njb-1	252	15	it	it	PRON
njb-1	252	16	difficult	difficult	ADJ
njb-1	252	17	to	to	PART
njb-1	252	18	deliver	deliver	VERB
njb-1	252	19	safely	safely	ADV
njb-1	252	20	to	to	ADP
njb-1	252	21	those	those	PRON
njb-1	252	22	aged	age	VERB
njb-1	252	23	above	above	ADP
njb-1	252	24	40	40	NUM
njb-1	252	25	years	year	NOUN
njb-1	252	26	[	[	PUNCT
njb-1	252	27	17	17	NUM
njb-1	252	28	]	]	PUNCT
njb-1	252	29	.	.	PUNCT
njb-1	253	1	similarly	similarly	ADV
njb-1	253	2	,	,	PUNCT
njb-1	253	3	when	when	SCONJ
njb-1	253	4	ribera	ribera	PROPN
njb-1	253	5	et	et	PROPN
njb-1	253	6	al	al	PROPN
njb-1	253	7	used	use	VERB
njb-1	253	8	native	native	ADJ
njb-1	253	9	or	or	CCONJ
njb-1	253	10	peg	peg	NOUN
njb-1	253	11	asparaginase	asparaginase	NOUN
njb-1	253	12	in	in	ADP
njb-1	253	13	adult	adult	NOUN
njb-1	253	14	patients	patient	NOUN
njb-1	253	15	there	there	ADV
njb-1	253	16	no	no	DET
njb-1	253	17	significant	significant	ADJ
njb-1	253	18	difference	difference	NOUN
njb-1	253	19	observed	observe	VERB
njb-1	253	20	in	in	ADP
njb-1	253	21	complete	complete	ADJ
njb-1	253	22	remission	remission	NOUN
njb-1	253	23	,	,	PUNCT
njb-1	253	24	diseases	disease	NOUN
njb-1	253	25	free	free	ADJ
njb-1	253	26	survival	survival	NOUN
njb-1	253	27	,	,	PUNCT
njb-1	253	28	and	and	CCONJ
njb-1	253	29	overall	overall	ADJ
njb-1	253	30	survival	survival	NOUN
njb-1	253	31	with	with	ADP
njb-1	253	32	no	no	DET
njb-1	253	33	influence	influence	NOUN
njb-1	253	34	in	in	ADP
njb-1	253	35	patient	patient	ADJ
njb-1	253	36	response	response	NOUN
njb-1	253	37	and	and	CCONJ
njb-1	253	38	outcome	outcome	NOUN
njb-1	253	39	[	[	X
njb-1	253	40	25	25	NUM
njb-1	253	41	]	]	PUNCT
njb-1	253	42	.	.	PUNCT
njb-1	254	1	based	base	VERB
njb-1	254	2	on	on	ADP
njb-1	254	3	numerous	numerous	ADJ
njb-1	254	4	previous	previous	ADJ
njb-1	254	5	studies	study	NOUN
njb-1	254	6	teenagers	teenager	NOUN
njb-1	254	7	and	and	CCONJ
njb-1	254	8	younger	young	ADJ
njb-1	254	9	adults	adult	NOUN
njb-1	254	10	typically	typically	ADV
njb-1	254	11	have	have	VERB
njb-1	254	12	better	well	ADJ
njb-1	254	13	outcome	outcome	NOUN
njb-1	254	14	from	from	ADP
njb-1	254	15	induction	induction	NOUN
njb-1	254	16	and	and	CCONJ
njb-1	254	17	consolidation	consolidation	NOUN
njb-1	254	18	treatment	treatment	NOUN
njb-1	254	19	compared	compare	VERB
njb-1	254	20	to	to	ADP
njb-1	254	21	adults	adult	NOUN
njb-1	254	22	(	(	PUNCT
njb-1	254	23	aged	age	VERB
njb-1	254	24	above	above	ADP
njb-1	254	25	40	40	NUM
njb-1	254	26	years	year	NOUN
njb-1	254	27	)	)	PUNCT
njb-1	254	28	.	.	PUNCT
njb-1	255	1	careful	careful	ADJ
njb-1	255	2	timing	timing	NOUN
njb-1	255	3	of	of	ADP
njb-1	255	4	administration	administration	NOUN
njb-1	255	5	and	and	CCONJ
njb-1	255	6	avoidance	avoidance	NOUN
njb-1	255	7	of	of	ADP
njb-1	255	8	overlapping	overlap	VERB
njb-1	255	9	toxicities	toxicity	NOUN
njb-1	255	10	are	be	AUX
njb-1	255	11	recommended	recommend	VERB
njb-1	255	12	for	for	ADP
njb-1	255	13	the	the	DET
njb-1	255	14	older	old	ADJ
njb-1	255	15	patients	patient	NOUN
njb-1	255	16	.	.	PUNCT
njb-1	256	1	nepal	nepal	PROPN
njb-1	256	2	j	j	PROPN
njb-1	256	3	biotechnol	biotechnol	PROPN
njb-1	256	4	.	.	PUNCT
njb-1	257	1	2	2	NUM
njb-1	257	2	0	0	NUM
njb-1	257	3	2	2	NUM
njb-1	257	4	1	1	NUM
njb-1	257	5	d	d	X
njb-1	257	6	e	e	X
njb-1	257	7	c	c	PROPN
njb-1	257	8	.	.	PUNCT
njb-1	258	1	9	9	NUM
njb-1	258	2	(	(	PUNCT
njb-1	258	3	2	2	NUM
njb-1	258	4	):	):	PUNCT
njb-1	258	5	39	39	NUM
njb-1	258	6	-	-	SYM
njb-1	258	7	47	47	NUM
njb-1	258	8	baral	baral	ADJ
njb-1	258	9	et	et	PROPN
njb-1	258	10	al	al	PROPN
njb-1	258	11	.	.	PUNCT
njb-1	259	1	©	©	PROPN
njb-1	259	2	njb	njb	PROPN
njb-1	259	3	,	,	PUNCT
njb-1	259	4	bsn	bsn	PROPN
njb-1	259	5	46	46	NUM
njb-1	259	6	in	in	ADP
njb-1	259	7	the	the	DET
njb-1	259	8	liang	liang	PROPN
njb-1	259	9	et	et	PROPN
njb-1	259	10	al	al	PROPN
njb-1	259	11	.	.	PUNCT
njb-1	260	1	study	study	NOUN
njb-1	260	2	authors	author	NOUN
njb-1	260	3	state	state	VERB
njb-1	260	4	that	that	SCONJ
njb-1	260	5	the	the	DET
njb-1	260	6	increased	increase	VERB
njb-1	260	7	mortality	mortality	NOUN
njb-1	260	8	was	be	AUX
njb-1	260	9	due	due	ADJ
njb-1	260	10	to	to	ADP
njb-1	260	11	immunosuppression	immunosuppression	NOUN
njb-1	260	12	via	via	ADP
njb-1	260	13	depletion	depletion	NOUN
njb-1	260	14	of	of	ADP
njb-1	260	15	blood	blood	NOUN
njb-1	260	16	asparagine	asparagine	NOUN
njb-1	260	17	by	by	ADP
njb-1	260	18	the	the	DET
njb-1	260	19	enzyme	enzyme	NOUN
njb-1	260	20	.	.	PUNCT
njb-1	261	1	they	they	PRON
njb-1	261	2	had	have	AUX
njb-1	261	3	increased	increase	VERB
njb-1	261	4	the	the	DET
njb-1	261	5	doses	dose	NOUN
njb-1	261	6	of	of	ADP
njb-1	261	7	the	the	DET
njb-1	261	8	leunase	leunase	ADJ
njb-1	261	9	brand	brand	NOUN
njb-1	261	10	asparaginase	asparaginase	NOUN
njb-1	261	11	to	to	PART
njb-1	261	12	match	match	VERB
njb-1	261	13	that	that	PRON
njb-1	261	14	of	of	ADP
njb-1	261	15	the	the	DET
njb-1	261	16	dose	dose	NOUN
njb-1	261	17	preparation	preparation	NOUN
njb-1	261	18	by	by	ADP
njb-1	261	19	nesbit	nesbit	PROPN
njb-1	261	20	et	et	PROPN
njb-1	261	21	al	al	PROPN
njb-1	261	22	.	.	PROPN
njb-1	261	23	of	of	ADP
njb-1	261	24	escherichia	escherichia	NOUN
njb-1	261	25	coli	coli	NOUN
njb-1	261	26	preparation	preparation	NOUN
njb-1	261	27	called	call	VERB
njb-1	261	28	crasnitin	crasnitin	NOUN
njb-1	261	29	.	.	PUNCT
njb-1	262	1	authors	author	NOUN
njb-1	262	2	attribute	attribute	VERB
njb-1	262	3	the	the	DET
njb-1	262	4	severe	severe	ADJ
njb-1	262	5	infection	infection	NOUN
njb-1	262	6	and	and	CCONJ
njb-1	262	7	unexpected	unexpected	ADJ
njb-1	262	8	mortality	mortality	NOUN
njb-1	262	9	to	to	ADP
njb-1	262	10	this	this	DET
njb-1	262	11	dose	dose	NOUN
njb-1	262	12	change	change	NOUN
njb-1	262	13	[	[	PUNCT
njb-1	262	14	22	22	NUM
njb-1	262	15	]	]	PUNCT
njb-1	262	16	.	.	PUNCT
njb-1	263	1	the	the	DET
njb-1	263	2	product	product	NOUN
njb-1	263	3	sold	sell	VERB
njb-1	263	4	as	as	ADP
njb-1	263	5	medac	medac	PROPN
njb-1	263	6	,	,	PUNCT
njb-1	263	7	is	be	AUX
njb-1	263	8	also	also	ADV
njb-1	263	9	known	know	VERB
njb-1	263	10	to	to	PART
njb-1	263	11	cause	cause	VERB
njb-1	263	12	excessive	excessive	ADJ
njb-1	263	13	toxicity	toxicity	NOUN
njb-1	263	14	when	when	SCONJ
njb-1	263	15	given	give	VERB
njb-1	263	16	at	at	ADP
njb-1	263	17	a	a	DET
njb-1	263	18	high	high	ADJ
njb-1	263	19	dose	dose	NOUN
njb-1	263	20	,	,	PUNCT
njb-1	263	21	leading	lead	VERB
njb-1	263	22	to	to	ADP
njb-1	263	23	a	a	DET
njb-1	263	24	50	50	NUM
njb-1	263	25	%	%	NOUN
njb-1	263	26	reduction	reduction	NOUN
njb-1	263	27	in	in	ADP
njb-1	263	28	the	the	DET
njb-1	263	29	dosage	dosage	NOUN
njb-1	263	30	[	[	PUNCT
njb-1	263	31	27	27	NUM
njb-1	263	32	]	]	PUNCT
njb-1	263	33	.	.	PUNCT
njb-1	264	1	karachunskiy	karachunskiy	PROPN
njb-1	264	2	et	et	PROPN
njb-1	264	3	al	al	PROPN
njb-1	264	4	.	.	PROPN
njb-1	264	5	have	have	AUX
njb-1	264	6	reported	report	VERB
njb-1	264	7	that	that	SCONJ
njb-1	264	8	patients	patient	NOUN
njb-1	264	9	treated	treat	VERB
njb-1	264	10	with	with	ADP
njb-1	264	11	e.	e.	PROPN
njb-1	264	12	coli	coli	PROPN
njb-1	264	13	asparaginase	asparaginase	NOUN
njb-1	264	14	of	of	ADP
njb-1	264	15	dose	dose	NOUN
njb-1	264	16	10000	10000	NUM
njb-1	264	17	u	u	NOUN
njb-1	264	18	/	/	SYM
njb-1	264	19	m2	m2	PROPN
njb-1	264	20	have	have	AUX
njb-1	264	21	reported	report	VERB
njb-1	264	22	the	the	DET
njb-1	264	23	severe	severe	ADJ
njb-1	264	24	hypersensitivity	hypersensitivity	NOUN
njb-1	264	25	reaction	reaction	NOUN
njb-1	264	26	more	more	ADV
njb-1	264	27	frequently	frequently	ADV
njb-1	264	28	than	than	ADP
njb-1	264	29	patients	patient	NOUN
njb-1	264	30	provided	provide	VERB
njb-1	264	31	with	with	ADP
njb-1	264	32	5000	5000	NUM
njb-1	264	33	u	u	NOUN
njb-1	264	34	/	/	SYM
njb-1	264	35	m2	m2	PROPN
njb-1	264	36	of	of	ADP
njb-1	264	37	dose	dose	NOUN
njb-1	264	38	.	.	PUNCT
njb-1	265	1	also	also	ADV
njb-1	265	2	,	,	PUNCT
njb-1	265	3	death	death	NOUN
njb-1	265	4	in	in	ADP
njb-1	265	5	complete	complete	ADJ
njb-1	265	6	remission	remission	NOUN
njb-1	265	7	occurred	occur	VERB
njb-1	265	8	significantly	significantly	ADV
njb-1	265	9	more	more	ADV
njb-1	265	10	in	in	ADP
njb-1	265	11	10000	10000	NUM
njb-1	265	12	u	u	SYM
njb-1	265	13	/	/	SYM
njb-1	265	14	m2	m2	PROPN
njb-1	265	15	provided	provide	VERB
njb-1	265	16	patients	patient	NOUN
njb-1	265	17	[	[	PUNCT
njb-1	265	18	24	24	NUM
njb-1	265	19	]	]	PUNCT
njb-1	265	20	.	.	PUNCT
njb-1	266	1	an	an	DET
njb-1	266	2	advantage	advantage	NOUN
njb-1	266	3	of	of	ADP
njb-1	266	4	higher	high	ADJ
njb-1	266	5	doses	dose	NOUN
njb-1	266	6	was	be	AUX
njb-1	266	7	not	not	PART
njb-1	266	8	found	find	VERB
njb-1	266	9	in	in	ADP
njb-1	266	10	the	the	DET
njb-1	266	11	group	group	NOUN
njb-1	266	12	.	.	PUNCT
njb-1	267	1	thus	thus	ADV
njb-1	267	2	,	,	PUNCT
njb-1	267	3	it	it	PRON
njb-1	267	4	will	will	AUX
njb-1	267	5	be	be	AUX
njb-1	267	6	advantageous	advantageous	ADJ
njb-1	267	7	to	to	PART
njb-1	267	8	discover	discover	VERB
njb-1	267	9	and	and	CCONJ
njb-1	267	10	use	use	VERB
njb-1	267	11	a	a	DET
njb-1	267	12	higher	high	ADJ
njb-1	267	13	activity	activity	NOUN
njb-1	267	14	asparaginase	asparaginase	NOUN
njb-1	267	15	,	,	PUNCT
njb-1	267	16	thereby	thereby	ADV
njb-1	267	17	allowing	allow	VERB
njb-1	267	18	use	use	NOUN
njb-1	267	19	of	of	ADP
njb-1	267	20	lower	low	ADJ
njb-1	267	21	dose	dose	NOUN
njb-1	267	22	of	of	ADP
njb-1	267	23	enzyme	enzyme	NOUN
njb-1	267	24	to	to	PART
njb-1	267	25	reduce	reduce	VERB
njb-1	267	26	the	the	DET
njb-1	267	27	incidences	incidence	NOUN
njb-1	267	28	of	of	ADP
njb-1	267	29	toxicity	toxicity	NOUN
njb-1	267	30	.	.	PUNCT
njb-1	268	1	enzymes	enzyme	NOUN
njb-1	268	2	with	with	ADP
njb-1	268	3	low	low	ADJ
njb-1	268	4	km	km	NOUN
njb-1	268	5	value	value	NOUN
njb-1	268	6	will	will	AUX
njb-1	268	7	have	have	VERB
njb-1	268	8	higher	high	ADJ
njb-1	268	9	activity	activity	NOUN
njb-1	268	10	against	against	ADP
njb-1	268	11	l	l	NOUN
njb-1	268	12	-	-	NOUN
njb-1	268	13	asparagine	asparagine	NOUN
njb-1	268	14	.	.	PUNCT
njb-1	269	1	besides	besides	SCONJ
njb-1	269	2	the	the	DET
njb-1	269	3	l	l	NOUN
njb-1	269	4	-	-	PUNCT
njb-1	269	5	asparagine	asparagine	NOUN
njb-1	269	6	activity	activity	NOUN
njb-1	269	7	of	of	ADP
njb-1	269	8	l	l	NOUN
njb-1	269	9	-	-	PUNCT
njb-1	269	10	asparaginase	asparaginase	NOUN
njb-1	269	11	,	,	PUNCT
njb-1	269	12	there	there	PRON
njb-1	269	13	is	be	VERB
njb-1	269	14	the	the	DET
njb-1	269	15	secondary	secondary	ADJ
njb-1	269	16	activity	activity	NOUN
njb-1	269	17	of	of	ADP
njb-1	269	18	mentioned	mention	VERB
njb-1	269	19	asparaginase	asparaginase	NOUN
njb-1	269	20	enzymes	enzyme	NOUN
njb-1	269	21	against	against	ADP
njb-1	269	22	lglutamine	lglutamine	PROPN
njb-1	269	23	,	,	PUNCT
njb-1	269	24	that	that	PRON
njb-1	269	25	has	have	AUX
njb-1	269	26	been	be	AUX
njb-1	269	27	linked	link	VERB
njb-1	269	28	to	to	ADP
njb-1	269	29	the	the	DET
njb-1	269	30	different	different	ADJ
njb-1	269	31	toxic	toxic	ADJ
njb-1	269	32	side	side	NOUN
njb-1	269	33	effects[28,29	effects[28,29	PROPN
njb-1	269	34	]	]	X
njb-1	269	35	.	.	PUNCT
njb-1	270	1	also	also	ADV
njb-1	270	2	,	,	PUNCT
njb-1	270	3	the	the	DET
njb-1	270	4	role	role	NOUN
njb-1	270	5	of	of	ADP
njb-1	270	6	l	l	NOUN
njb-1	270	7	-	-	PUNCT
njb-1	270	8	glutamine	glutamine	NOUN
njb-1	270	9	activity	activity	NOUN
njb-1	270	10	has	have	AUX
njb-1	270	11	not	not	PART
njb-1	270	12	been	be	AUX
njb-1	270	13	seen	see	VERB
njb-1	270	14	in	in	ADP
njb-1	270	15	anti	anti	ADJ
njb-1	270	16	-	-	ADJ
njb-1	270	17	cancer	cancer	ADJ
njb-1	270	18	activity	activity	NOUN
njb-1	270	19	of	of	ADP
njb-1	270	20	the	the	DET
njb-1	270	21	enzyme[30	enzyme[30	PROPN
njb-1	270	22	]	]	PUNCT
njb-1	270	23	.	.	PUNCT
njb-1	271	1	one	one	NUM
njb-1	271	2	method	method	NOUN
njb-1	271	3	of	of	ADP
njb-1	271	4	finding	find	VERB
njb-1	271	5	new	new	ADJ
njb-1	271	6	asparaginase	asparaginase	NOUN
njb-1	271	7	is	be	AUX
njb-1	271	8	to	to	PART
njb-1	271	9	extract	extract	VERB
njb-1	271	10	it	it	PRON
njb-1	271	11	from	from	ADP
njb-1	271	12	an	an	DET
njb-1	271	13	organism	organism	NOUN
njb-1	271	14	other	other	ADJ
njb-1	271	15	than	than	ADP
njb-1	271	16	escherichia	escherichia	NOUN
njb-1	271	17	coli	coli	NOUN
njb-1	271	18	or	or	CCONJ
njb-1	271	19	erwinia	erwinia	PROPN
njb-1	271	20	chrysanthemi	chrysanthemi	PROPN
njb-1	271	21	.	.	PUNCT
njb-1	272	1	we	we	PRON
njb-1	272	2	can	can	AUX
njb-1	272	3	expect	expect	VERB
njb-1	272	4	an	an	DET
njb-1	272	5	organism	organism	NOUN
njb-1	272	6	that	that	PRON
njb-1	272	7	is	be	AUX
njb-1	272	8	evolutionarily	evolutionarily	ADV
njb-1	272	9	distant	distant	ADJ
njb-1	272	10	from	from	ADP
njb-1	272	11	escherichia	escherichia	NOUN
njb-1	272	12	coli	coli	NOUN
njb-1	272	13	or	or	CCONJ
njb-1	272	14	erwinia	erwinia	PROPN
njb-1	272	15	chrysanthemi	chrysanthemi	PROPN
njb-1	272	16	to	to	PART
njb-1	272	17	have	have	VERB
njb-1	272	18	different	different	ADJ
njb-1	272	19	enzyme	enzyme	NOUN
njb-1	272	20	activity	activity	NOUN
njb-1	272	21	.	.	PUNCT
njb-1	273	1	thus	thus	ADV
njb-1	273	2	,	,	PUNCT
njb-1	273	3	we	we	PRON
njb-1	273	4	can	can	AUX
njb-1	273	5	expect	expect	VERB
njb-1	273	6	to	to	PART
njb-1	273	7	find	find	VERB
njb-1	273	8	better	well	ADJ
njb-1	273	9	alternatives	alternative	NOUN
njb-1	273	10	to	to	ADP
njb-1	273	11	commercially	commercially	ADV
njb-1	273	12	available	available	ADJ
njb-1	273	13	asparaginases	asparaginase	NOUN
njb-1	273	14	with	with	ADP
njb-1	273	15	higher	high	ADJ
njb-1	273	16	activity	activity	NOUN
njb-1	273	17	than	than	ADP
njb-1	273	18	escherichia	escherichia	NOUN
njb-1	273	19	coli	coli	NOUN
njb-1	273	20	and	and	CCONJ
njb-1	273	21	erwinia	erwinia	PROPN
njb-1	273	22	chrysanthemi	chrysanthemi	PROPN
njb-1	274	1	[	[	PUNCT
njb-1	274	2	31	31	NUM
njb-1	274	3	,	,	PUNCT
njb-1	274	4	32	32	NUM
njb-1	274	5	]	]	PUNCT
njb-1	274	6	.	.	PUNCT
njb-1	275	1	according	accord	VERB
njb-1	275	2	to	to	ADP
njb-1	275	3	this	this	DET
njb-1	275	4	study	study	NOUN
njb-1	275	5	,	,	PUNCT
njb-1	275	6	peg	peg	NOUN
njb-1	275	7	asparaginase	asparaginase	NOUN
njb-1	275	8	provides	provide	VERB
njb-1	275	9	better	well	ADJ
njb-1	275	10	enzyme	enzyme	NOUN
njb-1	275	11	concentration	concentration	NOUN
njb-1	275	12	than	than	ADP
njb-1	275	13	e.	e.	PROPN
njb-1	275	14	coli	coli	PROPN
njb-1	275	15	or	or	CCONJ
njb-1	275	16	erwinia	erwinia	PROPN
njb-1	275	17	chrysanthemi	chrysanthemi	PROPN
njb-1	275	18	asparaginase	asparaginase	PROPN
njb-1	275	19	in	in	ADP
njb-1	275	20	various	various	ADJ
njb-1	275	21	clinical	clinical	ADJ
njb-1	275	22	trials	trial	NOUN
njb-1	275	23	.	.	PUNCT
njb-1	276	1	similarly	similarly	ADV
njb-1	276	2	,	,	PUNCT
njb-1	276	3	two	two	NUM
njb-1	276	4	studies	study	NOUN
njb-1	276	5	show	show	VERB
njb-1	276	6	that	that	SCONJ
njb-1	276	7	peg	peg	NOUN
njb-1	276	8	asparaginase	asparaginase	NOUN
njb-1	276	9	has	have	VERB
njb-1	276	10	higher	high	ADJ
njb-1	276	11	2	2	NUM
njb-1	276	12	-	-	PUNCT
njb-1	276	13	year	year	NOUN
njb-1	276	14	overall	overall	ADJ
njb-1	276	15	survival	survival	NOUN
njb-1	276	16	than	than	ADP
njb-1	276	17	native	native	PROPN
njb-1	276	18	e.	e.	PROPN
njb-1	276	19	coli	coli	PROPN
njb-1	276	20	asparaginase	asparaginase	NOUN
njb-1	276	21	.	.	PUNCT
njb-1	277	1	the	the	DET
njb-1	277	2	difference	difference	NOUN
njb-1	277	3	is	be	AUX
njb-1	277	4	very	very	ADV
njb-1	277	5	minor	minor	ADJ
njb-1	277	6	to	to	PART
njb-1	277	7	conclusively	conclusively	ADV
njb-1	277	8	say	say	VERB
njb-1	277	9	peg	peg	NOUN
njb-1	277	10	asparaginase	asparaginase	NOUN
njb-1	277	11	is	be	AUX
njb-1	277	12	superior	superior	ADJ
njb-1	277	13	.	.	PUNCT
njb-1	278	1	using	use	VERB
njb-1	278	2	erwinia	erwinia	PROPN
njb-1	278	3	chrysanthemi	chrysanthemi	PROPN
njb-1	278	4	asparaginase	asparaginase	PROPN
njb-1	278	5	when	when	SCONJ
njb-1	278	6	e.	e.	PROPN
njb-1	278	7	coli	coli	PROPN
njb-1	278	8	and	and	CCONJ
njb-1	278	9	peg	peg	NOUN
njb-1	278	10	asparaginase	asparaginase	NOUN
njb-1	278	11	fail	fail	VERB
njb-1	278	12	,	,	PUNCT
njb-1	278	13	as	as	SCONJ
njb-1	278	14	is	be	AUX
njb-1	278	15	currently	currently	ADV
njb-1	278	16	done	do	VERB
njb-1	278	17	,	,	PUNCT
njb-1	278	18	is	be	AUX
njb-1	278	19	recommended	recommend	VERB
njb-1	278	20	from	from	ADP
njb-1	278	21	this	this	DET
njb-1	278	22	study	study	NOUN
njb-1	278	23	as	as	ADV
njb-1	278	24	well	well	ADV
njb-1	278	25	.	.	PUNCT
njb-1	279	1	furthermore	furthermore	ADV
njb-1	279	2	,	,	PUNCT
njb-1	279	3	alternative	alternative	ADJ
njb-1	279	4	source	source	NOUN
njb-1	279	5	of	of	ADP
njb-1	279	6	asparaginase	asparaginase	NOUN
njb-1	279	7	from	from	ADP
njb-1	279	8	the	the	DET
njb-1	279	9	organisms	organism	NOUN
njb-1	279	10	,	,	PUNCT
njb-1	279	11	which	which	PRON
njb-1	279	12	are	be	AUX
njb-1	279	13	evolutionarily	evolutionarily	ADV
njb-1	279	14	distant	distant	ADJ
njb-1	279	15	from	from	ADP
njb-1	279	16	escherichia	escherichia	NOUN
njb-1	279	17	coli	coli	NOUN
njb-1	279	18	and	and	CCONJ
njb-1	279	19	erwinia	erwinia	PROPN
njb-1	279	20	chrysanthemi	chrysanthemi	PROPN
njb-1	279	21	and	and	CCONJ
njb-1	279	22	with	with	ADP
njb-1	279	23	a	a	DET
njb-1	279	24	lower	low	ADJ
njb-1	279	25	km	km	NOUN
njb-1	279	26	value	value	NOUN
njb-1	279	27	i.e.	i.e.	ADV
njb-1	279	28	,	,	PUNCT
njb-1	279	29	higher	high	ADJ
njb-1	279	30	enzyme	enzyme	NOUN
njb-1	279	31	activity	activity	NOUN
njb-1	279	32	toward	toward	ADP
njb-1	279	33	l	l	NOUN
njb-1	279	34	-	-	PUNCT
njb-1	279	35	asparagine	asparagine	NOUN
njb-1	279	36	,	,	PUNCT
njb-1	279	37	and	and	CCONJ
njb-1	279	38	low	low	ADJ
njb-1	279	39	activity	activity	NOUN
njb-1	279	40	towards	towards	ADP
njb-1	279	41	the	the	DET
njb-1	279	42	l	l	NOUN
njb-1	279	43	-	-	PUNCT
njb-1	279	44	glutamine	glutamine	NOUN
njb-1	279	45	need	need	VERB
njb-1	279	46	to	to	PART
njb-1	279	47	be	be	AUX
njb-1	279	48	discovered	discover	VERB
njb-1	279	49	.	.	PUNCT
njb-1	280	1	such	such	ADJ
njb-1	280	2	novel	novel	ADJ
njb-1	280	3	asparaginases	asparaginase	NOUN
njb-1	280	4	can	can	AUX
njb-1	280	5	be	be	AUX
njb-1	280	6	used	use	VERB
njb-1	280	7	in	in	ADP
njb-1	280	8	lower	low	ADJ
njb-1	280	9	dose	dose	NOUN
njb-1	280	10	thereby	thereby	ADV
njb-1	280	11	by	by	ADP
njb-1	280	12	reducing	reduce	VERB
njb-1	280	13	toxicity	toxicity	NOUN
njb-1	280	14	.	.	PUNCT
njb-1	281	1	acknowledgement	acknowledgement	VERB
njb-1	281	2	the	the	DET
njb-1	281	3	authors	author	NOUN
njb-1	281	4	acknowledge	acknowledge	VERB
njb-1	281	5	the	the	DET
njb-1	281	6	department	department	NOUN
njb-1	281	7	of	of	ADP
njb-1	281	8	biotechnology	biotechnology	NOUN
njb-1	281	9	,	,	PUNCT
njb-1	281	10	kathmandu	kathmandu	PROPN
njb-1	281	11	university	university	PROPN
njb-1	281	12	,	,	PUNCT
njb-1	281	13	dhulikhel	dhulikhel	PROPN
njb-1	281	14	,	,	PUNCT
njb-1	281	15	nepal	nepal	ADJ
njb-1	281	16	for	for	ADP
njb-1	281	17	providing	provide	VERB
njb-1	281	18	all	all	DET
njb-1	281	19	support	support	NOUN
njb-1	281	20	during	during	ADP
njb-1	281	21	the	the	DET
njb-1	281	22	study	study	NOUN
njb-1	281	23	period	period	NOUN
njb-1	281	24	.	.	PUNCT
njb-1	282	1	competing	compete	VERB
njb-1	282	2	interests	interest	NOUN
njb-1	282	3	the	the	DET
njb-1	282	4	authors	author	NOUN
njb-1	282	5	declare	declare	VERB
njb-1	282	6	no	no	DET
njb-1	282	7	competing	compete	VERB
njb-1	282	8	interests	interest	NOUN
njb-1	282	9	.	.	PUNCT
njb-1	283	1	references	reference	NOUN
njb-1	283	2	:	:	PUNCT
njb-1	283	3	1	1	X
njb-1	283	4	.	.	PUNCT
njb-1	283	5	mitchell	mitchell	PROPN
njb-1	283	6	c	c	PROPN
njb-1	283	7	,	,	PUNCT
njb-1	283	8	hall	hall	PROPN
njb-1	283	9	g	g	PROPN
njb-1	283	10	,	,	PUNCT
njb-1	283	11	clarke	clarke	PROPN
njb-1	283	12	rt	rt	PROPN
njb-1	283	13	.	.	PROPN
njb-1	283	14	acute	acute	PROPN
njb-1	283	15	leukaemia	leukaemia	NOUN
njb-1	283	16	in	in	ADP
njb-1	283	17	children	child	NOUN
njb-1	283	18	:	:	PUNCT
njb-1	283	19	diagnosis	diagnosis	NOUN
njb-1	283	20	and	and	CCONJ
njb-1	283	21	management	management	NOUN
njb-1	283	22	.	.	PUNCT
njb-1	284	1	bmj	bmj	PROPN
njb-1	284	2	.	.	PUNCT
njb-1	285	1	2009;338(7709):1491–5	2009;338(7709):1491–5	NUM
njb-1	285	2	.	.	PUNCT
njb-1	285	3	2	2	NUM
njb-1	285	4	.	.	X
njb-1	285	5	terwilliger	terwilliger	PROPN
njb-1	285	6	t	t	PROPN
njb-1	285	7	,	,	PUNCT
njb-1	285	8	abdul	abdul	PROPN
njb-1	285	9	-	-	PUNCT
njb-1	285	10	hay	hay	NOUN
njb-1	285	11	m.	m.	NOUN
njb-1	285	12	acute	acute	ADJ
njb-1	285	13	lymphoblastic	lymphoblastic	NOUN
njb-1	285	14	leukemia	leukemia	NOUN
njb-1	285	15	:	:	PUNCT
njb-1	285	16	a	a	DET
njb-1	285	17	comprehensive	comprehensive	ADJ
njb-1	285	18	review	review	NOUN
njb-1	285	19	and	and	CCONJ
njb-1	285	20	2017	2017	NUM
njb-1	285	21	update	update	NOUN
njb-1	285	22	.	.	PUNCT
njb-1	286	1	blood	blood	NOUN
njb-1	286	2	cancer	cancer	PROPN
njb-1	286	3	j.	j.	PROPN
njb-1	286	4	2017;7:577.https://doi.org/10.1038	2017;7:577.https://doi.org/10.1038	PROPN
njb-1	286	5	/	/	SYM
njb-1	286	6	bcj.2017.53	bcj.2017.53	PROPN
njb-1	286	7	3	3	NUM
njb-1	286	8	.	.	PUNCT
njb-1	287	1	piatkowska	piatkowska	PROPN
njb-1	287	2	-	-	PUNCT
njb-1	287	3	jakubas	jakubas	PROPN
njb-1	287	4	b	b	PROPN
njb-1	287	5	,	,	PUNCT
njb-1	287	6	krawczyk	krawczyk	PROPN
njb-1	287	7	-	-	PUNCT
njb-1	287	8	kuliś	kuliś	PROPN
njb-1	287	9	m	m	PROPN
njb-1	287	10	,	,	PUNCT
njb-1	287	11	giebel	giebel	PROPN
njb-1	287	12	s	s	PROPN
njb-1	287	13	,	,	PUNCT
njb-1	287	14	adamczykcioch	adamczykcioch	PROPN
njb-1	287	15	m	m	PROPN
njb-1	287	16	,	,	PUNCT
njb-1	287	17	czyz	czyz	PROPN
njb-1	287	18	a	a	PRON
njb-1	287	19	,	,	PUNCT
njb-1	287	20	marańda	marańda	PROPN
njb-1	287	21	el	el	PROPN
njb-1	287	22	,	,	PUNCT
njb-1	287	23	et	et	PROPN
njb-1	287	24	al	al	PROPN
njb-1	287	25	.	.	PROPN
njb-1	287	26	use	use	NOUN
njb-1	287	27	of	of	ADP
njb-1	287	28	l	l	NOUN
njb-1	287	29	-	-	PUNCT
njb-1	287	30	asparaginase	asparaginase	NOUN
njb-1	287	31	in	in	ADP
njb-1	287	32	acute	acute	ADJ
njb-1	287	33	lymphoblastic	lymphoblastic	NOUN
njb-1	287	34	leukemia	leukemia	NOUN
njb-1	287	35	:	:	PUNCT
njb-1	287	36	recommendations	recommendation	NOUN
njb-1	287	37	of	of	ADP
njb-1	287	38	the	the	DET
njb-1	287	39	polish	polish	ADJ
njb-1	287	40	adult	adult	NOUN
njb-1	287	41	leukemia	leukemia	NOUN
njb-1	287	42	group	group	NOUN
njb-1	287	43	.	.	PUNCT
njb-1	288	1	pol	pol	NOUN
njb-1	288	2	arch	arch	NOUN
njb-1	288	3	med	me	VERB
njb-1	288	4	wewn	wewn	PROPN
njb-1	288	5	.	.	PUNCT
njb-1	289	1	2008;118(11):664–9	2008;118(11):664–9	PROPN
njb-1	289	2	.	.	PUNCT
njb-1	289	3	https://doi.org/10.20452/pamw.518	https://doi.org/10.20452/pamw.518	PROPN
njb-1	289	4	4	4	X
njb-1	289	5	.	.	PUNCT
njb-1	290	1	batool	batool	PROPN
njb-1	290	2	t	t	PROPN
njb-1	290	3	,	,	PUNCT
njb-1	290	4	makky	makky	PROPN
njb-1	290	5	ea	ea	PROPN
njb-1	290	6	,	,	PUNCT
njb-1	290	7	jalal	jalal	PROPN
njb-1	290	8	m	m	PROPN
njb-1	290	9	,	,	PUNCT
njb-1	290	10	yusoff	yusoff	PROPN
njb-1	290	11	mm	mm	INTJ
njb-1	290	12	.	.	PUNCT
njb-1	291	1	a	a	DET
njb-1	291	2	comprehensive	comprehensive	ADJ
njb-1	291	3	review	review	NOUN
njb-1	291	4	on	on	ADP
njb-1	291	5	l	l	NOUN
njb-1	291	6	-	-	PUNCT
njb-1	291	7	asparaginase	asparaginase	NOUN
njb-1	291	8	and	and	CCONJ
njb-1	291	9	its	its	PRON
njb-1	291	10	applications	application	NOUN
njb-1	291	11	.	.	PUNCT
njb-1	292	1	appl	appl	VERB
njb-1	292	2	biochem	biochem	NOUN
njb-1	292	3	biotechnol	biotechnol	NOUN
njb-1	292	4	.	.	PUNCT
njb-1	293	1	2016;178(5):900–23	2016;178(5):900–23	NUM
njb-1	293	2	.	.	PUNCT
njb-1	294	1	https://doi.org/10.1007/s12010015-1917-3	https://doi.org/10.1007/s12010015-1917-3	PROPN
njb-1	294	2	5	5	NUM
njb-1	294	3	.	.	PUNCT
njb-1	295	1	avramis	avramis	PROPN
njb-1	295	2	vi	vi	PROPN
njb-1	295	3	,	,	PUNCT
njb-1	295	4	sencer	sencer	PROPN
njb-1	295	5	s	s	PROPN
njb-1	295	6	,	,	PUNCT
njb-1	295	7	periclou	periclou	PROPN
njb-1	295	8	ap	ap	PROPN
njb-1	295	9	,	,	PUNCT
njb-1	295	10	sather	sather	PROPN
njb-1	295	11	h	h	PROPN
njb-1	295	12	,	,	PUNCT
njb-1	295	13	bostrom	bostrom	PROPN
njb-1	295	14	bc	bc	PROPN
njb-1	295	15	,	,	PUNCT
njb-1	295	16	cohen	cohen	PROPN
njb-1	295	17	lj	lj	PROPN
njb-1	295	18	,	,	PUNCT
njb-1	295	19	et	et	PROPN
njb-1	295	20	al	al	PROPN
njb-1	295	21	.	.	PUNCT
njb-1	296	1	a	a	DET
njb-1	296	2	randomized	randomized	ADJ
njb-1	296	3	comparison	comparison	NOUN
njb-1	296	4	of	of	ADP
njb-1	296	5	native	native	ADJ
njb-1	296	6	escherichia	escherichia	NOUN
njb-1	296	7	coli	coli	NOUN
njb-1	296	8	asparaginase	asparaginase	NOUN
njb-1	296	9	and	and	CCONJ
njb-1	296	10	polyethylene	polyethylene	NOUN
njb-1	296	11	glycol	glycol	PROPN
njb-1	296	12	conjugated	conjugate	VERB
njb-1	296	13	asparaginase	asparaginase	NOUN
njb-1	296	14	for	for	ADP
njb-1	296	15	treatment	treatment	NOUN
njb-1	296	16	of	of	ADP
njb-1	296	17	children	child	NOUN
njb-1	296	18	with	with	ADP
njb-1	296	19	newly	newly	ADV
njb-1	296	20	diagnosed	diagnose	VERB
njb-1	296	21	standard	standard	ADJ
njb-1	296	22	-	-	PUNCT
njb-1	296	23	risk	risk	NOUN
njb-1	296	24	acute	acute	ADJ
njb-1	296	25	lymphoblastic	lymphoblastic	NOUN
njb-1	296	26	leukemia	leukemia	NOUN
njb-1	296	27	:	:	PUNCT
njb-1	296	28	a	a	DET
njb-1	296	29	children	child	NOUN
njb-1	296	30	’s	’s	PART
njb-1	296	31	cancer	cancer	NOUN
njb-1	296	32	group	group	NOUN
njb-1	296	33	study	study	NOUN
njb-1	296	34	.	.	PUNCT
njb-1	297	1	blood	blood	NOUN
njb-1	297	2	.	.	PUNCT
njb-1	298	1	2002	2002	NUM
njb-1	298	2	mar;99	mar;99	PROPN
njb-1	298	3	(	(	PUNCT
njb-1	298	4	6	6	NUM
njb-1	298	5	):	):	PUNCT
njb-1	298	6	1986–94	1986–94	NUM
njb-1	298	7	.	.	PUNCT
njb-1	299	1	https://doi.org	https://doi.org	PROPN
njb-1	299	2	/10.1182	/10.1182	PUNCT
njb-1	300	1	/blood.v99.6.1986	/blood.v99.6.1986	PUNCT
njb-1	300	2	6	6	X
njb-1	300	3	.	.	PUNCT
njb-1	301	1	müller	müller	PROPN
njb-1	301	2	hj	hj	PROPN
njb-1	301	3	,	,	PUNCT
njb-1	301	4	boos	boo	VERB
njb-1	301	5	j.	j.	PROPN
njb-1	301	6	use	use	PROPN
njb-1	301	7	of	of	ADP
njb-1	301	8	l	l	NOUN
njb-1	301	9	-	-	PUNCT
njb-1	301	10	asparaginase	asparaginase	NOUN
njb-1	301	11	in	in	ADP
njb-1	301	12	childhood	childhood	NOUN
njb-1	301	13	all	all	PRON
njb-1	301	14	.	.	PUNCT
njb-1	302	1	vol	vol	PROPN
njb-1	302	2	.	.	PROPN
njb-1	303	1	28	28	NUM
njb-1	303	2	,	,	PUNCT
njb-1	303	3	critical	critical	ADJ
njb-1	303	4	reviews	review	NOUN
njb-1	303	5	in	in	ADP
njb-1	303	6	oncology	oncology	NOUN
njb-1	303	7	/	/	SYM
njb-1	303	8	hematology	hematology	NOUN
njb-1	303	9	.	.	PUNCT
njb-1	304	1	elsevier	elsevi	ADJ
njb-1	304	2	;	;	PUNCT
njb-1	304	3	1998	1998	NUM
njb-1	304	4	.	.	PUNCT
njb-1	305	1	p.	p.	NOUN
njb-1	305	2	97–113	97–113	PROPN
njb-1	305	3	.	.	PUNCT
njb-1	306	1	https://doi.org/10.1016/s1040-8428(98)00015-8	https://doi.org/10.1016/s1040-8428(98)00015-8	PROPN
njb-1	306	2	7	7	NUM
njb-1	306	3	.	.	PUNCT
njb-1	307	1	ettinger	ettinger	PROPN
njb-1	307	2	lj	lj	PROPN
njb-1	307	3	,	,	PUNCT
njb-1	307	4	kurtzberg	kurtzberg	PROPN
njb-1	307	5	j	j	PROPN
njb-1	307	6	,	,	PUNCT
njb-1	307	7	voǔte	voǔte	PROPN
njb-1	307	8	pa	pa	PROPN
njb-1	307	9	,	,	PUNCT
njb-1	307	10	jürgens	jürgens	PROPN
njb-1	307	11	h	h	PROPN
njb-1	307	12	,	,	PUNCT
njb-1	307	13	halpern	halpern	PROPN
njb-1	307	14	sl	sl	PROPN
njb-1	307	15	.	.	PROPN
njb-1	308	1	an	an	DET
njb-1	308	2	open‐label	open‐label	PROPN
njb-1	308	3	,	,	PUNCT
njb-1	308	4	multicenter	multicenter	NOUN
njb-1	308	5	study	study	NOUN
njb-1	308	6	of	of	ADP
njb-1	308	7	polyethylene	polyethylene	NOUN
njb-1	308	8	glycol‐l‐	glycol‐l‐	CCONJ
njb-1	308	9	asparaginase	asparaginase	NOUN
njb-1	308	10	for	for	ADP
njb-1	308	11	the	the	DET
njb-1	308	12	treatment	treatment	NOUN
njb-1	308	13	of	of	ADP
njb-1	308	14	acute	acute	ADJ
njb-1	308	15	lymphoblastic	lymphoblastic	NOUN
njb-1	308	16	leukemia	leukemia	NOUN
njb-1	308	17	.	.	PUNCT
njb-1	309	1	cancer	cancer	NOUN
njb-1	309	2	.	.	PUNCT
njb-1	310	1	1995;75(5):1176–81	1995;75(5):1176–81	NUM
njb-1	310	2	.	.	PUNCT
njb-1	310	3	https://doi.org/10.1002/10970142(19950301)75:5<1176::aid-cncr2820750519>3.0.co;2-y	https://doi.org/10.1002/10970142(19950301)75:5<1176::aid-cncr2820750519>3.0.co;2-y	NUM
njb-1	310	4	8	8	NUM
njb-1	310	5	.	.	PUNCT
njb-1	310	6	ogawa	ogawa	PROPN
njb-1	310	7	c	c	PROPN
njb-1	310	8	,	,	PUNCT
njb-1	310	9	taguchi	taguchi	PROPN
njb-1	310	10	f	f	PROPN
njb-1	310	11	,	,	PUNCT
njb-1	310	12	goto	goto	PROPN
njb-1	310	13	h	h	PROPN
njb-1	310	14	,	,	PUNCT
njb-1	310	15	koh	koh	PROPN
njb-1	310	16	k	k	PROPN
njb-1	310	17	,	,	PUNCT
njb-1	310	18	tomizawa	tomizawa	PROPN
njb-1	310	19	d	d	PROPN
njb-1	310	20	,	,	PUNCT
njb-1	310	21	ohara	ohara	PROPN
njb-1	310	22	a	a	PROPN
njb-1	310	23	,	,	PUNCT
njb-1	310	24	et	et	PROPN
njb-1	310	25	al	al	PROPN
njb-1	310	26	.	.	PROPN
njb-1	311	1	plasma	plasma	NOUN
njb-1	311	2	asparaginase	asparaginase	NOUN
njb-1	311	3	activity	activity	NOUN
njb-1	311	4	,	,	PUNCT
njb-1	311	5	asparagine	asparagine	ADJ
njb-1	311	6	concentration	concentration	NOUN
njb-1	311	7	,	,	PUNCT
njb-1	311	8	and	and	CCONJ
njb-1	311	9	toxicity	toxicity	NOUN
njb-1	311	10	after	after	ADP
njb-1	311	11	administration	administration	NOUN
njb-1	311	12	of	of	ADP
njb-1	311	13	erwinia	erwinia	PROPN
njb-1	311	14	asparaginase	asparaginase	NOUN
njb-1	311	15	in	in	ADP
njb-1	311	16	children	child	NOUN
njb-1	311	17	and	and	CCONJ
njb-1	311	18	young	young	ADJ
njb-1	311	19	adults	adult	NOUN
njb-1	311	20	with	with	ADP
njb-1	311	21	acute	acute	ADJ
njb-1	311	22	lymphoblastic	lymphoblastic	NOUN
njb-1	311	23	leukemia	leukemia	NOUN
njb-1	311	24	:	:	PUNCT
njb-1	311	25	phase	phase	NOUN
njb-1	311	26	i	i	PROPN
njb-1	311	27	/	/	SYM
njb-1	311	28	ii	ii	PROPN
njb-1	311	29	clinical	clinical	ADJ
njb-1	311	30	trial	trial	NOUN
njb-1	311	31	in	in	ADP
njb-1	311	32	japan	japan	PROPN
njb-1	311	33	.	.	PUNCT
njb-1	312	1	pediatr	pediatr	VERB
njb-1	312	2	blood	blood	NOUN
njb-1	312	3	cancer	cancer	NOUN
njb-1	312	4	.	.	PUNCT
njb-1	313	1	2017;64(9):1–8	2017;64(9):1–8	NUM
njb-1	313	2	.	.	PUNCT
njb-1	314	1	https://doi.org/10.1002/pbc.26475	https://doi.org/10.1002/pbc.26475	PROPN
njb-1	314	2	9	9	NUM
njb-1	314	3	.	.	PUNCT
njb-1	315	1	schore	schore	PROPN
njb-1	315	2	rj	rj	PROPN
njb-1	315	3	,	,	PUNCT
njb-1	315	4	devidas	devida	NOUN
njb-1	315	5	m	m	VERB
njb-1	315	6	,	,	PUNCT
njb-1	315	7	bleyer	bleyer	PROPN
njb-1	315	8	a	a	PRON
njb-1	315	9	,	,	PUNCT
njb-1	315	10	reaman	reaman	PROPN
njb-1	315	11	gh	gh	PROPN
njb-1	315	12	,	,	PUNCT
njb-1	315	13	winick	winick	PROPN
njb-1	315	14	n	n	PROPN
njb-1	315	15	,	,	PUNCT
njb-1	315	16	loh	loh	PROPN
njb-1	315	17	ml	ml	PROPN
njb-1	315	18	,	,	PUNCT
njb-1	315	19	et	et	PROPN
njb-1	315	20	al	al	PROPN
njb-1	315	21	.	.	PROPN
njb-1	316	1	plasma	plasma	NOUN
njb-1	316	2	asparaginase	asparaginase	NOUN
njb-1	316	3	activity	activity	NOUN
njb-1	316	4	and	and	CCONJ
njb-1	316	5	asparagine	asparagine	NOUN
njb-1	316	6	depletion	depletion	NOUN
njb-1	316	7	in	in	ADP
njb-1	316	8	acute	acute	ADJ
njb-1	316	9	lymphoblastic	lymphoblastic	NOUN
njb-1	316	10	leukemia	leukemia	NOUN
njb-1	316	11	patients	patient	NOUN
njb-1	316	12	treated	treat	VERB
njb-1	316	13	with	with	ADP
njb-1	316	14	pegaspargase	pegaspargase	NOUN
njb-1	316	15	on	on	ADP
njb-1	316	16	children	child	NOUN
njb-1	316	17	’s	’s	PART
njb-1	316	18	oncology	oncology	NOUN
njb-1	316	19	group	group	NOUN
njb-1	316	20	aall07p4	aall07p4	PROPN
njb-1	316	21	*	*	PUNCT
njb-1	316	22	.	.	PUNCT
njb-1	317	1	leuk	leuk	PROPN
njb-1	317	2	lymphoma	lymphoma	NOUN
njb-1	317	3	.	.	PUNCT
njb-1	318	1	2019	2019	NUM
njb-1	318	2	;	;	PUNCT
njb-1	318	3	60(7	60(7	X
njb-1	318	4	):	):	PUNCT
njb-1	318	5	1740–8	1740–8	NUM
njb-1	318	6	.	.	PUNCT
njb-1	319	1	https://doi.org/	https://doi.org/	VERB
njb-1	319	2	10.1080/	10.1080/	NUM
njb-1	319	3	10428194	10428194	NUM
njb-1	319	4	.	.	PUNCT
njb-1	320	1	2018	2018	NUM
njb-1	320	2	.	.	PUNCT
njb-1	321	1	1542146	1542146	NUM
njb-1	321	2	10	10	NUM
njb-1	321	3	.	.	PUNCT
njb-1	322	1	van	van	PROPN
njb-1	322	2	der	der	PROPN
njb-1	322	3	sluis	sluis	PROPN
njb-1	322	4	i	i	NOUN
njb-1	322	5	m	m	VERB
njb-1	322	6	,	,	PUNCT
njb-1	322	7	de	de	PROPN
njb-1	322	8	groot	groot	PROPN
njb-1	322	9	-	-	PUNCT
njb-1	322	10	kruseman	kruseman	PROPN
njb-1	322	11	h	h	PROPN
njb-1	322	12	,	,	PUNCT
njb-1	322	13	te	te	PROPN
njb-1	322	14	loo	loo	PROPN
njb-1	322	15	m	m	PROPN
njb-1	322	16	,	,	PUNCT
njb-1	322	17	tissing	tisse	VERB
njb-1	322	18	wje	wje	PROPN
njb-1	322	19	,	,	PUNCT
njb-1	322	20	van	van	PROPN
njb-1	322	21	den	den	PROPN
njb-1	322	22	bos	bos	PROPN
njb-1	322	23	c	c	PROPN
njb-1	322	24	,	,	PUNCT
njb-1	322	25	kaspers	kaspers	PROPN
njb-1	322	26	gjl	gjl	PROPN
njb-1	322	27	,	,	PUNCT
njb-1	322	28	et	et	PROPN
njb-1	322	29	al	al	PROPN
njb-1	322	30	.	.	PROPN
njb-1	323	1	efficacy	efficacy	NOUN
njb-1	323	2	and	and	CCONJ
njb-1	323	3	safety	safety	NOUN
njb-1	323	4	of	of	ADP
njb-1	323	5	recombinant	recombinant	ADJ
njb-1	323	6	e.	e.	PROPN
njb-1	323	7	coli	coli	PROPN
njb-1	323	8	asparaginase	asparaginase	NOUN
njb-1	323	9	in	in	ADP
njb-1	323	10	children	child	NOUN
njb-1	323	11	with	with	ADP
njb-1	323	12	previously	previously	ADV
njb-1	323	13	untreated	untreated	ADJ
njb-1	323	14	acute	acute	ADJ
njb-1	323	15	lymphoblastic	lymphoblastic	NOUN
njb-1	323	16	leukemia	leukemia	NOUN
njb-1	323	17	:	:	PUNCT
njb-1	323	18	a	a	DET
njb-1	323	19	randomized	randomized	ADJ
njb-1	323	20	multicenter	multicenter	NOUN
njb-1	323	21	study	study	NOUN
njb-1	323	22	of	of	ADP
njb-1	323	23	the	the	DET
njb-1	323	24	dutch	dutch	ADJ
njb-1	323	25	childhood	childhood	PROPN
njb-1	323	26	oncology	oncology	NOUN
njb-1	323	27	group	group	NOUN
njb-1	323	28	.	.	PUNCT
njb-1	324	1	pediatr	pediatr	VERB
njb-1	324	2	blood	blood	NOUN
njb-1	324	3	cancer	cancer	NOUN
njb-1	324	4	.	.	PUNCT
njb-1	325	1	2018;65(8):1–8	2018;65(8):1–8	NUM
njb-1	325	2	.	.	PUNCT
njb-1	326	1	https://doi.org/10.1002/	https://doi.org/10.1002/	PROPN
njb-1	326	2	pbc.27083	pbc.27083	PROPN
njb-1	326	3	11	11	NUM
njb-1	326	4	.	.	PUNCT
njb-1	327	1	pieters	pieter	NOUN
njb-1	327	2	r	r	PROPN
njb-1	327	3	,	,	PUNCT
njb-1	327	4	appel	appel	PROPN
njb-1	327	5	i	i	PROPN
njb-1	327	6	,	,	PUNCT
njb-1	327	7	kuehnel	kuehnel	PROPN
njb-1	327	8	hj	hj	PROPN
njb-1	327	9	,	,	PUNCT
njb-1	327	10	tetzlaff	tetzlaff	ADJ
njb-1	327	11	-	-	PUNCT
njb-1	327	12	fohr	fohr	ADJ
njb-1	327	13	i	i	PROPN
njb-1	327	14	,	,	PUNCT
njb-1	327	15	pichlmeier	pichlmeier	X
njb-1	327	16	u	u	NOUN
njb-1	327	17	,	,	PUNCT
njb-1	327	18	van	van	PROPN
njb-1	327	19	der	der	PROPN
njb-1	327	20	vaart	vaart	PROPN
njb-1	327	21	i	i	PROPN
njb-1	327	22	,	,	PUNCT
njb-1	327	23	et	et	PROPN
njb-1	327	24	al	al	PROPN
njb-1	327	25	.	.	PUNCT
njb-1	328	1	pharmacokinetics	pharmacokinetic	NOUN
njb-1	328	2	,	,	PUNCT
njb-1	328	3	pharmacodynamics	pharmacodynamic	NOUN
njb-1	328	4	,	,	PUNCT
njb-1	328	5	efficacy	efficacy	NOUN
njb-1	328	6	,	,	PUNCT
njb-1	328	7	and	and	CCONJ
njb-1	328	8	safety	safety	NOUN
njb-1	328	9	of	of	ADP
njb-1	328	10	a	a	DET
njb-1	328	11	new	new	ADJ
njb-1	328	12	recombinant	recombinant	ADJ
njb-1	328	13	asparaginase	asparaginase	NOUN
njb-1	328	14	preparation	preparation	NOUN
njb-1	328	15	in	in	ADP
njb-1	328	16	children	child	NOUN
njb-1	328	17	with	with	ADP
njb-1	328	18	previously	previously	ADV
njb-1	328	19	untreated	untreated	ADJ
njb-1	328	20	acute	acute	ADJ
njb-1	328	21	lymphoblastic	lymphoblastic	NOUN
njb-1	328	22	leukemia	leukemia	NOUN
njb-1	328	23	:	:	PUNCT
njb-1	328	24	a	a	DET
njb-1	328	25	randomized	randomized	ADJ
njb-1	328	26	phase	phase	NOUN
njb-1	328	27	2	2	NUM
njb-1	328	28	clinical	clinical	ADJ
njb-1	328	29	trial	trial	NOUN
njb-1	328	30	.	.	PUNCT
njb-1	329	1	blood	blood	NOUN
njb-1	329	2	.	.	PUNCT
njb-1	330	1	2008	2008	NUM
njb-1	331	1	dec;112(13):4832–8	dec;112(13):4832–8	PROPN
njb-1	331	2	.	.	PUNCT
njb-1	332	1	https://doi.org/10.1182/blood-2008-04https://doi.org/10.1038/bcj.2017.53	https://doi.org/10.1182/blood-2008-04https://doi.org/10.1038/bcj.2017.53	PROPN
njb-1	332	2	https://doi.org/10.20452/pamw.518	https://doi.org/10.20452/pamw.518	PROPN
njb-1	332	3	https://doi.org/10.1007/s12010-015-1917-3	https://doi.org/10.1007/s12010-015-1917-3	X
njb-1	332	4	https://doi.org/10.1007/s12010-015-1917-3	https://doi.org/10.1007/s12010-015-1917-3	X
njb-1	332	5	https://doi.org/10.1016/s1040-8428(98)00015-8	https://doi.org/10.1016/s1040-8428(98)00015-8	PROPN
njb-1	332	6	https://doi.org/10.1002/1097-0142(19950301)75:5%3c1176::aid-cncr2820750519%3e3.0.co;2-y	https://doi.org/10.1002/1097-0142(19950301)75:5%3c1176::aid-cncr2820750519%3e3.0.co;2-y	PROPN
njb-1	332	7	https://doi.org/10.1002/1097-0142(19950301)75:5%3c1176::aid-cncr2820750519%3e3.0.co;2-y	https://doi.org/10.1002/1097-0142(19950301)75:5%3c1176::aid-cncr2820750519%3e3.0.co;2-y	PROPN
njb-1	333	1	https://doi.org/10.1002/pbc.26475	https://doi.org/10.1002/pbc.26475	PROPN
njb-1	333	2	https://doi.org/10.1002/pbc.27083	https://doi.org/10.1002/pbc.27083	PROPN
njb-1	333	3	https://doi.org/10.1002/pbc.27083	https://doi.org/10.1002/pbc.27083	PROPN
njb-1	333	4	https://doi.org/10.1182/blood-2008-04-149443	https://doi.org/10.1182/blood-2008-04-149443	NUM
njb-1	333	5	nepal	nepal	PROPN
njb-1	333	6	j	j	PROPN
njb-1	333	7	biotechnol	biotechnol	PROPN
njb-1	333	8	.	.	PUNCT
njb-1	334	1	2	2	NUM
njb-1	334	2	0	0	NUM
njb-1	334	3	2	2	NUM
njb-1	334	4	1	1	NUM
njb-1	334	5	d	d	X
njb-1	334	6	e	e	X
njb-1	334	7	c	c	PROPN
njb-1	334	8	.	.	PUNCT
njb-1	335	1	9	9	NUM
njb-1	335	2	(	(	PUNCT
njb-1	335	3	2	2	NUM
njb-1	335	4	):	):	PUNCT
njb-1	335	5	39	39	NUM
njb-1	335	6	-	-	SYM
njb-1	335	7	47	47	NUM
njb-1	335	8	baral	baral	ADJ
njb-1	335	9	et	et	PROPN
njb-1	335	10	al	al	PROPN
njb-1	335	11	.	.	PUNCT
njb-1	336	1	©	©	PROPN
njb-1	336	2	njb	njb	PROPN
njb-1	336	3	,	,	PUNCT
njb-1	336	4	bsn	bsn	PROPN
njb-1	336	5	47	47	NUM
njb-1	336	6	149443	149443	NUM
njb-1	336	7	12	12	NUM
njb-1	336	8	.	.	PUNCT
njb-1	337	1	van	van	PROPN
njb-1	337	2	der	der	PROPN
njb-1	337	3	sluis	sluis	PROPN
njb-1	337	4	i	i	PROPN
njb-1	337	5	,	,	PUNCT
njb-1	337	6	möricke	möricke	PROPN
njb-1	337	7	a	a	PRON
njb-1	337	8	,	,	PUNCT
njb-1	337	9	escherich	escherich	PROPN
njb-1	337	10	g	g	PROPN
njb-1	337	11	,	,	PUNCT
njb-1	337	12	von	von	PROPN
njb-1	337	13	stackelberg	stackelberg	PROPN
njb-1	337	14	a	a	PRON
njb-1	337	15	,	,	PUNCT
njb-1	337	16	holter	holter	NOUN
njb-1	337	17	w	w	PROPN
njb-1	337	18	,	,	PUNCT
njb-1	337	19	klingebiel	klingebiel	PROPN
njb-1	337	20	t	t	PROPN
njb-1	337	21	,	,	PUNCT
njb-1	337	22	et	et	PROPN
njb-1	337	23	al	al	PROPN
njb-1	337	24	.	.	PROPN
njb-1	337	25	efficacy	efficacy	NOUN
njb-1	337	26	and	and	CCONJ
njb-1	337	27	safety	safety	NOUN
njb-1	337	28	of	of	ADP
njb-1	337	29	recombinant	recombinant	ADJ
njb-1	337	30	e.	e.	PROPN
njb-1	337	31	coli	coli	NOUN
njb-1	337	32	-	-	PUNCT
njb-1	337	33	asparaginase	asparaginase	NOUN
njb-1	337	34	in	in	ADP
njb-1	337	35	infants	infant	NOUN
njb-1	337	36	(	(	PUNCT
njb-1	337	37	less	less	ADJ
njb-1	337	38	than	than	ADP
njb-1	337	39	one	one	NUM
njb-1	337	40	year	year	NOUN
njb-1	337	41	of	of	ADP
njb-1	337	42	age	age	NOUN
njb-1	337	43	)	)	PUNCT
njb-1	337	44	with	with	ADP
njb-1	337	45	acute	acute	ADJ
njb-1	337	46	lymphoblastic	lymphoblastic	NOUN
njb-1	337	47	leukemia	leukemia	NOUN
njb-1	337	48	.	.	PUNCT
njb-1	338	1	haematologica	haematologica	PROPN
njb-1	338	2	.	.	PUNCT
njb-1	338	3	2013	2013	NUM
njb-1	338	4	nov;98(11):1697–701	nov;98(11):1697–701	PROPN
njb-1	338	5	.	.	PUNCT
njb-1	339	1	https://doi.org/10.3324/haematol.2013	https://doi.org/10.3324/haematol.2013	PROPN
njb-1	339	2	.	.	PROPN
njb-1	339	3	090563	090563	NUM
njb-1	339	4	13	13	NUM
njb-1	339	5	.	.	PUNCT
njb-1	340	1	albertsen	albertsen	PROPN
njb-1	340	2	bk	bk	PROPN
njb-1	340	3	,	,	PUNCT
njb-1	340	4	grell	grell	PROPN
njb-1	340	5	k	k	PROPN
njb-1	340	6	,	,	PUNCT
njb-1	340	7	abrahamsson	abrahamsson	PROPN
njb-1	340	8	j	j	PROPN
njb-1	340	9	,	,	PUNCT
njb-1	340	10	lund	lund	PROPN
njb-1	340	11	b	b	PROPN
njb-1	340	12	,	,	PUNCT
njb-1	340	13	vettenranta	vettenranta	PROPN
njb-1	340	14	k	k	PROPN
njb-1	340	15	,	,	PUNCT
njb-1	340	16	jónsson	jónsson	PROPN
njb-1	340	17	óg	óg	PROPN
njb-1	340	18	,	,	PUNCT
njb-1	340	19	et	et	PROPN
njb-1	340	20	al	al	PROPN
njb-1	340	21	.	.	PROPN
njb-1	341	1	intermittent	intermittent	PROPN
njb-1	341	2	versus	versus	ADP
njb-1	341	3	continuous	continuous	ADJ
njb-1	341	4	pegasparaginase	pegasparaginase	NOUN
njb-1	341	5	to	to	PART
njb-1	341	6	reduce	reduce	VERB
njb-1	341	7	asparaginase	asparaginase	NOUN
njb-1	341	8	-	-	PUNCT
njb-1	341	9	associated	associate	VERB
njb-1	341	10	toxicities	toxicity	NOUN
njb-1	341	11	:	:	PUNCT
njb-1	341	12	a	a	DET
njb-1	341	13	nopho	nopho	PROPN
njb-1	341	14	all2008	all2008	PROPN
njb-1	341	15	randomized	randomize	VERB
njb-1	341	16	study	study	NOUN
njb-1	341	17	.	.	PUNCT
njb-1	342	1	j	j	PROPN
njb-1	342	2	clin	clin	PROPN
njb-1	342	3	oncol	oncol	PROPN
njb-1	342	4	.	.	PUNCT
njb-1	343	1	2019;37(19):1638–46	2019;37(19):1638–46	NUM
njb-1	343	2	.	.	PUNCT
njb-1	344	1	https://doi.org/10.1200/jco.18.01877	https://doi.org/10.1200/jco.18.01877	NUM
njb-1	344	2	14	14	NUM
njb-1	344	3	.	.	PUNCT
njb-1	345	1	kurtzberg	kurtzberg	PROPN
njb-1	345	2	j	j	PROPN
njb-1	345	3	,	,	PUNCT
njb-1	345	4	asselin	asselin	PROPN
njb-1	345	5	b	b	PROPN
njb-1	345	6	,	,	PUNCT
njb-1	345	7	bernstein	bernstein	PROPN
njb-1	345	8	m	m	PROPN
njb-1	345	9	,	,	PUNCT
njb-1	345	10	buchanan	buchanan	PROPN
njb-1	345	11	gr	gr	PROPN
njb-1	345	12	,	,	PUNCT
njb-1	345	13	pollock	pollock	NOUN
njb-1	345	14	bh	bh	NOUN
njb-1	345	15	,	,	PUNCT
njb-1	345	16	camitta	camitta	PROPN
njb-1	345	17	bm	bm	PROPN
njb-1	345	18	.	.	PUNCT
njb-1	346	1	polyethylene	polyethylene	PROPN
njb-1	346	2	glycol	glycol	PROPN
njb-1	346	3	-	-	PUNCT
njb-1	346	4	conjugated	conjugate	VERB
njb-1	346	5	l	l	NOUN
njb-1	346	6	-	-	PUNCT
njb-1	346	7	asparaginase	asparaginase	NOUN
njb-1	346	8	versus	versus	ADP
njb-1	346	9	native	native	ADJ
njb-1	346	10	l	l	NOUN
njb-1	346	11	-	-	PUNCT
njb-1	346	12	asparaginase	asparaginase	NOUN
njb-1	346	13	in	in	ADP
njb-1	346	14	combination	combination	NOUN
njb-1	346	15	with	with	ADP
njb-1	346	16	standard	standard	ADJ
njb-1	346	17	agents	agent	NOUN
njb-1	346	18	for	for	ADP
njb-1	346	19	children	child	NOUN
njb-1	346	20	with	with	ADP
njb-1	346	21	acute	acute	ADJ
njb-1	346	22	lymphoblastic	lymphoblastic	NOUN
njb-1	346	23	leukemia	leukemia	NOUN
njb-1	346	24	in	in	ADP
njb-1	346	25	second	second	ADJ
njb-1	346	26	bone	bone	NOUN
njb-1	346	27	marrow	marrow	NOUN
njb-1	346	28	relapse	relapse	NOUN
njb-1	346	29	:	:	PUNCT
njb-1	346	30	a	a	DET
njb-1	346	31	children	child	NOUN
njb-1	346	32	’s	’s	PART
njb-1	346	33	oncology	oncology	NOUN
njb-1	346	34	group	group	NOUN
njb-1	346	35	study	study	NOUN
njb-1	346	36	(	(	PUNCT
njb-1	346	37	pog	pog	PROPN
njb-1	346	38	8866	8866	NUM
njb-1	346	39	)	)	PUNCT
njb-1	346	40	.	.	PUNCT
njb-1	347	1	j	j	PROPN
njb-1	347	2	pediatr	pediatr	PROPN
njb-1	347	3	hematol	hematol	PROPN
njb-1	347	4	oncol	oncol	PROPN
njb-1	347	5	.	.	PUNCT
njb-1	348	1	2011;33(8):610–6	2011;33(8):610–6	NUM
njb-1	348	2	.	.	PUNCT
njb-1	349	1	https://doi.org/10.1097/mph.0b013e31822d4d4e	https://doi.org/10.1097/mph.0b013e31822d4d4e	PROPN
njb-1	349	2	15	15	NUM
njb-1	349	3	.	.	PUNCT
njb-1	350	1	duval	duval	NOUN
njb-1	350	2	m	m	PROPN
njb-1	350	3	,	,	PUNCT
njb-1	350	4	suciu	suciu	PROPN
njb-1	350	5	s	s	PROPN
njb-1	350	6	,	,	PUNCT
njb-1	350	7	ferster	ferster	VERB
njb-1	350	8	a	a	PRON
njb-1	350	9	,	,	PUNCT
njb-1	350	10	rialland	rialland	PROPN
njb-1	350	11	x	x	PROPN
njb-1	350	12	,	,	PUNCT
njb-1	350	13	nelken	nelken	PROPN
njb-1	350	14	b	b	PROPN
njb-1	350	15	,	,	PUNCT
njb-1	350	16	lutz	lutz	PROPN
njb-1	350	17	p	p	PROPN
njb-1	350	18	,	,	PUNCT
njb-1	350	19	et	et	PROPN
njb-1	350	20	al	al	PROPN
njb-1	350	21	.	.	PUNCT
njb-1	351	1	comparison	comparison	NOUN
njb-1	351	2	of	of	ADP
njb-1	351	3	escherichia	escherichia	NOUN
njb-1	351	4	coli	coli	NOUN
njb-1	351	5	-	-	PUNCT
njb-1	351	6	asparaginase	asparaginase	NOUN
njb-1	351	7	with	with	ADP
njb-1	351	8	erwiniaasparaginase	erwiniaasparaginase	NOUN
njb-1	351	9	in	in	ADP
njb-1	351	10	the	the	DET
njb-1	351	11	treatment	treatment	NOUN
njb-1	351	12	of	of	ADP
njb-1	351	13	childhood	childhood	NOUN
njb-1	351	14	lymphoid	lymphoid	NOUN
njb-1	351	15	malignancies	malignancy	NOUN
njb-1	351	16	:	:	PUNCT
njb-1	351	17	results	result	NOUN
njb-1	351	18	of	of	ADP
njb-1	351	19	a	a	DET
njb-1	351	20	randomized	randomized	ADJ
njb-1	351	21	european	european	ADJ
njb-1	351	22	organisation	organisation	PROPN
njb-1	351	23	for	for	ADP
njb-1	351	24	research	research	NOUN
njb-1	351	25	and	and	CCONJ
njb-1	351	26	treatment	treatment	NOUN
njb-1	351	27	of	of	ADP
njb-1	351	28	cancer	cancer	NOUN
njb-1	351	29	children	child	NOUN
njb-1	351	30	’s	’s	PART
njb-1	351	31	leukemia	leukemia	NOUN
njb-1	351	32	group	group	NOUN
njb-1	351	33	phase	phase	NOUN
njb-1	351	34	3	3	NUM
njb-1	351	35	trial	trial	NOUN
njb-1	351	36	.	.	PUNCT
njb-1	352	1	blood	blood	NOUN
njb-1	352	2	.	.	PUNCT
njb-1	353	1	2002	2002	NUM
njb-1	353	2	apr;99(8):2734–9	apr;99(8):2734–9	NOUN
njb-1	353	3	.	.	PUNCT
njb-1	354	1	https://doi.org/10.1182/blood.v99.8.2734	https://doi.org/10.1182/blood.v99.8.2734	PROPN
njb-1	354	2	16	16	NUM
njb-1	354	3	.	.	PUNCT
njb-1	355	1	vyas	vyas	PROPN
njb-1	355	2	c	c	PROPN
njb-1	355	3	,	,	PUNCT
njb-1	355	4	jain	jain	PROPN
njb-1	355	5	s	s	PROPN
njb-1	355	6	,	,	PUNCT
njb-1	355	7	kapoor	kapoor	PROPN
njb-1	355	8	g	g	PROPN
njb-1	355	9	,	,	PUNCT
njb-1	355	10	mehta	mehta	PROPN
njb-1	355	11	a	a	PROPN
njb-1	355	12	,	,	PUNCT
njb-1	355	13	takkar	takkar	PROPN
njb-1	355	14	chugh	chugh	NOUN
njb-1	355	15	p.	p.	NOUN
njb-1	355	16	experience	experience	NOUN
njb-1	355	17	with	with	ADP
njb-1	355	18	generic	generic	ADJ
njb-1	355	19	pegylated	pegylate	VERB
njb-1	355	20	l	l	NOUN
njb-1	355	21	-	-	PUNCT
njb-1	355	22	asparaginase	asparaginase	NOUN
njb-1	355	23	in	in	ADP
njb-1	355	24	children	child	NOUN
njb-1	355	25	with	with	ADP
njb-1	355	26	acute	acute	ADJ
njb-1	355	27	lymphoblastic	lymphoblastic	NOUN
njb-1	355	28	leukemia	leukemia	NOUN
njb-1	355	29	and	and	CCONJ
njb-1	355	30	monitoring	monitoring	NOUN
njb-1	355	31	of	of	ADP
njb-1	355	32	serum	serum	NOUN
njb-1	355	33	asparaginase	asparaginase	NOUN
njb-1	355	34	activity	activity	NOUN
njb-1	355	35	.	.	PUNCT
njb-1	356	1	pediatr	pediatr	PROPN
njb-1	356	2	hematol	hematol	PROPN
njb-1	356	3	oncol	oncol	PROPN
njb-1	356	4	.	.	PUNCT
njb-1	357	1	2018;35(5–6):331–40	2018;35(5–6):331–40	NUM
njb-1	357	2	.	.	PUNCT
njb-1	357	3	https://doi.org/10.1080/08880018.2018.1538277	https://doi.org/10.1080/08880018.2018.1538277	PROPN
njb-1	357	4	17	17	NUM
njb-1	357	5	.	.	PUNCT
njb-1	358	1	patel	patel	PROPN
njb-1	358	2	b	b	PROPN
njb-1	358	3	,	,	PUNCT
njb-1	358	4	kirkwood	kirkwood	PROPN
njb-1	358	5	aa	aa	PROPN
njb-1	358	6	,	,	PUNCT
njb-1	358	7	dey	dey	PROPN
njb-1	358	8	a	a	PROPN
njb-1	358	9	,	,	PUNCT
njb-1	358	10	marks	marks	PROPN
njb-1	358	11	di	di	PROPN
njb-1	358	12	,	,	PUNCT
njb-1	358	13	mcmillan	mcmillan	PROPN
njb-1	358	14	ak	ak	PROPN
njb-1	358	15	,	,	PUNCT
njb-1	358	16	menne	menne	PROPN
njb-1	358	17	tf	tf	PROPN
njb-1	358	18	,	,	PUNCT
njb-1	358	19	et	et	PROPN
njb-1	358	20	al	al	PROPN
njb-1	358	21	.	.	PUNCT
njb-1	359	1	pegylated	pegylate	VERB
njb-1	359	2	-	-	PUNCT
njb-1	359	3	asparaginase	asparaginase	NOUN
njb-1	359	4	during	during	ADP
njb-1	359	5	induction	induction	NOUN
njb-1	359	6	therapy	therapy	NOUN
njb-1	359	7	for	for	ADP
njb-1	359	8	adult	adult	NOUN
njb-1	359	9	acute	acute	ADJ
njb-1	359	10	lymphoblastic	lymphoblastic	NOUN
njb-1	359	11	leukaemia	leukaemia	NOUN
njb-1	359	12	:	:	PUNCT
njb-1	359	13	toxicity	toxicity	NOUN
njb-1	359	14	data	datum	NOUN
njb-1	359	15	from	from	ADP
njb-1	359	16	the	the	DET
njb-1	359	17	ukall14	ukall14	ADJ
njb-1	359	18	trial	trial	NOUN
njb-1	359	19	.	.	PUNCT
njb-1	360	1	leukemia	leukemia	NOUN
njb-1	360	2	.	.	PUNCT
njb-1	361	1	2017	2017	NUM
njb-1	361	2	jan;31(1):58–64	jan;31(1):58–64	NOUN
njb-1	361	3	.	.	PUNCT
njb-1	362	1	https://doi.org/10.1038/leu.2016.219	https://doi.org/10.1038/leu.2016.219	PROPN
njb-1	362	2	18	18	NUM
njb-1	362	3	.	.	PUNCT
njb-1	363	1	salzer	salzer	PROPN
njb-1	363	2	wl	wl	PROPN
njb-1	363	3	,	,	PUNCT
njb-1	363	4	asselin	asselin	PROPN
njb-1	363	5	b	b	PROPN
njb-1	363	6	,	,	PUNCT
njb-1	363	7	supko	supko	VERB
njb-1	363	8	jg	jg	PROPN
njb-1	363	9	,	,	PUNCT
njb-1	363	10	devidas	devida	NOUN
njb-1	363	11	m	m	PROPN
njb-1	363	12	,	,	PUNCT
njb-1	363	13	kaiser	kaiser	PROPN
njb-1	363	14	na	na	PROPN
njb-1	363	15	,	,	PUNCT
njb-1	363	16	plourde	plourde	PROPN
njb-1	363	17	p	p	PROPN
njb-1	363	18	,	,	PUNCT
njb-1	363	19	et	et	PROPN
njb-1	363	20	al	al	PROPN
njb-1	363	21	.	.	PROPN
njb-1	364	1	erwinia	erwinia	PROPN
njb-1	364	2	asparaginase	asparaginase	PROPN
njb-1	364	3	achieves	achieve	VERB
njb-1	364	4	therapeutic	therapeutic	ADJ
njb-1	364	5	activity	activity	NOUN
njb-1	364	6	after	after	ADP
njb-1	364	7	pegaspargase	pegaspargase	PROPN
njb-1	364	8	allergy	allergy	NOUN
njb-1	364	9	:	:	PUNCT
njb-1	364	10	a	a	DET
njb-1	364	11	report	report	NOUN
njb-1	364	12	from	from	ADP
njb-1	364	13	the	the	DET
njb-1	364	14	children	child	NOUN
njb-1	364	15	’s	’s	PART
njb-1	364	16	oncology	oncology	NOUN
njb-1	364	17	group	group	NOUN
njb-1	364	18	.	.	PUNCT
njb-1	365	1	blood	blood	NOUN
njb-1	365	2	.	.	PUNCT
njb-1	366	1	2013	2013	NUM
njb-1	366	2	jul;122(4):507–14	jul;122(4):507–14	PROPN
njb-1	366	3	.	.	PUNCT
njb-1	367	1	https://doi.org/10.1182/blood-2013-01-480822	https://doi.org/10.1182/blood-2013-01-480822	SYM
njb-1	367	2	19	19	NUM
njb-1	367	3	.	.	PUNCT
njb-1	368	1	place	place	PROPN
njb-1	368	2	ae	ae	PROPN
njb-1	368	3	,	,	PUNCT
njb-1	368	4	stevenson	stevenson	PROPN
njb-1	368	5	ke	ke	PROPN
njb-1	368	6	,	,	PUNCT
njb-1	368	7	vrooman	vrooman	PROPN
njb-1	368	8	lm	lm	PROPN
njb-1	368	9	,	,	PUNCT
njb-1	368	10	harris	harris	PROPN
njb-1	368	11	mh	mh	PROPN
njb-1	368	12	,	,	PUNCT
njb-1	368	13	hunt	hunt	PROPN
njb-1	368	14	sk	sk	PROPN
njb-1	368	15	,	,	PUNCT
njb-1	368	16	o’brien	o’brien	PROPN
njb-1	368	17	je	je	PROPN
njb-1	368	18	,	,	PUNCT
njb-1	368	19	et	et	PROPN
njb-1	368	20	al	al	PROPN
njb-1	368	21	.	.	PROPN
njb-1	369	1	intravenous	intravenous	PROPN
njb-1	369	2	pegylated	pegylate	VERB
njb-1	369	3	asparaginase	asparaginase	NOUN
njb-1	369	4	versus	versus	ADP
njb-1	369	5	intramuscular	intramuscular	ADJ
njb-1	369	6	native	native	ADJ
njb-1	369	7	escherichia	escherichia	NOUN
njb-1	369	8	coli	coli	NOUN
njb-1	369	9	l	l	NOUN
njb-1	369	10	-	-	PUNCT
njb-1	369	11	asparaginase	asparaginase	NOUN
njb-1	369	12	in	in	ADP
njb-1	369	13	newly	newly	ADV
njb-1	369	14	diagnosed	diagnose	VERB
njb-1	369	15	childhood	childhood	NOUN
njb-1	369	16	acute	acute	ADJ
njb-1	369	17	lymphoblastic	lymphoblastic	NOUN
njb-1	369	18	leukaemia	leukaemia	NOUN
njb-1	369	19	(	(	PUNCT
njb-1	369	20	dfci	dfci	NOUN
njb-1	369	21	05001	05001	NUM
njb-1	369	22	):	):	PUNCT
njb-1	369	23	a	a	DET
njb-1	369	24	randomised	randomised	ADJ
njb-1	369	25	,	,	PUNCT
njb-1	369	26	open	open	ADJ
njb-1	369	27	-	-	PUNCT
njb-1	369	28	label	label	NOUN
njb-1	369	29	phase	phase	NOUN
njb-1	369	30	3	3	NUM
njb-1	369	31	trial	trial	NOUN
njb-1	369	32	.	.	PUNCT
njb-1	370	1	lancet	lancet	PROPN
njb-1	370	2	oncol	oncol	PROPN
njb-1	370	3	.	.	PUNCT
njb-1	371	1	2015;16(16):1677–90	2015;16(16):1677–90	NUM
njb-1	371	2	.	.	PUNCT
njb-1	372	1	https://doi.org/10.1016/s1470-2045(15	https://doi.org/10.1016/s1470-2045(15	PROPN
njb-1	372	2	)	)	PUNCT
njb-1	372	3	00363	00363	NUM
njb-1	372	4	-	-	SYM
njb-1	372	5	0	0	NUM
njb-1	372	6	20	20	NUM
njb-1	372	7	.	.	PUNCT
njb-1	373	1	dinndorf	dinndorf	PROPN
njb-1	373	2	pa	pa	PROPN
njb-1	373	3	,	,	PUNCT
njb-1	373	4	gootenberg	gootenberg	PROPN
njb-1	373	5	j	j	PROPN
njb-1	373	6	,	,	PUNCT
njb-1	373	7	cohen	cohen	PROPN
njb-1	373	8	mh	mh	PROPN
njb-1	373	9	,	,	PUNCT
njb-1	373	10	keegan	keegan	PROPN
njb-1	373	11	p	p	PROPN
njb-1	373	12	,	,	PUNCT
njb-1	373	13	pazdur	pazdur	PROPN
njb-1	373	14	r.	r.	PROPN
njb-1	373	15	fda	fda	PROPN
njb-1	373	16	drug	drug	NOUN
njb-1	373	17	approval	approval	NOUN
njb-1	373	18	summary	summary	NOUN
njb-1	373	19	:	:	PUNCT
njb-1	373	20	pegaspargase	pegaspargase	PROPN
njb-1	373	21	(	(	PUNCT
njb-1	373	22	oncaspar	oncaspar	ADJ
njb-1	373	23	®	®	NOUN
njb-1	373	24	)	)	PUNCT
njb-1	373	25	for	for	ADP
njb-1	373	26	the	the	DET
njb-1	373	27	first‐line	first‐line	ADJ
njb-1	373	28	treatment	treatment	NOUN
njb-1	373	29	of	of	ADP
njb-1	373	30	children	child	NOUN
njb-1	373	31	with	with	ADP
njb-1	373	32	acute	acute	ADJ
njb-1	373	33	lymphoblastic	lymphoblastic	NOUN
njb-1	373	34	leukemia	leukemia	NOUN
njb-1	373	35	(	(	PUNCT
njb-1	373	36	all	all	ADV
njb-1	373	37	)	)	PUNCT
njb-1	373	38	.	.	PUNCT
njb-1	374	1	oncologist	oncologist	NOUN
njb-1	374	2	.	.	PUNCT
njb-1	375	1	2007;12(8):991–8	2007;12(8):991–8	NUM
njb-1	375	2	.	.	PUNCT
njb-1	376	1	https://doi.org/10.1634/	https://doi.org/10.1634/	PROPN
njb-1	376	2	theoncologist.12	theoncologist.12	PROPN
njb-1	376	3	-	-	PUNCT
njb-1	376	4	8	8	NUM
njb-1	376	5	-	-	PUNCT
njb-1	376	6	991	991	NUM
njb-1	376	7	21	21	NUM
njb-1	376	8	.	.	PUNCT
njb-1	377	1	rau	rau	PROPN
njb-1	377	2	re	re	PROPN
njb-1	377	3	,	,	PUNCT
njb-1	377	4	dreyer	dreyer	PROPN
njb-1	377	5	za	za	PROPN
njb-1	377	6	,	,	PUNCT
njb-1	377	7	choi	choi	NOUN
njb-1	377	8	mr	mr	PROPN
njb-1	377	9	,	,	PUNCT
njb-1	377	10	liang	liang	PROPN
njb-1	377	11	w	w	PROPN
njb-1	377	12	,	,	PUNCT
njb-1	377	13	skowronski	skowronski	PROPN
njb-1	377	14	r	r	PROPN
njb-1	377	15	,	,	PUNCT
njb-1	377	16	allamneni	allamneni	PROPN
njb-1	377	17	kp	kp	PROPN
njb-1	377	18	,	,	PUNCT
njb-1	377	19	et	et	PROPN
njb-1	377	20	al	al	PROPN
njb-1	377	21	.	.	PROPN
njb-1	378	1	outcome	outcome	NOUN
njb-1	378	2	of	of	ADP
njb-1	378	3	pediatric	pediatric	ADJ
njb-1	378	4	patients	patient	NOUN
njb-1	378	5	with	with	ADP
njb-1	378	6	acute	acute	ADJ
njb-1	378	7	lymphoblastic	lymphoblastic	NOUN
njb-1	378	8	leukemia	leukemia	NOUN
njb-1	378	9	/	/	SYM
njb-1	378	10	lymphoblastic	lymphoblastic	NOUN
njb-1	378	11	lymphoma	lymphoma	NOUN
njb-1	378	12	with	with	ADP
njb-1	378	13	hypersensitivity	hypersensitivity	NOUN
njb-1	378	14	to	to	ADP
njb-1	378	15	pegaspargase	pegaspargase	NOUN
njb-1	378	16	treated	treat	VERB
njb-1	378	17	with	with	ADP
njb-1	378	18	pegylated	pegylated	ADJ
njb-1	378	19	erwinia	erwinia	PROPN
njb-1	378	20	asparaginase	asparaginase	PROPN
njb-1	378	21	,	,	PUNCT
njb-1	378	22	pegcrisantaspase	pegcrisantaspase	NOUN
njb-1	378	23	:	:	PUNCT
njb-1	378	24	a	a	DET
njb-1	378	25	report	report	NOUN
njb-1	378	26	from	from	ADP
njb-1	378	27	the	the	DET
njb-1	378	28	children	child	NOUN
njb-1	378	29	’s	’s	PART
njb-1	378	30	oncology	oncology	NOUN
njb-1	378	31	group	group	NOUN
njb-1	378	32	.	.	PUNCT
njb-1	379	1	pediatr	pediatr	VERB
njb-1	379	2	blood	blood	NOUN
njb-1	379	3	cancer	cancer	NOUN
njb-1	379	4	.	.	PUNCT
njb-1	380	1	2018	2018	NUM
njb-1	380	2	mar;65(3	mar;65(3	NUM
njb-1	380	3	)	)	PUNCT
njb-1	380	4	.	.	PUNCT
njb-1	381	1	https://doi.org/10.1002/pbc.26873	https://doi.org/10.1002/pbc.26873	X
njb-1	381	2	22	22	NUM
njb-1	381	3	.	.	PUNCT
njb-1	382	1	liang	liang	PROPN
njb-1	382	2	dc	dc	PROPN
njb-1	382	3	,	,	PUNCT
njb-1	382	4	hung	hung	PROPN
njb-1	382	5	ij	ij	PROPN
njb-1	382	6	,	,	PUNCT
njb-1	382	7	yang	yang	PROPN
njb-1	382	8	cp	cp	PROPN
njb-1	382	9	,	,	PUNCT
njb-1	382	10	lin	lin	PROPN
njb-1	382	11	kh	kh	PROPN
njb-1	382	12	,	,	PUNCT
njb-1	382	13	chen	chen	PROPN
njb-1	382	14	js	js	PROPN
njb-1	382	15	,	,	PUNCT
njb-1	382	16	hsiao	hsiao	PROPN
njb-1	382	17	tc	tc	PROPN
njb-1	382	18	,	,	PUNCT
njb-1	382	19	et	et	PROPN
njb-1	382	20	al	al	PROPN
njb-1	382	21	.	.	PROPN
njb-1	383	1	unexpected	unexpected	ADJ
njb-1	383	2	mortality	mortality	NOUN
njb-1	383	3	from	from	ADP
njb-1	383	4	the	the	DET
njb-1	383	5	use	use	NOUN
njb-1	383	6	of	of	ADP
njb-1	383	7	e.	e.	PROPN
njb-1	383	8	coli	coli	PROPN
njb-1	383	9	l	l	NOUN
njb-1	383	10	-	-	PUNCT
njb-1	383	11	asparaginase	asparaginase	NOUN
njb-1	383	12	during	during	ADP
njb-1	383	13	remission	remission	NOUN
njb-1	383	14	induction	induction	NOUN
njb-1	383	15	therapy	therapy	NOUN
njb-1	383	16	for	for	ADP
njb-1	383	17	childhood	childhood	NOUN
njb-1	383	18	acute	acute	ADJ
njb-1	383	19	lymphoblastic	lymphoblastic	NOUN
njb-1	383	20	leukemia	leukemia	NOUN
njb-1	383	21	:	:	PUNCT
njb-1	383	22	a	a	DET
njb-1	383	23	report	report	NOUN
njb-1	383	24	from	from	ADP
njb-1	383	25	the	the	DET
njb-1	383	26	taiwan	taiwan	PROPN
njb-1	383	27	pediatric	pediatric	ADJ
njb-1	383	28	oncology	oncology	NOUN
njb-1	383	29	group	group	NOUN
njb-1	383	30	.	.	PUNCT
njb-1	384	1	leukemia	leukemia	NOUN
njb-1	384	2	.	.	PUNCT
njb-1	385	1	1999;13(2):155–60	1999;13(2):155–60	NUM
njb-1	385	2	.	.	PUNCT
njb-1	386	1	https://doi.org/	https://doi.org/	PRON
njb-1	386	2	10.1038	10.1038	NUM
njb-1	386	3	/	/	SYM
njb-1	386	4	sj.leu.2401260	sj.leu.2401260	NUM
njb-1	386	5	23	23	NUM
njb-1	386	6	.	.	PUNCT
njb-1	387	1	abshire	abshire	PROPN
njb-1	387	2	tc	tc	PROPN
njb-1	387	3	,	,	PUNCT
njb-1	387	4	pollock	pollock	PROPN
njb-1	387	5	bh	bh	NOUN
njb-1	387	6	,	,	PUNCT
njb-1	387	7	billett	billett	PROPN
njb-1	387	8	al	al	PROPN
njb-1	387	9	,	,	PUNCT
njb-1	387	10	bradley	bradley	PROPN
njb-1	387	11	p	p	PROPN
njb-1	387	12	,	,	PUNCT
njb-1	387	13	buchanan	buchanan	PROPN
njb-1	387	14	gr	gr	PROPN
njb-1	387	15	.	.	PROPN
njb-1	388	1	weekly	weekly	ADJ
njb-1	388	2	polyethylene	polyethylene	PROPN
njb-1	388	3	glycol	glycol	PROPN
njb-1	388	4	conjugated	conjugate	VERB
njb-1	388	5	l	l	NOUN
njb-1	388	6	-	-	PUNCT
njb-1	388	7	asparaginase	asparaginase	NOUN
njb-1	388	8	compared	compare	VERB
njb-1	388	9	with	with	ADP
njb-1	388	10	biweekly	biweekly	ADJ
njb-1	388	11	dosing	dosing	NOUN
njb-1	388	12	produces	produce	VERB
njb-1	388	13	superior	superior	ADJ
njb-1	388	14	induction	induction	NOUN
njb-1	388	15	remission	remission	NOUN
njb-1	388	16	rates	rate	NOUN
njb-1	388	17	in	in	ADP
njb-1	388	18	childhood	childhood	NOUN
njb-1	388	19	relapsed	relapse	VERB
njb-1	388	20	acute	acute	ADJ
njb-1	388	21	lymphoblastic	lymphoblastic	NOUN
njb-1	388	22	leukemia	leukemia	NOUN
njb-1	388	23	:	:	PUNCT
njb-1	388	24	a	a	DET
njb-1	388	25	pediatric	pediatric	ADJ
njb-1	388	26	oncology	oncology	NOUN
njb-1	388	27	group	group	NOUN
njb-1	388	28	study	study	NOUN
njb-1	388	29	.	.	PUNCT
njb-1	389	1	blood	blood	NOUN
njb-1	389	2	.	.	PUNCT
njb-1	390	1	2000;96(5):1709–15	2000;96(5):1709–15	NUM
njb-1	390	2	.	.	PUNCT
njb-1	391	1	https://doi.org/10.1182/blood.v96.5.1709	https://doi.org/10.1182/blood.v96.5.1709	NUM
njb-1	391	2	24	24	NUM
njb-1	391	3	.	.	PUNCT
njb-1	392	1	karachunskiy	karachunskiy	PROPN
njb-1	392	2	a	a	PROPN
njb-1	392	3	,	,	PUNCT
njb-1	392	4	tallen	tallen	PROPN
njb-1	392	5	g	g	PROPN
njb-1	392	6	,	,	PUNCT
njb-1	392	7	roumiantseva	roumiantseva	PROPN
njb-1	392	8	j	j	PROPN
njb-1	392	9	,	,	PUNCT
njb-1	392	10	lagoiko	lagoiko	PROPN
njb-1	392	11	s	s	PROPN
njb-1	392	12	,	,	PUNCT
njb-1	392	13	chervova	chervova	VERB
njb-1	392	14	a	a	PRON
njb-1	392	15	,	,	PUNCT
njb-1	392	16	von	von	PROPN
njb-1	392	17	stackelberg	stackelberg	PROPN
njb-1	392	18	a	a	PRON
njb-1	392	19	,	,	PUNCT
njb-1	392	20	et	et	PROPN
njb-1	392	21	al	al	PROPN
njb-1	392	22	.	.	PROPN
njb-1	393	1	reduced	reduced	PROPN
njb-1	393	2	vs.	vs.	ADP
njb-1	393	3	standard	standard	PROPN
njb-1	393	4	dose	dose	PROPN
njb-1	393	5	native	native	PROPN
njb-1	393	6	e.	e.	PROPN
njb-1	393	7	coli	coli	PROPN
njb-1	393	8	-	-	PUNCT
njb-1	393	9	asparaginase	asparaginase	NOUN
njb-1	393	10	therapy	therapy	NOUN
njb-1	393	11	in	in	ADP
njb-1	393	12	childhood	childhood	NOUN
njb-1	393	13	acute	acute	ADJ
njb-1	393	14	lymphoblastic	lymphoblastic	NOUN
njb-1	393	15	leukemia	leukemia	NOUN
njb-1	393	16	:	:	PUNCT
njb-1	393	17	long	long	ADJ
njb-1	393	18	-	-	PUNCT
njb-1	393	19	term	term	NOUN
njb-1	393	20	results	result	NOUN
njb-1	393	21	of	of	ADP
njb-1	393	22	the	the	DET
njb-1	393	23	randomized	randomized	ADJ
njb-1	393	24	trial	trial	NOUN
njb-1	393	25	moscow	moscow	PROPN
njb-1	393	26	–	–	PUNCT
njb-1	393	27	berlin	berlin	PROPN
njb-1	393	28	2002	2002	NUM
njb-1	393	29	.	.	PUNCT
njb-1	394	1	j	j	PROPN
njb-1	394	2	cancer	cancer	PROPN
njb-1	394	3	res	res	PROPN
njb-1	394	4	clin	clin	PROPN
njb-1	394	5	oncol	oncol	PROPN
njb-1	394	6	.	.	PUNCT
njb-1	395	1	2019	2019	NUM
njb-1	395	2	apr;145(4):1001–12	apr;145(4):1001–12	NOUN
njb-1	395	3	.	.	PUNCT
njb-1	396	1	https://doi.org/10.1007/s00432-019-02854-x	https://doi.org/10.1007/s00432-019-02854-x	PROPN
njb-1	396	2	25	25	NUM
njb-1	396	3	.	.	PUNCT
njb-1	397	1	ribera	ribera	PROPN
njb-1	397	2	jm	jm	PROPN
njb-1	397	3	,	,	PUNCT
njb-1	397	4	morgades	morgades	PROPN
njb-1	397	5	m	m	PROPN
njb-1	397	6	,	,	PUNCT
njb-1	397	7	montesinos	montesinos	PROPN
njb-1	397	8	p	p	PROPN
njb-1	397	9	,	,	PUNCT
njb-1	397	10	martino	martino	PROPN
njb-1	397	11	r	r	PROPN
njb-1	397	12	,	,	PUNCT
njb-1	397	13	barba	barba	PROPN
njb-1	397	14	p	p	PROPN
njb-1	397	15	,	,	PUNCT
njb-1	397	16	soria	soria	PROPN
njb-1	397	17	b	b	PROPN
njb-1	397	18	,	,	PUNCT
njb-1	397	19	et	et	PROPN
njb-1	397	20	al	al	PROPN
njb-1	397	21	.	.	PROPN
njb-1	397	22	efficacy	efficacy	NOUN
njb-1	397	23	and	and	CCONJ
njb-1	397	24	safety	safety	NOUN
njb-1	397	25	of	of	ADP
njb-1	397	26	native	native	PROPN
njb-1	397	27	versus	versus	ADP
njb-1	397	28	pegylated	pegylated	ADJ
njb-1	397	29	escherichia	escherichia	NOUN
njb-1	397	30	coli	coli	NOUN
njb-1	397	31	asparaginase	asparaginase	NOUN
njb-1	397	32	for	for	ADP
njb-1	397	33	treatment	treatment	NOUN
njb-1	397	34	of	of	ADP
njb-1	397	35	adults	adult	NOUN
njb-1	397	36	with	with	ADP
njb-1	397	37	high	high	ADJ
njb-1	397	38	-	-	PUNCT
njb-1	397	39	risk	risk	NOUN
njb-1	397	40	,	,	PUNCT
njb-1	397	41	philadelphia	philadelphia	PROPN
njb-1	397	42	chromosome	chromosome	NOUN
njb-1	397	43	-	-	PUNCT
njb-1	397	44	negative	negative	ADJ
njb-1	397	45	acute	acute	ADJ
njb-1	397	46	lymphoblastic	lymphoblastic	NOUN
njb-1	397	47	leukemia	leukemia	NOUN
njb-1	397	48	.	.	PUNCT
njb-1	398	1	leuk	leuk	PROPN
njb-1	398	2	lymphoma	lymphoma	NOUN
njb-1	398	3	.	.	PUNCT
njb-1	399	1	2018;59(7):1634–43	2018;59(7):1634–43	NUM
njb-1	399	2	.	.	PUNCT
njb-1	400	1	https://doi.org/10.1080/10428194.2017.1397661	https://doi.org/10.1080/10428194.2017.1397661	X
njb-1	400	2	26	26	NUM
njb-1	400	3	.	.	PUNCT
njb-1	401	1	pession	pession	NOUN
njb-1	401	2	a	a	DET
njb-1	401	3	,	,	PUNCT
njb-1	401	4	valsecchi	valsecchi	PROPN
njb-1	401	5	mg	mg	PROPN
njb-1	401	6	,	,	PUNCT
njb-1	401	7	masera	masera	PROPN
njb-1	401	8	g	g	PROPN
njb-1	401	9	,	,	PUNCT
njb-1	401	10	kamps	kamps	PROPN
njb-1	401	11	wa	wa	PROPN
njb-1	401	12	,	,	PUNCT
njb-1	401	13	magyarosy	magyarosy	PROPN
njb-1	401	14	e	e	PROPN
njb-1	401	15	,	,	PUNCT
njb-1	401	16	rizzari	rizzari	PROPN
njb-1	401	17	c	c	PROPN
njb-1	401	18	,	,	PUNCT
njb-1	401	19	et	et	PROPN
njb-1	401	20	al	al	PROPN
njb-1	401	21	.	.	PUNCT
njb-1	402	1	long	long	ADJ
njb-1	402	2	-	-	PUNCT
njb-1	402	3	term	term	NOUN
njb-1	402	4	results	result	NOUN
njb-1	402	5	of	of	ADP
njb-1	402	6	a	a	DET
njb-1	402	7	randomized	randomized	ADJ
njb-1	402	8	trial	trial	NOUN
njb-1	402	9	on	on	ADP
njb-1	402	10	extended	extend	VERB
njb-1	402	11	use	use	NOUN
njb-1	402	12	of	of	ADP
njb-1	402	13	high	high	ADJ
njb-1	402	14	dose	dose	NOUN
njb-1	402	15	l	l	NOUN
njb-1	402	16	-	-	PUNCT
njb-1	402	17	asparaginase	asparaginase	NOUN
njb-1	402	18	for	for	ADP
njb-1	402	19	standard	standard	ADJ
njb-1	402	20	risk	risk	NOUN
njb-1	402	21	childhood	childhood	NOUN
njb-1	402	22	acute	acute	NOUN
njb-1	402	23	lymphoblastic	lymphoblastic	NOUN
njb-1	402	24	leukemia	leukemia	NOUN
njb-1	402	25	.	.	PUNCT
njb-1	403	1	j	j	PROPN
njb-1	403	2	clin	clin	PROPN
njb-1	403	3	oncol	oncol	PROPN
njb-1	403	4	.	.	PUNCT
njb-1	404	1	2005;23(28):7161–7	2005;23(28):7161–7	NUM
njb-1	404	2	.	.	PUNCT
njb-1	404	3	https://doi.org/10.1200/jco.2005.11.411	https://doi.org/10.1200/jco.2005.11.411	NUM
njb-1	404	4	27	27	NUM
njb-1	404	5	.	.	PUNCT
njb-1	405	1	ahlke	ahlke	PROPN
njb-1	405	2	e	e	PROPN
njb-1	405	3	,	,	PUNCT
njb-1	405	4	nowak	nowak	PROPN
njb-1	405	5	-	-	PUNCT
njb-1	405	6	göttl	göttl	PROPN
njb-1	405	7	u	u	PROPN
njb-1	405	8	,	,	PUNCT
njb-1	405	9	schulze	schulze	PROPN
njb-1	405	10	-	-	PUNCT
njb-1	405	11	westhoff	westhoff	NOUN
njb-1	405	12	p	p	PROPN
njb-1	405	13	,	,	PUNCT
njb-1	405	14	werber	werber	PROPN
njb-1	405	15	g	g	PROPN
njb-1	405	16	,	,	PUNCT
njb-1	405	17	börste	börste	PROPN
njb-1	405	18	h	h	PROPN
njb-1	405	19	,	,	PUNCT
njb-1	405	20	würthwein	würthwein	PROPN
njb-1	405	21	g	g	PROPN
njb-1	405	22	,	,	PUNCT
njb-1	405	23	et	et	PROPN
njb-1	405	24	al	al	PROPN
njb-1	405	25	.	.	PROPN
njb-1	405	26	dose	dose	NOUN
njb-1	405	27	reduction	reduction	NOUN
njb-1	405	28	of	of	ADP
njb-1	405	29	asparaginase	asparaginase	NOUN
njb-1	405	30	under	under	ADP
njb-1	405	31	pharmacokinetic	pharmacokinetic	ADJ
njb-1	405	32	and	and	CCONJ
njb-1	405	33	pharmacodynamic	pharmacodynamic	ADJ
njb-1	405	34	control	control	NOUN
njb-1	405	35	during	during	ADP
njb-1	405	36	induction	induction	NOUN
njb-1	405	37	therapy	therapy	NOUN
njb-1	405	38	in	in	ADP
njb-1	405	39	children	child	NOUN
njb-1	405	40	with	with	ADP
njb-1	405	41	acute	acute	ADJ
njb-1	405	42	lymphoblastic	lymphoblastic	NOUN
njb-1	405	43	leukaemia	leukaemia	NOUN
njb-1	405	44	.	.	PUNCT
njb-1	406	1	br	br	PROPN
njb-1	406	2	j	j	PROPN
njb-1	406	3	haematol	haematol	PROPN
njb-1	406	4	.	.	PUNCT
njb-1	407	1	1997;96(4):675–81	1997;96(4):675–81	NUM
njb-1	407	2	.	.	PUNCT
njb-1	407	3	https://doi.org/	https://doi.org/	PRON
njb-1	407	4	10.1046/	10.1046/	NUM
njb-1	407	5	j.1365	j.1365	NOUN
njb-1	407	6	-	-	PUNCT
njb-1	407	7	2141.1997.d01	2141.1997.d01	NUM
njb-1	407	8	-	-	PUNCT
njb-1	407	9	2089.x	2089.x	NUM
njb-1	407	10	28	28	NUM
njb-1	407	11	.	.	PUNCT
njb-1	408	1	parmentier	parmentier	PROPN
njb-1	408	2	jh	jh	PROPN
njb-1	408	3	,	,	PUNCT
njb-1	408	4	maggi	maggi	NOUN
njb-1	408	5	m	m	PROPN
njb-1	408	6	,	,	PUNCT
njb-1	408	7	tarasco	tarasco	PROPN
njb-1	408	8	e	e	PROPN
njb-1	408	9	,	,	PUNCT
njb-1	408	10	scotti	scotti	PROPN
njb-1	408	11	c	c	PROPN
njb-1	408	12	,	,	PUNCT
njb-1	408	13	avramis	avramis	PROPN
njb-1	408	14	vi	vi	PROPN
njb-1	408	15	,	,	PUNCT
njb-1	408	16	mittelman	mittelman	PROPN
njb-1	408	17	sd	sd	PROPN
njb-1	408	18	.	.	PROPN
njb-1	409	1	glutaminase	glutaminase	PROPN
njb-1	409	2	activity	activity	NOUN
njb-1	409	3	determines	determine	VERB
njb-1	409	4	cytotoxicity	cytotoxicity	NOUN
njb-1	409	5	of	of	ADP
njb-1	409	6	lasparaginases	lasparaginase	NOUN
njb-1	409	7	on	on	ADP
njb-1	409	8	most	most	ADJ
njb-1	409	9	leukemia	leukemia	NOUN
njb-1	409	10	cell	cell	NOUN
njb-1	409	11	lines	line	NOUN
njb-1	409	12	.	.	PUNCT
njb-1	410	1	leuk	leuk	PROPN
njb-1	410	2	res	res	PROPN
njb-1	410	3	.	.	PUNCT
njb-1	410	4	2015	2015	NUM
njb-1	410	5	jul;39(7):757–62	jul;39(7):757–62	PROPN
njb-1	410	6	.	.	PUNCT
njb-1	411	1	https://doi.org/10.1016/j.leukres.2015.04.008	https://doi.org/10.1016/j.leukres.2015.04.008	NOUN
njb-1	411	2	29	29	NUM
njb-1	411	3	.	.	PUNCT
njb-1	412	1	warrell	warrell	PROPN
njb-1	412	2	rpj	rpj	PROPN
njb-1	412	3	,	,	PUNCT
njb-1	412	4	chou	chou	PROPN
njb-1	412	5	tc	tc	PROPN
njb-1	412	6	,	,	PUNCT
njb-1	412	7	gordon	gordon	PROPN
njb-1	412	8	c	c	PROPN
njb-1	412	9	,	,	PUNCT
njb-1	412	10	tan	tan	PROPN
njb-1	412	11	c	c	PROPN
njb-1	412	12	,	,	PUNCT
njb-1	412	13	roberts	roberts	PROPN
njb-1	412	14	j	j	PROPN
njb-1	412	15	,	,	PUNCT
njb-1	412	16	sternberg	sternberg	PROPN
njb-1	412	17	ss	ss	PROPN
njb-1	412	18	,	,	PUNCT
njb-1	412	19	et	et	PROPN
njb-1	412	20	al	al	PROPN
njb-1	412	21	.	.	PUNCT
njb-1	413	1	phase	phase	PROPN
njb-1	413	2	i	i	PRON
njb-1	413	3	evaluation	evaluation	NOUN
njb-1	413	4	of	of	ADP
njb-1	413	5	succinylated	succinylated	ADJ
njb-1	413	6	acinetobacter	acinetobacter	ADJ
njb-1	413	7	glutaminase	glutaminase	NOUN
njb-1	413	8	-	-	PUNCT
njb-1	413	9	asparaginase	asparaginase	NOUN
njb-1	413	10	in	in	ADP
njb-1	413	11	adults	adult	NOUN
njb-1	413	12	.	.	PUNCT
njb-1	414	1	cancer	cancer	NOUN
njb-1	414	2	res	res	NOUN
njb-1	414	3	.	.	PUNCT
njb-1	415	1	1980	1980	NUM
njb-1	415	2	dec;40(12):4546–51	dec;40(12):4546–51	NOUN
njb-1	415	3	.	.	PROPN
njb-1	415	4	30	30	NUM
njb-1	415	5	.	.	PUNCT
njb-1	416	1	chan	chan	PROPN
njb-1	416	2	wk	wk	PROPN
njb-1	416	3	,	,	PUNCT
njb-1	416	4	lorenzi	lorenzi	PROPN
njb-1	416	5	pl	pl	PROPN
njb-1	416	6	,	,	PUNCT
njb-1	416	7	anishkin	anishkin	PROPN
njb-1	416	8	a	a	PROPN
njb-1	416	9	,	,	PUNCT
njb-1	416	10	purwaha	purwaha	PROPN
njb-1	416	11	p	p	PROPN
njb-1	416	12	,	,	PUNCT
njb-1	416	13	rogers	rogers	PROPN
njb-1	416	14	dm	dm	PROPN
njb-1	416	15	,	,	PUNCT
njb-1	416	16	sukharev	sukharev	PROPN
njb-1	416	17	s	s	PROPN
njb-1	416	18	,	,	PUNCT
njb-1	416	19	et	et	PROPN
njb-1	416	20	al	al	PROPN
njb-1	416	21	.	.	PUNCT
njb-1	417	1	the	the	DET
njb-1	417	2	glutaminase	glutaminase	NOUN
njb-1	417	3	activity	activity	NOUN
njb-1	417	4	of	of	ADP
njb-1	417	5	l	l	NOUN
njb-1	417	6	-	-	PUNCT
njb-1	417	7	asparaginase	asparaginase	NOUN
njb-1	417	8	is	be	AUX
njb-1	417	9	not	not	PART
njb-1	417	10	required	require	VERB
njb-1	417	11	for	for	ADP
njb-1	417	12	anticancer	anticancer	NOUN
njb-1	417	13	activity	activity	NOUN
njb-1	417	14	against	against	ADP
njb-1	417	15	asns	asns	PROPN
njb-1	417	16	-	-	PUNCT
njb-1	417	17	negative	negative	ADJ
njb-1	417	18	cells	cell	NOUN
njb-1	417	19	.	.	PUNCT
njb-1	418	1	blood	blood	NOUN
njb-1	418	2	.	.	PUNCT
njb-1	419	1	2014	2014	NUM
njb-1	419	2	jun;123(23):3596–606	jun;123(23):3596–606	PROPN
njb-1	419	3	.	.	PUNCT
njb-1	420	1	https://doi.org/10.1182/	https://doi.org/10.1182/	NOUN
njb-1	420	2	blood-2013	blood-2013	VERB
njb-1	420	3	-	-	PUNCT
njb-1	420	4	10	10	NUM
njb-1	420	5	-	-	SYM
njb-1	420	6	535112	535112	NUM
njb-1	420	7	31	31	NUM
njb-1	420	8	.	.	PUNCT
njb-1	421	1	baral	baral	ADJ
njb-1	421	2	a	a	PRON
njb-1	421	3	,	,	PUNCT
njb-1	421	4	gorkhali	gorkhali	ADJ
njb-1	421	5	r	r	PROPN
njb-1	421	6	,	,	PUNCT
njb-1	421	7	basnet	basnet	PROPN
njb-1	421	8	a	a	PROPN
njb-1	421	9	,	,	PUNCT
njb-1	421	10	koirala	koirala	PROPN
njb-1	421	11	s	s	PROPN
njb-1	421	12	,	,	PUNCT
njb-1	421	13	bhattarai	bhattarai	PROPN
njb-1	421	14	hk	hk	PROPN
njb-1	421	15	.	.	PUNCT
njb-1	422	1	selection	selection	NOUN
njb-1	422	2	of	of	ADP
njb-1	422	3	the	the	DET
njb-1	422	4	optimal	optimal	ADJ
njb-1	422	5	l	l	PROPN
njb-1	422	6	-	-	PUNCT
njb-1	422	7	asparaginase	asparaginase	NOUN
njb-1	422	8	ii	ii	PROPN
njb-1	422	9	against	against	ADP
njb-1	422	10	acute	acute	ADJ
njb-1	422	11	lymphoblastic	lymphoblastic	NOUN
njb-1	422	12	leukemia	leukemia	NOUN
njb-1	422	13	:	:	PUNCT
njb-1	422	14	an	an	DET
njb-1	422	15	in	in	ADP
njb-1	422	16	silico	silico	NOUN
njb-1	422	17	approach	approach	NOUN
njb-1	422	18	.	.	PUNCT
njb-1	423	1	jmirx	jmirx	PROPN
njb-1	423	2	med	me	VERB
njb-1	423	3	.	.	PROPN
njb-1	423	4	2021	2021	NUM
njb-1	423	5	sep;2(3):e29844	sep;2(3):e29844	VERB
njb-1	423	6	.	.	PROPN
njb-1	424	1	https://doi.org/10.2196/29844	https://doi.org/10.2196/29844	ADJ
njb-1	424	2	32	32	NUM
njb-1	424	3	.	.	PUNCT
njb-1	425	1	thomas	thomas	PROPN
njb-1	425	2	j.	j.	PROPN
njb-1	425	3	kindt	kindt	PROPN
njb-1	425	4	,	,	PUNCT
njb-1	425	5	barbara	barbara	PROPN
njb-1	425	6	a.	a.	PROPN
njb-1	425	7	osborne	osborne	PROPN
njb-1	425	8	rag	rag	PROPN
njb-1	425	9	.	.	PROPN
njb-1	425	10	kuby	kuby	PROPN
njb-1	425	11	immunology	immunology	NOUN
njb-1	425	12	,	,	PUNCT
njb-1	425	13	sixth	sixth	ADJ
njb-1	425	14	edition	edition	NOUN
njb-1	425	15	.	.	PUNCT
njb-1	426	1	6th	6th	ADJ
njb-1	426	2	ed	ed	NOUN
njb-1	426	3	.	.	PUNCT
njb-1	427	1	w.	w.	PROPN
njb-1	427	2	h.	h.	PROPN
njb-1	427	3	freeman	freeman	PROPN
njb-1	427	4	&	&	CCONJ
njb-1	427	5	company	company	PROPN
njb-1	427	6	;	;	PUNCT
njb-1	427	7	2006	2006	NUM
njb-1	427	8	.	.	PUNCT
njb-1	428	1	9–11	9–11	NUM
njb-1	428	2	p.	p.	NOUN
njb-1	428	3	https://doi.org/10.1182/blood-2008-04-149443	https://doi.org/10.1182/blood-2008-04-149443	X
njb-1	428	4	https://doi.org/10.1200/jco.18.01877	https://doi.org/10.1200/jco.18.01877	PUNCT
njb-1	428	5	https://doi.org/10.1097/mph.0b013e31822d4d4e	https://doi.org/10.1097/mph.0b013e31822d4d4e	PROPN
njb-1	429	1	https://doi.org/10.1182/blood.v99.8.2734	https://doi.org/10.1182/blood.v99.8.2734	PROPN
njb-1	429	2	https://doi.org/10.1080/08880018.2018.1538277	https://doi.org/10.1080/08880018.2018.1538277	PROPN
njb-1	430	1	https://doi.org/10.1038/leu.2016.219	https://doi.org/10.1038/leu.2016.219	PROPN
njb-1	430	2	https://doi.org/10.1182/blood-2013-01-480822	https://doi.org/10.1182/blood-2013-01-480822	X
njb-1	430	3	https://doi.org/10.1016/s1470-2045(15)00363-0	https://doi.org/10.1016/s1470-2045(15)00363-0	ADV
njb-1	430	4	https://doi.org/10.1016/s1470-2045(15)00363-0	https://doi.org/10.1016/s1470-2045(15)00363-0	ADV
njb-1	431	1	https://doi.org/10.1002/pbc.26873	https://doi.org/10.1002/pbc.26873	PROPN
njb-1	431	2	https://doi.org/10.1007/s00432-019-02854-x	https://doi.org/10.1007/s00432-019-02854-x	PROPN
njb-1	431	3	https://doi.org/10.1080/10428194.2017.1397661	https://doi.org/10.1080/10428194.2017.1397661	PROPN
njb-1	432	1	https://doi.org/10.1200/jco.2005.11.411	https://doi.org/10.1200/jco.2005.11.411	ADP
njb-1	433	1	https://doi.org/10.1016/j.leukres.2015.04.008	https://doi.org/10.1016/j.leukres.2015.04.008	PROPN
njb-1	433	2	https://doi.org/10.1182/blood-2013-10-535112	https://doi.org/10.1182/blood-2013-10-535112	SYM
njb-1	433	3	https://doi.org/10.1182/blood-2013-10-535112	https://doi.org/10.1182/blood-2013-10-535112	X
njb-1	433	4	https://doi.org/10.2196/29844	https://doi.org/10.2196/29844	ADJ